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SCIENTIFIC OPINION 
Scientific Opinion on the identification of pesticides to be included in 
cumulative assessment groups on the basis of their toxicological profile
1 
EFSA Panel on Plant Protection Products and their Residues (PPR)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
This is an updated version of the Scientific Opinion published on 12 July 2013 which was amended after a public 
consultation that ran from 17 July to 30 September 2013. The outcome of the public consultation is available at 
http://www.efsa.europa.eu/en/efsajournal/doc/538e.pdf
4.  
 
ABSTRACT 
The European Food Safety Authority asked the Panel on Plant Protection Products and their Residues to develop 
an Opinion on the identification of pesticides to be included in cumulative assessment groups (CAGs) on the 
basis of their toxicological profile. In 2008, the PPR Panel adopted an Opinion on the suitability of existing 
methodologies for cumulative risk assessment of pesticides and a tiered approach was proposed, which was 
applied to a selected group of triazole pesticides in 2009. The present Opinion suggests a methodology for 
grouping  of  pesticides  based  on  phenomenological  effects  and  provides  CAGs  for  the  thyroid  and  nervous 
system. This approach can be applied even when the underlying biochemical events mediating the effects are not 
understood, and is based on a standardised and thorough review of Draft Assessment Reports (DARs) supporting 
the approval of all pesticides in Europe, and on recommendations from the European Commission. Pesticidal 
active substances exhibiting neurotoxic properties were allocated to CAGs for acute effects on motor, sensory 
and autonomic divisions of the nervous system and neurochemical endpoints. Chronic effects across the same 
divisions/endpoints and neuropathological effects were collated. Active substances having adverse effects on the 
                                                       
 
1  On request from EFSA, Question No EFSA-Q-2009-00860, adopted on 19 June 2013. Updated version adopted on 8 
October 2014. 
2  Panel members: Alf Aagaard, Theo Brock, Ettore Capri, Sabine Duquesne, Metka Filipic, Antonio Hernandez-Jerez, Karen 
Ildico Hirsch-Ernst, Susanne Hougaard Bennekou,  Michael Klein, Thomas Kuhl, Ryszard Laskowski, Matthias Liess, 
Alberto Mantovani,  Colin Ockleford,  Bernadette Ossendorp,  Daniel Pickford  (until June 2014),  Robert Smith,  Paulo 
Sousa, Ingvar Sundh, Aaldrik Tiktak, Ton Van Der Linden. Correspondence: pesticides.ppr@efsa.europa.eu  
3   Acknowledgement: The Panel wishes to thank the members of the Working Group on Cumulative Assessment Groups of 
Pesticides Claudia Bolognesi (until June 2012), Alan Boobis (until June 2012), Antonio Hernandez-Jerez, Karen Ildico 
Hirsch-Ernst, Susanne Hougaard Bennekou, Andreas Kortenkamp, Kyriaki Machera (until June 2012), Alberto Mantovani, 
Angelo Moretto (until January 2011), Roland Solecki, Maria Tasheva (until June 2012), Christiane Vleminckx (until June 
2012)  and  the  EFSA  staff  members  Charlotte  Bergkvist,  Federica  Crivellente,  Edgars  Felkers  (until  March  2012), 
Frédérique Istace, István Sebestyén (until May 2012), Luc Mohimont, Hans Steinkellner, Andrea Terron and Manuela 
Tiramani for the support provided to this scientific opinion. 
4  The main changes from the original opinion are as follows: (1) data collection spread -sheets: some NOAELs/LOAELs 
were replaced, clarifications were added to the remarks column, and a number of substances missing from the original data 
collection were added; (2) the cumulative assessment groups for both the nervous and the thyroid systems have been 
updated in the text; (3) the lists of substances that were assessed and selected for cumulative assessment groups (Appendix 
H) have been updated; (4) the paragraph on developmental neurotoxicity has been updated according to the new data 
requirements for active substances used in plant protection products in Regulation (EU) No 283/2013. The original opinion 
and spread-sheets are available on request as are copies showing all the changes that were made. 
 Cumulative Assessment Groups for Pesticides update 
 
 
2  EFSA Journal 2013;11(7):3293 
thyroid  system  were  allocated  to  CAGs  for  effects  either  on  C-cells/the  calcitonin  system  or  on  follicular 
cells/the T3/T4 system. The PPR Panel notes that the resulting groups encompass many pesticides and also that 
individual pesticides could appear in several groups and therefore the data entries for performing cumulative risk 
assessment (CRA) are of considerable magnitude. Although some CAGs contain a large number of pesticides, 
little indication of cumulative risk may be inferred from the size of CAGs per se. The PPR Panel recommends 
that the methodology is implemented for all major organ/systems but the approach used should be considered 
specific for pesticides. 
© European Food Safety Authority, 2014 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Plant Protection Products and their 
Residues (PPR) to deliver a scientific Opinion on the identification of pesticides to be included in 
cumulative assessment groups (CAGs) based on their toxicological profile, the aim being to develop 
cumulative risk assessment (CRA) methodology. 
This Opinion was preceded by two previous Opinions (EFSA, 2008, 2009). In the first one, the PPR 
Panel evaluated existing methodologies on cumulative risk assessment (CRA), and recommended that 
a tiered approach should be adopted both for hazard and exposure assessments. Criteria for grouping 
active substances into CAGs were proposed, based on the chemical structure, mechanism of pesticidal 
action, mode/mechanism of mammalian toxicity and common toxic effects. In the second Opinion an 
exercise was carried out to test the proposed approach by a worked example of a group of triazole 
pesticides, a well-defined group in terms of structure, pesticidal mode of action and toxicological 
effects (EFSA, 2009). Thus, the previous opinions dealt with CRA, encompassing both hazard and 
exposure assessment. In the Terms of Reference of the current opinion, EFSA has requested for a 
scientific Opinion on the identification of pesticides to be included in CAGs on the basis of their 
toxicological profile and deals therefore solely with hazard assessment. The Panel is aware that the 
conduct of CRA is a process that involves several steps and multiple considerations, many of which go 
beyond the scope and Terms of Reference of this opinion. CRA has to include the outcome of the 
current Opinion as well as other critical elements, such as the availability of occurrence data and the 
scientific and technical capacity of exposure assessment  methodologies. Recommendations on the 
conduct of CRA were outside the scope of the present opinion. 
 
The  present  Opinion  presents  a  general  methodology  and  criteria  specifically  developed  for 
establishment  of  CAGs  for  pesticides.  The  methodology  has  been  applied  to  establish  CAGs  for 
pesticides having effects on the thyroid and nervous system, and has been developed on the basis of 
datasets of oral toxicity studies evaluated in draft assessment reports (DARs). The methodology was 
developed in order to take cumulative effects into account in the decision on applications concerning 
maximum residue levels (MRLs) of pesticides in or on food and feed of plant and animal origin. The 
CAGs derived from this methodology could in principle be used to support CRA resulting from non-
dietary exposures (i.e. operator, worker, bystander and resident exposure). 
The allocation of pesticide active substances into CAGs requires a standardised and thorough review 
of the DARs for effects on individual organs and organ systems of all approved pesticides relevant for 
dietary exposure. Therefore, two preparatory projects for collecting toxicological data from pesticides 
were initiated. In the first project, all pesticides authorised prior to 31
st of May 2009 were evaluated. 
The contractors proposed a grouping approach starting from identifying toxicological target organs 
and  organ  systems  and  then  subsequently  refining  the  grouping  by  identifying  a  specific 
phenomenological effect. If data allowed, the grouping was further refined by identifying a common 
mode or  mechanism of action. The data collection and approach  proposed by the contractor  was 
scrutinised and partly consolidated by the PPR Working Group. It was decided that the data collection 
needed  to  be  re-evaluated  and,  hence,  a  second  project  was  launched  specifically  consolidating 
identified  pesticides  having  effects  on  the  nervous  system,  the  liver  and  the  reproductive  and 
developmental system. In addition, pesticides approved from 31
st of May 2009 until 1
st of January 
2012 were included in the scope of the second project. 
The PPR Panel acknowledges that EU residue monitoring programmes indicate that there is some 
consumer exposure to residues of non-approved pesticides which should also be included in CAGs.  
Following the work undertaken by the PPR Working Group for the current Opinion on reviewing 
pesticides for inclusion in various  CAGs, it became apparent that there are  often few or no data 
available  on  mode  of  action,  but  that  many  compounds  affect  the  same  target  organ  and/or  cell 
population. On this basis, the proposed methodology follows a phenomenological approach based on 
organ or system toxicity, consisting in including in a CAG for a specific effect all pesticides causing Cumulative Assessment Groups for Pesticides update 
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this effect, even if the underlying mode of action (MoA) is unknown. Interactions (synergisms or 
antagonisms) are not expected to occur at the low exposure levels of residues that are observed in 
monitoring programs. Thus, the PPR Panel considers that mainly dose additive effects of substances 
are normally relevant to CAGs that may be used in the context of MRL setting (EFSA, 2008; Boobis 
et a., 2008). 
As there may be limited opportunity for refinement of CAGs on the basis of available information on 
mode/mechanism  of  action,  the  proposed  grouping  methodology  makes  a  sufficient  precautionary 
approach, which is agreed upon by the European Commission and EFSA: when insufficient or no 
information is available, it is assumed that chemicals with the same effects may have a similar mode 
of action, even though they exhibit a wide range of chemical structural features. This view is based on 
empirical  evidence  that  chemically  unrelated  substances  may  have  a  common  effect  in  target 
organs/organ systems, which can be well approximated by dose addition (Kortenkamp et al., 2009). 
This has to be considered within the context of pesticide evaluations by EFSA and hence the approach 
recommended in the present Opinion differs from the approach tentatively used by the PPR Panel in 
its previous work. 
The stepwise methodology for grouping has been elaborated to address  acute and chronic dietary 
efects.  
 
The methodology comprises four main steps as follows: 
 
  Identification of the specific effects by:  
 
i) exclusion of local effects 
ii) exclusion of non-adverse effects 
iii) exclusion of effects not relevant to humans 
iv) evaluation of the unambiguous nature of the effect  
v) identification of non-specific effects 
 
  Characterisation of the specific effects 
  Data collection  
  Grouping of pesticides into CAGs 
 
The PPR Panel recommends that the implementation of the methodology based on specific effects 
should  be  supported  by  expert  judgement  in  order  to  identify  the  effects  relevant  for  grouping 
according  to  the  criteria  laid  down  in  the  opinion.  In  particular,  expert  judgement  is  required  to 
identify and characterise substances that can trigger different outcomes of the same toxicity pathway 
(e.g. different effects on motor division of the nervous system) or that may cause toxic effects at 
multiple sites by a single mode of action (e.g. acetylcholinesterase inhibition). 
The CAG methodology in the current Opinion has been applied to the nervous system and the thyroid 
system. 
For the identification and characterisation of the potential neurotoxicity of pesticide active substances, 
the  functional  divisions  of  the  nervous  system  (motor,  sensory  and  autonomic)  along  with  the 
cognitive  domain,  neurochemistry  and  neuropathology  parameters  were  considered  as  potential 
targets. Indicators of specific neurotoxic effects were identified and applied to characterise the CAGs 
for the nervous system. 
A total of 68 active substances, were identified as having specific effects on the nervous system. 
Additional four substances were excluded from grouping because the methodological criteria were not 
met and/or the exposure to these substances by the oral route was highly unlikely following their 
authorised use. 
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The CAGs of substances identified as neurotoxic are presented in two separate tables for acute and 
chronic effects, respectively. Data were tabulated according to the level of organisation of the nervous 
system, the indicator of the specific neurotoxic effect, the active substance, its mode of action and the 
lowest NOAELs and/or LOAELs for each indicator. Non-specific or secondary effects, as well as 
effects that occur after administration of high doses, resulting in severe systemic toxicity, were not 
included in these CAGs according to the criteria for identification of specific effects listed above.  
The following groups were proposed (number of pesticides in each group):  
  Acute exposure (47) 
-  Motor division (45) 
-  Sensory division (20) 
-  Autonomic division (29) 
 
  Chronic exposure (64) 
-  Motor division (53) 
-  Sensory division (21) 
-  Autonomic division (24) 
-  Neuropathological changes (19) 
 
The Panel recognises that the neurochemical parameters, i.e. brain or erythrocyte AChE inhibition, 
represent a level of grouping for neurotoxic substances based on mechanism of action rather than on 
phenomenological effect. However, AChE inhibitors play a prominent role in the risk assessment that 
would result in an increased sensitivity for some substances. For this reason, and to keep consistency 
in the grouping approach, the neurochemical parameters should be used for further refinement when 
this  mechanism  of  action  is  recognised.  In  addition,  neuropathological  changes  were  considered 
relevant  only  for  chronic  CAGs  since  some  pesticide  active  substances  induced  morphological 
changes as the only adverse effect or they were found to be the most sensitive ones. 
Despite the effects of pesticides on the cognitive domain e.g. learning and memory, which are relevant 
for assessment of neurotoxicity, the information available in the DARs failed to identify these effects. 
This  is  very  likely  because  these  effects  correspond  to  a  higher  tier  of  assessment  that  was  not 
performed on a routine basis during the toxicological assessment of pesticides. 
Owing to the absence of systematic testing of pesticides  for Developmental Neurotoxicity (DNT) in 
the European Union, and in consideration that new data requirements for active substances used in 
plant  protection  products  have  just been recently  introduced  (Regulation (EU)  No  283/2013  of 1 
March 2013)
5, results from such tests, even when in certain instances available (e.g. for dimethoate, 
fenamiphos, fipronil, malathion and molinate), have not been considered for CAGs in the present 
opinion. Since the thyroid functions as a gland that produces systemically acting hormones (calcitonin, 
thyroxin (T4) and triiodothyronine (T3)), the most conser vative level of grouping  (CAG 1)  was 
defined by effects occurring on the organ (thyroid) or  organ system (hypothalamic-pituitary-thyroid 
axis), e.g. through changes in thyroid hormone levels (in total 101 of 287 screened substances were 
identified as affecting the thyroid or thyroid hormone systems ). Identification of specific effects 
concerning  two  different thyroidal cell populations/hormone systems formed the basis for further 
refinement, yielding two sub-groups at the second level (CAG2A and CAG2B). 
Substances affecting C-cells of the calcitonin system were allocated to CAG2A ( 22  substances). 
Owing to interrelationship of the specific effects between C -cell hyperplasia and neoplasms, and 
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absence of information on underlying mechanisms, further sub-grouping of thyroid CAG2A was not 
possible. 
Substances  affecting  the  thyroid  follicular  cells  and  the  T3/T4  system,  i.e.  displaying  changes  in 
circulating T3/T4 or TSH levels, follicular cell hypertrophy/hyperplasia or follicular cell neoplasia, 
were allocated to CAG2B (in total 96 substances). The specific effects that were used to define the 
CAG2B sub-group were apparently interrelated or connected to one another by a chain of events. 
While the precise mechanism of action is currently unknown for many substances within CAG2B, 
several different mechanisms of action are expected to contribute to a final deleterious common effect 
(i.e. decrease in T3/T4 action). For these reasons and based on the information available in DARs, 
further  refinement  of  grouping  is  currently  not  possible.  In  exceptional  cases,  where  there  is 
convincing evidence for substance-dependent direct stimulation of the thyroid or hyperthyroidism, 
exclusion of substances from this sub-group might be considered.   
The  application  of  grouping  methodology  has  yielded  CAGs  with  sometimes  large  numbers  of 
pesticides.The  Panel  notes  that  although  some  CAGs  contain  a  large  number  of  pesticides,  little 
indication of cumulative risk may be inferred from the size of CAGs per se. The Panel further notes 
that, even within large CAGs, the majority of pesticides might not contribute significantly to a given 
combination effect, either because exposure is very low, and/or because potency in relation to the 
effect considered is weak. Instead, cumulative effects are likely to be driven mainly by a few active 
substances within the group. 
Comprehensive  preliminary  work  has  been  done  on  effects  on  the  liver,  adrenals,  eye  and 
developmental and reproductive system and provides a starting point for developing CAGs also for 
these systems in the future.  
The PPR Panel identified a number of uncertainties and limitations in grouping of pesticides according 
to a common or shared toxic effect. In particular, a grouping based on toxic effects rather than on 
mode of action will lead to more uncertainties in predicting possible combination effects. However, 
the  Panel  acknowledges  that  when  limiting  CAGs  to  known  common  mode  of  action,  thereby 
excluding pesticides for which information on mode of action is not available to enable their inclusion 
in relevant CAGs, the degree of uncertainty in CRA would also increase. Thus, a higher level of 
protection can be afforded by considering a wider range of pesticides and until information on precise 
modes of action becomes available, the cost of this is to use an effect-based approach that introduces 
some  uncertainties  around  combination  effects.  Additional  uncertainties  considered  by  the  Panel 
included the levels of details of the toxicological assessments in the DARs, changes occurring over the 
years  in  regard  to  data  requirements  and  study  protocols  of  the  toxicological  assessments,  and 
inconsistency and variability in terminology of the DARs.  
The PPR Panel also makes recommendations for the implementation of CAG grouping methodology 
in CRA to support MRL setting. The PPR Panel also notes that further refinement of grouping maybe 
achieved when data on the precise toxicological mode of action are available. However, information 
that  justifies  any  deviation  from  dose-addition  might  also  be  necessary  to  consider  for  such  a 
refinement. In addition, non-approved pesticides detected in food commodities should be included in 
CAGs, and a sound and consistent procedure for data retrieval should be developed  for both the 
methodology and the inclusion of new substances into the relevant groups.  
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BACKGROUND AS PROVIDED BY EFSA  
Regulation of the European Council and the European Parliament (EC) No. 396/2005
6 on Maximum 
Residue  Levels  (MRLs)  emphasizes  the  importance  “of  carrying  out  further  work  to  develop  a 
methodology to take into account cumulative and synergistic effects of pesticides” as there is currently 
no internationally agreed methodology available for these purposes.  
On 28/29 November 2006, EFSA started working on CRA of pesticides by organising a colloquium on 
“Cumulative risk assessment of pesticides to human health: the way forward”. The summary report of 
this colloquium is published on EFSA‟s website: 
http://www.efsa.europa.eu/en/science/colloquium_series/colloquium_7.html  
This report includes the results from two discussion groups dealing with cumulative exposure. 
In addition to this colloquium organised by EFSA, WHO/IPCS hosted an International Workshop on 
Aggregate/Cumulative Risk Assessment in Washington in March 2007. The report can be found on: 
http://www.who.int/ipcs/en 
Based on the results from these international events, EFSA‟s Scientific Panel on Plant Protection 
Products and their Residues (PPR Panel) elaborated an Opinion “to evaluate the suitability of existing 
methodologies  and,  if  appropriate,  the  identification  of  new  approaches  to  assess  cumulative  and 
synergistic risk from pesticides to human health with a view to set MRLs for those pesticides in the 
frame of Regulation (EC) No. 396/2005”. 
In this Opinion the PPR Panel proposed criteria required to be met for inclusion of compounds in a 
cumulative  assessment  group  (CAG).  It  highlighted  the  possibility  of  using  different  levels  of 
refinement in a step-wise approach. The grouping can be based on general criteria like chemical 
structure, or mechanism of pesticidal action, or higher level criteria like common toxic effect, common 
phenomenological effect or even toxic mode of action. 
Following this opinion, a worked example of the proposed methodology was developed for a group of 
triazole compounds and the results are reported in a separate Opinion with suggested refinements as 
necessary. This Opinion of the PPR Panel was adopted in June 2009. 
As a third step the PPR Panel is providing assistance to the evaluators and regulators elaborating an 
Opinion containing lists of pesticides included in cumulative assessment groups on the basis of their 
toxicological characteristics. In the preparatory phase of this Opinion the PPR Panel has launched a 
call for proposals CFP/EFSA/PPR/2009/01 based on article 36 of European Parliament and Council 
Regulation (EC) No. 178/2002
7. The aim of this project is to set  the basis for carrying out  CRA 
routinely in the context of MRL regulation by searching for and exploring the existing pesticide data 
bases, open literature and Draft Assessment Reports (DARs)  to identify the toxicological effects and 
their indicators that can be  used for  CRA.  Proposals for cumulative assessment groups of active  
substances causing these identified effects and  related indicators (including the selection of index 
compounds) are to be made in the final report of this project. 
This report will be the starting document for the scientific Opinion of the PPR Panel on identification 
of cumulative assessment groups. 
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7 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
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TERMS OF REFERENCE AS PROVIDED BY EFSA 
The Scientific Panel on Plant Protection Products and their Residues is asked by EFSA to prepare a 
Scientific Opinion on the identification of pesticides to be included in cumulative assessment groups 
on the basis of their toxicological profile. 
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ASSESSMENT 
1.  Interpretation of the Terms of Reference by the PPR Panel  
In  the  Terms  of  Reference  EFSA  has  requested  for  a  scientific  Opinion  on  the  identification  of 
pesticides to be included in cumulative assessment groups (CAGs) on the basis of their toxicological 
profile.  
 
In  the  explanatory  background  provided  by  EFSA, reference is  made to the Regulation  (EC)  No 
396/2005  of  the  European  Council  and  the  European  Parliament  on  Maximum  Residue  Levels 
(MRLs), which lays down in article 14 that, in decisions on applications concerning MRLs, account 
shall be taken of the possible presence of pesticide residues arising from sources other than current 
plant protection uses of active substances, and their known cumulative and synergistic effects, when 
the methods to assess such effects are available. As the regulation stipulates that only pesticides need 
to be considered for cumulative and synergistic effects, the Panel restricted its Opinion to CAGs of 
pesticides with a view of supporting specifically the regulatory MRL-setting process of pesticides in 
the European Union. The Terms of Reference state that the CAGs should be based on the toxicological 
profile  of  pesticides  and  not  on  exposure  considerations.  The  PPR  Panel  will  therefore  only  use 
toxicological considerations  for recommendations  regarding  CAGs  of  pesticides.  Accordingly,  the 
current  Opinion  does  not  consider  the  assessment  of  cumulative  effects  of  chemicals  other  than 
pesticides;  the  opinion‟s  outcomes  might,  however,  contribute  to  the  on-going  elaboration  of  a 
possible  all-embracing  methodology  for  the  assessment  of  cumulative  risks  from  all  types  of 
chemicals and from all sources of exposure. 
 
The Panel recognises that the conduct of CRA is a process that involves several steps and multiple 
considerations, many of which go beyond the scope and Terms of Reference of this opinion. CRA is 
therefore an exercise which has to consider the outcome of this opinion, as well as other critical 
elements,  such  as  the  availability  of  occurrence  data  and  the  scientific  and  technical  capacity  of 
exposure  assessment  methodologies.  In  this  Opinion  the  PPR  Panel  does  not  make  any 
recommendations for the conduct of CRA in a general sense. 
 
To ensure coherence between risk assessment and risk management in dealing with the request of the 
current  opinion,  EFSA  has  in  addition  formally  consulted  the  European  Commission  on  general 
recommendations  regarding  the  desired  level  of  protection  and  has  informed  the  Panel  about  the 
outcome of this consultation. 
 
   Cumulative Assessment Groups for Pesticides update 
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2.  Introduction 
The European Food Safety Authority (EFSA) asked the Panel on Plant Protection Products and their 
Residues (PPR) to provide a scientific Opinion on the identification of pesticides to be included in 
cumulative  assessment  groups  (CAGs)  based  on  their  toxicological  profile  to  develop  CRA 
methodology. 
A  key  step  in  CRA  is  to  decide  which  substances  should  be  grouped  together  in  CAGs  for  an 
assessment of their combined effects, and which criteria should be applied in defining such CAGs. 
The PPR Panel has already adopted two opinions on CRA that deal with this issue.  
In the first of these opinions (EFSA, 2008), the Panel highlighted the possibility of different levels of 
refinement for defining CAGs in a step-wise approach. It was proposed that groupings can be based on 
general criteria including the chemical structures of active substances, mechanism of pesticidal action, 
or more refined criteria such as shared toxic effects, or toxic modes of action. In addition, the Panel 
identified more specific  criteria for selecting  CAGs  for consideration in  CRA. These include: (a) 
frequency of detection in monitoring programmes, (b) high use based on surveys or sales statistics, (c) 
evidence  of  “high”  intake  from  bio  monitoring  data  for  the  general  population  or  for  sub-
populations/geographical areas, (d) compounds with high exposures relative to their reference values 
(i.e. ADI, ARfD), (e) CRA carried out elsewhere showing possible unacceptable exposure, (f) high 
number of compounds (e.g. 5 or more) in a group, and (g) predictions of upward future trends in use of 
pesticides. 
 
The second Opinion (EFSA, 2009) elaborated a case study in which a method for taking account of 
cumulative effects was applied to a group of pesticides with similar chemical structures, the triazole 
fungicides. The Opinion proved to be very valuable in testing the methodology and identifying the 
necessary steps to be taken before the methodology could be recommended and applied on a routine 
basis. The PPR Panel concluded that previously proposed criteria can be simplified by starting with a 
CAG that is as refined as the data allows it to be and by using the same criteria in all steps of the 
assessment. The PPR Panel also concluded that, although a tiered approach is an appropriate way to 
address cumulative dietary risk assessment, it cannot yet be applied on a routine basis. The basis for, 
and  establishment  of,  relevant  CAGs  needs  to  be  provided  first.  The  Panel  also  highlighted  the 
difficulties in defining CAGs and in finding a consensus at the international level on the criteria to be 
used for establishing CAGs for active substances in pesticide formulations. 
For the purpose of the present opinion, and in recognition of the mandate defined by EFSA, the PPR 
Panel had to clearly distinguish between the approaches used for CRA of pesticides and those required 
during the process of MRL setting. The  Panel recognised that tiered, exposure assessment-driven 
approaches  are  powerful  tools  for  risk  assessment  but  are  difficult  to  apply  in  the  context  of 
establishing MRLs. Since in principle (although rarely in practice) every authorised pesticide may 
occur in a food item, the grouping of active substances in CAGs for the purpose of MRL setting 
cannot be driven by exposure assessments. Instead, grouping has to be based on criteria solely derived 
from  the  intrinsic  properties  of  the  chemicals  under  consideration.  These  may  include  chemical 
structure, mode of action or the induction of common adverse effects. The Panel recognised that such 
grouping criteria and CAGs may also be of use in exposure assessment-driven CRA, especially at 
higher tiers of the analysis. 
In the present opinion, the PPR Panel makes an effort to define criteria and a methodology for the 
grouping of active substances in CAGs for the purpose of taking account of cumulative effects during 
the setting of MRLs. In doing so, the Panel recognised that grouping criteria based on overly narrow 
definitions of modes of action or chemical structural criteria might miss substances that also contribute 
to  a  combined  effect.  This  became  evident  as  new  data  in  experimental  studies  appeared  in  the 
literature published after the latter Opinion (EFSA, 2009). These studies showed that combinations of 
chemicals with shared toxicity but diverse modes of action also exhibited joint effects (reviewed in 
Kortenkamp et al., 2009, 2012). Cumulative Assessment Groups for Pesticides update 
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In the light of this evidence, the Panel took a new approach in defining CAGs. This approach takes as 
its starting point the common or shared adverse effects of components in a mixture. Thus, the Panel 
proposed CAGs for selected shared adverse effects of active substances in pesticide formulations, also 
called specific effects in this opinion. As more information about modes of action of active substances 
becomes available, these groupings can be further refined through consideration on the possible joint 
effects following combination of chemicals with shared toxicity, but diverse mode of action. During 
the preparation of this Opinion it became obvious that the information available from pesticide Draft 
Assessment Reports (DARs) and the literature is in many cases not adequate to make conclusions 
regarding the mode of action. To deal with this difficulty in a pragmatic way when defining CAGs, 
two  main  options  were  identified  as  follows.  In  what  might  be  termed  an  “inclusion  approach”, 
evidence is sought that a pesticide acts according to a specific mode of action before it can be included 
in a CAG. Alternatively, a so-called “exclusion approach” can be applied where decisions on forming 
CAGs are based on a weight of evidence and analysis of the nature of the toxicological effects even if 
a mode of action has not been clearly established. A compound is excluded from the CAG only if it 
can be shown that it does not exhibit the shared toxic effect (specific effect). 
The  Panel  recognised  that  the  “inclusion  approach”  could  result  in  an  underestimation  of  the 
cumulative risk while conversely the “exclusion approach” could result in an overestimation of the 
cumulative risk. The Panel felt that the choice of approach was essentially a risk management decision 
and therefore the European Commission was consulted to obtain guidance on this question. 
The  direction  from  the  Commission  was  as  follows:  In  the  case  of  absence  of  information  it  is 
certainly not justified to assume that chemicals have no common mechanism of action, especially not 
when these are chemically related substances. Incidentally, chemically unrelated substances can also 
have  a  common  mechanism  or  could  show  dose  addition  for  some  toxic  effects  even  without  a 
common mechanism. The direction given by the risk managers of the European Commission was in 
favour of the “exclusion approach”. Consequently, this approach was adopted in the present opinion. 
The applicability of this approach in other areas under the EFSA remit remains to be explored.  
In preparing the present opinion, EFSA commissioned a project with the aim of identifying adverse 
effects relevant for CRA, and of forming a basis for CAGs of pesticide active substances authorised in 
the EU. The results of this project were published by EFSA in January 2012 (DTU, 2012) and formed 
the starting point for this opinion. Subsequently, the PPR Panel established the need to further review 
the data collection provided by DTU. This led to the commissioning of a second project on data 
collection for specific organs/organ systems, and which was published in 2013 (ANSES/ICPS/RIVM, 
2013). 
 
Finally, the PPR Panel acknowledges that, according to EU residue monitoring programmes, some 
consumer exposure may occur from residues of non-approved pesticides. Pesticides not authorised in 
EU but where import tolerances exist should in the future also be included in CAG. However, in the 
present  Opinion  these  substances  were  not  evaluated  for  grouping  due  to  the  lack  of  recent  and 
suitable peer-reviewed data. 
 
To  make  the  present  Opinion  relevant  in  a  regulatory  context,  its  scope  was  adjusted  to  the 
development of a general grouping methodology applicable to all organ and organ systems. However, 
this methodology was initially applied to the nervous system and the thyroid system.  
Although not presented in this opinion, substantial work has been carried out to define CAGs for 
additional organ and organ systems and could seed continuation of the CRA in the future. 
This Opinion might also inform cumulative exposures by multiple routes and to a wide variety of 
chemicals, not only active substances in pesticide formulations.   Cumulative Assessment Groups for Pesticides update 
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3.  Overview on grouping approaches for chemicals  
CRA often begins with the identification of chemicals that should be grouped together and subjected 
to joint risk assessment. Traditionally, chemicals regarded as having the ability to induce a common 
toxic effect by a common mechanism of toxicity have been considered together. This requirement for 
“similarity in mode (or mechanism) of action” is rooted in a specific interpretation of the mixture 
assessment concept of dose addition. However, as more and more experimental data with mixtures of 
a wide variety of chemicals became available, the practical applicability of criteria for similarity of 
action has come under scrutiny. In this section, the Panel briefly discusses notions of similar action, 
how  they  link  with  mixture  assessment  concepts,  and  summarises  practices  for  the  grouping  of 
chemicals for CRA. 
3.1.  Similar  and  dissimilar  joint  action  -  the  underpinnings  of  the  mixture  assessment 
concepts of dose addition and independent action 
Dose addition, also known as concentration addition, is based on the idea that all components in a 
mixture behave as if they were simple dilutions of one another. Although, the original formulation of 
dose  addition  by  Loewe  and  Muischneck  (1926)  contains  nothing  that  relates  dose  addition  to 
mechanisms,  the  dilution concept is often taken to mean  that  dose  addition  is  only  applicable  to 
mixtures of compounds with a similar mechanism of action. There is good evidence (Kortenkamp et 
al., 2009) that combinations of chemicals which interact with the same well-defined molecular target 
indeed follow the dilution principles of dose addition: each component can be replaced totally or in 
part by an equal fraction of an equi-effective concentration (e.g. an EC50) of another, without changing 
the overall combined effect. 
The alternative mixture assessment concept of independent action, sometimes also termed response 
addition, effect multiplication or Abbotts Rule, conceptualises mixture effects in a different way. It 
assumes that a combination effect can be calculated from the responses of the individual mixture 
components by following the statistical concept of independent random events (Bliss, 1939). Although 
independent action is also applicable to chemicals that act through similar modes of action when these 
are  administered  sequentially,  the  principles  of  independence  of  action  are  thought  to  be  met  by 
substances with strictly dissimilar modes of action only when exposures occur simultaneously. 
These distinctions are relevant when it comes to deciding which of the two concepts should be used 
for  the  assessment  of  a  specific  mixture.  In  the  past,  independent  action  was  often  held  to  be 
applicable when the similarity criteria of dose addition appeared to be violated (COT, 2002). By 
implicitly taking “dissimilar action” as the simple negation of “similar action”, it was then assumed 
that independent action must apply, even without further proof that the underlying mechanisms satisfy 
the dissimilarity criterion.  
What complicates decisions about the application of dose addition or independent action is a lack of 
reliable criteria for similarity of mechanisms and modes of action. Accordingly, opinions about what 
should qualify for “similarity” differ considerably. While it is widely accepted to regard mixtures 
composed of chemicals that act on the same molecular structure as acting similarly in accordance with 
dose addition, the issue is complicated by observations that dose addition sometimes also provides 
good  descriptions  of  experimentally  observed  combination  effects  when  strict  mechanism-based 
criteria of similarity are not met (Kortenkamp, et al., 2009). This has lent support to the idea that 
notions of similarity of action are also applicable when all mixture components produce the same 
phenomenological effect. On the other hand, that approach could turn out to be inappropriate for some 
combinations  of  chemicals  when  they  induce  a  common  effect  through  distinct  molecular 
mechanisms. Conversely, demands for a strict mechanistic similarity criterion can mean that very few 
chemicals actually qualify for the inclusion in a CAG. 
This would leave many other chemicals, which also produce the same adverse outcome unaccounted 
for,  with  the  consequence  of  underestimating  combined  risks.  Others  hold  the  middle  view  that 
interactions with the same site, tissue, or target organ should qualify for similarity (US EPA 1986, 
1989; Mileson et al., 1998). Cumulative Assessment Groups for Pesticides update 
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As a way of dealing with these difficulties, IPCS (2009) proposed to use dose addition as the default 
concept in cumulative risk assessment until evidence to the contrary, in support of dissimilar modes of 
action, becomes available. 
3.2.  Similarity of action as a grouping criterion 
The problem regarding the choice of dose addition or independent action for the assessment of specific 
mixtures can be solved pragmatically by evaluating experimental data using both concepts side-by-
side, with the aim of investigating which concept produces the best approximations of the observed 
effects.  Such  comparative  evaluations  have  revealed  a  great  deal  about  the  applicability  of  dose 
addition and independent action (Kortenkamp et al., 2009, 2012). 
However,  post  hoc  analyses  of  this  kind  are  not  an  option  when  it  comes  to  judging  whether 
substances whose combined effects are untested will produce a combination effect, let alone whether 
this combination effect can be approximated by dose addition and is in line with notions of similarity 
of joint action. In principle, such judgements, and the corresponding grouping decisions, can be made 
by considering the effect profile of each substance individually in terms of common adverse outcomes.  
The alternative option can be to use narrower criteria of similarity, based on common mechanisms and 
molecular targets. In practice, this has often meant that chemicals with shared structural characteristics 
were  grouped  together. The  Panel recognises  that any  grouping  effort  requires  information  about 
mechanisms  or  modes  of  action  in  relation  to  multiple  toxic  endpoints.  Unfortunately,  such 
information is often not available for many pesticides. The data requirements for the  approval of 
pesticides,  as  laid  down  in  Commission  Regulation  (EU)  No  283/2013
8,  are not geared towards 
meeting the requirements of CRA. 
To gain an impression of how other agencies and institutions deal with the issue of grouping pesticides 
and other chemicals for the purpose of CRA the Panel briefly reviewed examples of current practice. 
3.3.  Grouping approaches by other international bodies  
The US Environmental Protection Agency (US EPA) has evolved one of the most elaborate regulatory 
frameworks for CRA. For pesticides, this derives from a mandate laid down in a clause of the US 
Food Quality Protection Act (FQPA). This clause requires US EPA to conduct CRA for human health 
effects that result from exposure to multiple chemicals with a common mechanism of toxicity.  
US EPA currently conducts CRA for five groups of pesticides: organophosphorus compounds, N-
methyl carbamates, s-triazines, chloroacetanilides and pyrethrins/pyrethroids. 
In all these cases, CRA begins with the identification of a common mechanism group where pesticides 
that induce a common toxic effect by a common mechanism of toxicity are grouped together. US EPA 
determines that a common mechanism of toxicity exists if chemicals act in the same way in the body, 
i.e. the same toxic effect occurs in the same organ or tissue by essentially the same sequence of 
biochemical events. If necessary, temporal aspects are also considered to determine exposure durations 
relevant for the induction of a common toxic effect. 
Common  mechanism  groups  are  then  used  to  define  common  assessment  groups,  essentially  by 
excluding substances whose uses, routes and pathways of exposure are deemed to contribute little to a 
cumulative risk. 
The earliest CRA was conducted for organophosphates in 1999, with the establishment of a common 
mechanism group based on the ability of these pesticides to inhibit acetylcholinesterase (AChE) by 
phosphorylation.  The  CRA  for  organophosphates  was  most  recently  updated  in  2006  (US  EPA, 
2006a). 
                                                       
 
8 Commission Regulation (EU) No 283/2013 of 1 March 2013 setting out the data requirements for active substances, in 
accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of 
plant protection products on the market. Official Journal L 93, 1-84. 3 April 2013. Cumulative Assessment Groups for Pesticides update 
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A second common assessment group encompasses N-methyl carbamates which also inhibit AChE, but 
by  carbamylation of a  serine in the active  centre  of  the  enzyme  (US  EPA,  2007).  In  contrast to 
organophosphates, there is fairly rapid recovery of the enzyme after maximal inhibition. Presumably, 
this was the justification for not grouping N-methyl carbamates and organophosphates together in one 
assessment group. 
Another assessment group is made up of s-triazine pesticides, consisting of atrazine, simazine and 
their common metabolites. These substances are judged to produce neuroendocrine and endocrine-
related developmental toxicity by a common mechanism involving disruption of the hypothalamic-
pituitary-gonadal axis (US EPA, 2006b). 
Chloroacetanilide  pesticides  that  produce  tumours  of  the  rat  nasal  olfactory  epithelium  via  the 
cytotoxic action of common tissue metabolites are also subjected to CRA (US EPA, 2006c). The 
corresponding common  mechanism groups consist of acetochlor, alachlor and butachlor, but only 
acetochlor and alachlor are subjected to CRA in a common assessment group, because butachlor has 
no registered uses in the USA.  
The most recent cumulative assessment deals with pyrethroids and pyrethrins (US EPA, 2011). These 
insecticides were included in a common mechanism group based on shared structural characteristics, a 
common  ability  to  interact  with  voltage-gated  sodium  channels,  resulting  in  the  disruption  of 
membrane  excitability  in  the  nervous  system,  and  finally  neurotoxic  effects  characterised  by  two 
different toxicity syndromes. US EPA considered it appropriate to include  ad interim all relevant 
substances together in a single CAG, selecting deltamethrin as Index Compound (IC). As low-hazard 
pyrethroids that do not induce the typical neurobehavioral effects at the limit dose of 5000 mg/kg bw, 
tetramethrin and sumithrin were not included in the common assessment group. Pyrethroids that are 
not detected as residues in crops were also excluded. 
In settings where non-pesticide chemicals are considered (e.g. for the assessment of superfund sites; 
United States federal law designed to clean up sites contaminated with hazardous substances), the US 
(1989) has developed approaches involving multi-step procedures for the classification of chemicals 
into groups suitable for CRA. Here, the process begins by grouping chemicals of concern according to 
their potential of occurring together in the same medium and at the same time. The groupings derived 
in this way are then divided into subgroups defined according to their propensity to cause common 
toxicity by common modes of action or in terms of their capability of affecting the same target organ. 
This approach has similarities to the IPCS tiered framework for CRA which uses dose addition as the 
default risk assessment method (IPCS, 2009; Meek et al., 2011). The IPCS framework is essentially 
exposure-driven. For each chemical included in the assessment, exposure and hazard assessments are 
conducted in a step-wise (tiered) manner, but separately. At lower tiers, fairly crude estimates can be 
used, and the analysis is discontinued when guidance values are not exceeded. Only when lower tier 
assessments signal potential risks, is the analysis refined by introducing higher quality exposure and 
hazard data. At lower tiers, all chemicals that co-occur in the setting under consideration can be 
included, irrespective of any assumptions about their modes of action. Groupings based on modes of 
action or mechanisms can be introduced at higher tiers, if necessary. The IPCS framework was applied 
in two cases studies, on polybrominated diphenyl ethers (PBDE) and surface water contaminants. 
Some guidance was given on factors that could be taken into account in CAG, e.g. chemical structure, 
identification of common potential toxicophores (structural alerts), similarity of target tissue and/or 
manifestations of toxicity. 
A  report  on  CRA  for  phthalates  and  other  antiandrogenic  chemicals,  and  their  impacts  on 
developmental toxicity, by the US National Research Council highlighted the shortcomings of using 
too narrowly focused mechanistic criteria as the basis for groupings (US NRC, 2008). The US NRC 
report  noted  that  several  phthalates  produced  joint  effects  with  other,  structurally  diverse  anti-
androgenic  substances.  The  NRC  Panel  recognised  that  disruption  of  male  sexual  differentiation 
depends  on  proper  androgen  action  in  foetal  life  and  concluded  that  the  available  experimental Cumulative Assessment Groups for Pesticides update 
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evidence showed that dose addition applied, despite the fact that androgen action can be diminished by 
a variety of mechanisms. Independent action-based prediction consistently led to underestimations of 
combination effects of these chemicals. On the basis of these observations, the US NRC proposed that 
a physiological concept based on common adverse outcomes should underpin decisions about the 
similarity of action of mixture components. It recognised that such similarity criteria go far beyond 
criteria derived from similarities in chemical structures. 
3.4.  Activities in the EU 
The  non-food  Committees  of  DG  SANCO  (Scientific  Committee  on  Consumer  Safety-SCCS; 
Scientific Committee on Health and Environmental Risks-SCHER; Scientific Committee on Emerging 
and Newly Identified Health Risks-SCENIHR) dealt with issues relevant to the grouping of chemicals 
in CRA in 2009 with an Opinion on the assessment of the antibiotic resistance effects of biocides 
(SCENIHR, 2009). One problem within the Biocides Directive 98/8/EC
9 is that cumulative risks that 
arise from the use of  an active substance outside the scope of the Directive ( e.g. in plant protection 
products, consumer products, human or veterinary medicines, food hygiene, etc.) are not addressed in 
the evaluation process. This was regarded as particularly problematic for the selection of antimicrobial 
resistant bacterial strains, which can arise from the combined action of different substances with 
diverse mechanisms when  these substances are in different regulatory domains. However, w ith the 
new  EU  Biocides Regulation  EC (No)  528/2012
10  further provisions  with  regard to cumulative 
assessments of biocides have been introduced taking into account such effects for the authoris ation 
process. Also a guidance document addressing the issue of cumulative effects is currently being 
developed. 
At the request of the European Commission, t he non-food Committees of DG SANCO (SCCS, 
SCHER, SCENIHR) produced a joint Opinion on the Toxicity and Assessment of Chemical Mixtures 
in 2011. Their conclusions broadly agreed with the EFSA PPR Opinion (2008). Relevant to the topic 
under consideration here is the observation of the committees that there  are a limited number of 
chemicals for which sufficient information on their mode of action is available. A n agreed inventory 
of mode of actions, as well as a defined set of criteria for ways of characterising or predicting modes 
of action in data-poor situations is missing. The committees also suggested the use of dose addition as 
a default in cases where evidence to the contrary is not available. 
3.5.  The grouping approach adopted by the PPR Panel - general considerations 
In defining CAGs to take cumulative effects into account in the decision on applications concerning 
MRLs,  the  Panel  has  chosen  to  follow  an  approach  that  focuses  on  shared  toxicity  profiles  of 
pesticides. In view of the mandate and the regulatory context in the EU, a purely exposure-driven 
grouping procedure was considered inappropriate, mainly because all authorised active substances 
used in pesticide formulations can theoretically occur in human diet.  
However, when the objective is to conduct risk assessments for combinations of pesticide residues in 
food, an exposure-driven approach according to the tiering principles developed by IPCS (2009) and 
also in the previous opinions of the PPR Panel (EFSA 2008, 2009) would be the method of choice. 
The Panel recognises that the use of the quite narrow mechanistic grouping criteria by US EPA is 
mandated by the US Food Quality Protection Act
11 with its focus on subjecting pesticides with a 
common mechanism of action to CRA. Such restrictions do not exist in the EU. The Panel shares 
concerns that quite narrowly defined mechanistic grouping criteria migh t leave out pesticides that 
contribute to common toxic effects. In the interest of consumer protection, a grouping approach which 
                                                       
 
9 Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal 
products on the market. Official Journal L 123 , 24/04/1998 P. 1 – 63. 
10 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making 
available on the market and use of biocidal products. Official Journal L 167, 27.6. 2012. 1- 123. 
11 Available from: http://www.epa.gov/pesticides/regulating/laws/fqpa/gpogate.pdf Cumulative Assessment Groups for Pesticides update 
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emphasises common adverse outcomes was adopted for the purposes of MRL setting. Where the 
relevant data were available, more refined groupings based on modes of action were made. 
In many cases, however, the lack of relevant data about modes of action and pathways leading to 
common adverse outcomes made it necessary to use common target organs as proxy. In choosing this 
approach, the Panel does not exclude that common effects in tissues, organs or physiological systems 
could be the result of different toxicity pathways. A second assumption underpinning this grouping 
approach was that pesticides with common toxicity pathways will elicit common toxic effects in an 
additive fashion. 
Accordingly,  the  groupings  were  based  on  common  toxic  effects  regardless  of  whether  these 
represented the critical effects that drive the risk assessment of single pesticides, i.e. the effects from 
which health-based guidance values such as acceptable daily intake (ADI) or acute reference dose 
(ARfD) are derived. 
   Cumulative Assessment Groups for Pesticides update 
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4.  Summary of the previous opinions - lessons learnt  
In 2008, the PPR Panel adopted an Opinion to evaluate the suitability of existing methodologies and, if 
appropriate,  the  identification  of  new  approaches  to  assess  cumulative  and  synergistic  risks  from 
pesticides to human health with a view to set MRLs for those pesticides in the frame of Regulation 
(EC) No 396/2005.  
Having  considered  the  evidence  on  the  different  forms  of  combined  toxicity  and  their  potential 
relevance to risk assessment for pesticide residues at the levels occurring in food, the PPR Panel 
limited this Opinion to the possible impact of dose-addition. In particular, the PPR Panel noted that 
although toxic interactions from pesticide residues in food cannot be ruled out, there is no empirical 
evidence for their occurrence at the expected levels of exposure from pesticide residues in food. This 
approach has since then been supported by the analysis carried out for the Scientific Report on the 
investigation of the state of the art of science on combined actions in food through dissimilar modes of 
action  and  proposal  for  science-based  approach  for  performing  related  CRA  (Kortenkamp  et  al., 
2012). 
The key steps leading to toxic effects and criteria by which to define a cumulative assessment group as 
proposed by the US EPA were outlined in the Opinion of 2008. These steps included the following;  
1. Preliminary identification of a candidate set of substances that might cause a common toxic effect 
by a common mode of action. This preliminary grouping is based on one or more of the following 
criteria: 
a. chemical structure. This can be explored by substructure searches in databases for toxophore (or 
a metabolic precursor of a toxophore), core molecular structure, functional groups; 
b. mechanism of pesticidal action. This is considered informative because it is not uncommon that 
pesticides are toxic to humans through a mechanism that is similar to that of their activity 
against their target pests; 
c. general mode/mechanism of mammalian toxicity; 
d. a particular toxic effect. It is conceivable that similar toxic effects by different compounds might 
be caused via a  common  mode/mechanism. This criterion might allow the identification of 
structurally unrelated substances that act by the same mode of action. It is emphasized that non-
specific effects such as body weight changes or death can result from many unrelated factors 
and  consequently  are  of  limited  value  in  identifying  potential  candidate  substances  for  a 
common mode/mechanism group. 
 
2. Identify those substances from step 1 that cause a common toxic effect(s). This step allows a first 
refinement  of  the  preliminary  grouping  described  above.  This  is  to  be  performed  by  detailed 
evaluation of available toxicology data for each substance and those not causing a common (i.e. 
concordant in both site and nature) toxic effect are excluded. 
 
3. Determine the toxic mode/mechanism of action by which each substance causes a common toxic 
effect.  
 
4. Compare the mechanisms of toxicity/modes of action of the different substances. 
 
5.  Refine  groupings  by  excluding  substances  that  cause  a  common  toxic  effect  by  a  different 
mechanism/mode of action. 
 
The PPR Panel concludes that full consideration of all of these criteria will provide the most sound 
and robust grouping. However, such a detailed evaluation up to the last step might not be necessary or 
even possible in all cases. For the purposes of risk assessment, compounds might be grouped even in 
the absence of such detailed data and thus on the basis of a less refined evaluation of the mode of 
action (e.g. based only on target organ toxicity).  Cumulative Assessment Groups for Pesticides update 
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An additional consideration arises from evidence in the literature that certain reproductive toxicants 
show dose-addition even if they do not share the same primary molecular target (Kortenkamp, 2007 
and papers there reviewed). Therefore, the issue is the definition of the concept of common mode of 
action and what this would mean for these reproductive toxicants. For instance, compounds affecting 
male  sexual  development  via  interference  with  steroid  synthesis  and  not  by  antagonism  of  the 
androgen receptor would not be grouped according to a narrow definition of mode of action whereas it 
has been shown that a mixture of such compounds results in a dose-additive effect (Gray et al., 2001; 
Hotchkiss et al., 2004; Jacobsen et al., 2012; Hass et al., 2012). Similar considerations can be applied 
to estrogenic or estrogen-like chemicals (Picard, 2003). Therefore, it appears that in these cases the 
criterion for grouping should rather be that of a common phenomenological effect (e.g. altered ano-
genital distance for antiandrogens) (Kortenkamp, 2007). 
Following this opinion, an exercise to test the proposed methodology on CRA was applied to a group 
of  triazole  fungicides,  and  the  results  were  reported  in  a  separate  Opinion  with  any  suggested 
refinements necessary to the methodology. This Opinion of the PPR Panel was adopted in June 2009. 
The triazole exercise was not to be considered as the definitive EU risk assessment of the combined 
triazole  group,  but  rather  as  a  worked  example,  which  illustrated  and  tested  the  proposed 
methodology. 
Thus, in the triazole Opinion the proposed CRA methodology was applied to a selected group of 
substances. The  grouping  was  based  on  the  structure  of  the  substances,  i.e.  the  triazole  ring,  the 
pesticidal mode of action i.e. the inhibition of the sterol biosynthesis (C14-demethylase), and the mode 
of  action  that  cause  a  common  toxic  effect  collected  from  DARs,  JMPR  reports  or  US  EPA 
assessments. For acute assessment, cranio-facial malformations induced by triazoles were ascribed to a 
common mechanism of toxicity. In the chronic assessment the triazoles liver toxicity was the common 
adverse outcome used. A common  mode of action has not been established for these effects and 
further refinement of the grouping was not possible for this group of pesticides. 
The previous opinions (EFSA, 2008, 2009) dealt with possible models for a CRA, encompassing 
hazard  and  exposure  assessment  and  proposing  a  tiered  approach.  According  to  the  Terms  of 
Reference, the current Opinion deals therefore only with hazard assessment and the identification of 
CAGs based on toxicological profiles of pesticides.  
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5.  Supporting projects 
5.1.  Identification of cumulative assessment groups for pesticides  
EFSA commissioned the Danish Technical University (DTU) to form Common Assessment Groups 
based on organ specific effects for active substances included in Annex I of Directive 91/414/EEC
12 
(up to 31
st of May 2009). Active substances were considered for CRA if these were chemically well-
defined and if there was adequate toxicological data available for the substances of interest. Active 
substances not considered for grouping were micro-organisms, complex and poorly defined mixtures 
of chemicals (e.g. pheromones), those with insufficient toxicological data, and substances considered 
as having no harmful effects on human and animal health (i.e. with no established reference value). As 
a result, 224 of the 344 active substances in Annex I were considered relevant by DTU. 
Information on toxicological effects and modes/mechanisms of action was collected from EU peer 
reviewed  documents  (e.g.  draft  assessment  reports  (DARs),  ECCO  and  EPCO  assessments). 
Additional  relevant  toxicological  information  was  collected  from  Joint  FAO/WHO  Meeting  on 
Pesticide Residues (JMPR) reports and from the open literature. 
The criteria for grouping proposed by the PPR Panel in 2008 was the starting point for the outsourced 
work  performed  at  DTU.  It  was  soon  recognised  during  the  review  of  the  active  substances  for 
inclusion in cumulative assessment groups, that there was often little or no data available on mode of 
action  but  that  many  substances  affected  the  same  target  organ  and/or  cell  population.  Thus,  the 
grouping methodology proposed by DTU was based on phenomenological effects of the substances 
and the following approach was applied:  
 
  CAG level 1: Toxicological target organ 
  CAG level 2: Common specific phenomenological effect  
  CAG level 3: Common mode of action 
  CAG level 4: Common mechanism of action 
 
CAG level 1. The initial screening of toxic effect(s) on target organ/organ systems resulted in an 
allocation of active substances into CAGs at level 1. Many of the substances showed effects on several 
organ/organ systems and were therefore allocated into more than one CAG.  
The following organ systems were suggested for CRA: adrenal gland, bone marrow, bones/skeleton, 
cardiovascular  system,  eye,  gallbladder,  haematological  system,  kidney,  liver,  muscles,  nervous 
system,  parathyroid  gland,  reproductive  system  and  developmental  toxicity,  spleen,  thyroid  and 
urinary bladder. CAGs for CRA were not recommended for the gastrointestinal tract, immune system, 
lung, lymph node, pancreas, pituitary gland, salivary gland, skin and thymus. 
 
CAG level 2. This group was proposed to include substances that exert a specific phenomenological 
effect on the target organ/organ system in question without any consideration of mode of action. In 
many cases, an active substance was found to lead to several specific phenomenological effects in a 
given target organ/organ system. The reason for this is that the proposed different specific effects 
could  be  considered  as  representing  a  continuum  of  pathological  findings  for  a  given  target 
organ/organ system.  
Wherever possible, NOAELs and LOAELs were noted in each study for each effect. For many of the 
specific effects, NOAELs and LOAELs were identical to or even higher than the NOAEL and LOAEL 
of the study used to set regulatory reference values. 
                                                       
 
12 Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market. Official 
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In  assessing  adversity,  some  effects  are  considered  in  single  substance  assessment  as  being  non-
adverse if they occur below a certain limit. For CRA, the DTU considered it not relevant to distinguish 
between adverse and non-adverse effects based on limits because the accumulated increase caused by 
several substances, each contributing with an increase under the specified limit, may exceed the limits. 
There were cases in which effects for individual substances were observed after a short period of 
exposure,  but  became  undetectable  in  the  course  of  prolonged  exposure.  Such  effects  might  be 
considered adaptive for single substance assessment, but DTU considered that it could not be excluded 
that an organism will not be able to adapt if exposure occurs to several substances simultaneously. 
Accordingly,  an  effect  was  regarded  as  being  adverse  even  if  it  was  no  longer  measurable  after 
prolonged exposure. 
CAG level 3. This group was proposed when information or a hypothesis was available on a common 
mode of action behind a specific effect. For a number of specific effects data did not allow for further 
allocation of substances into CAGs at level 3. For some of the organ systems, for example for parts of 
the endocrine system and the nervous system, modes of action were proposed.  
CAG level 4. For some of the active substances, mainly in vitro data reported in the open literature 
could support a further refinement of the mode of action at level 3, and hence a specific mechanism of 
action could be proposed. For example, active substances that are acetylcholinesterase inhibitors (and 
thus modulate the cholinergic system; CAG level 3) or active substances being antagonistic to the 
androgen receptor (and thus affecting for example the male reproductive organs via anti-androgenic 
mode of action; CAG level 3) were allocated to a CAG at level 4.  
All together, this resulted in (i) a number of groups that could not be further refined into CAGs at level 
3 and 4 because data on mode/mechanism of action for many endpoints were inconclusive, (ii) the 
groups proposed were, therefore, mostly for phenomenological effects, i.e. CAG level 2, (iii) due to 
lack of mechanistic data many of the proposed groups contain several substances, and (iv) many of the 
substances caused several effects and were therefore allocated into more than one CAG of the same 
level. Since many active substances appear in many groups, the data entries for performing CRA are 
of considerable magnitude. 
In association with an external scientific report, published in April 2012 by the DTU, a database 
(CAPEG) was developed. The database fields contain toxic effects and respective indicators that can 
be used for establishing common assessment groups on which a CRA could be performed. Also, 
NOAELs and LOAELs were listed for each effect in the database.  
The DTU collection and assessment of the active substances included in Annex I prior to 31
st of May 
2009 was evaluated by the present working group, which concluded that further consolidation of the 
outcome of the DTU evaluation was needed. This consolidation was performed jointly by working 
group members and staff of the Pesticides Unit at EFSA.  
5.2.  Toxicological  data  analysis  for  effects  on  the  liver,  on  the  nervous  system  and  on 
reproduction and development 
As a result of the consolidation exercise performed on the DTU study output, EFSA launched a call 
for tender “Toxicological data analysis to support grouping of pesticide active substances for CRA of 
effects  on  the  liver,  on  the  nervous  system  and  on  reproduction  and  development” 
(ANSES/ICPS/RIVM,  2013),  which  was  awarded to  a  consortium  of  the  International  Centre  for 
Pesticides and Health Risk Prevention (ICPS; Italy), the National Institute for Public Health and the 
Environment  (RIVM;  The  Netherlands),  and  the  French  Agency  for  Food,  Environmental  and 
Occupational Health and Safety (ANSES; France) which lead the project. In addition to the pesticides 
evaluated by DTU, 60 new active substances were added to Annex I from 31
st of May 2009 until 1
st of 
January 2012, and 3 pesticides (flurtamone, oxadiargyl and pyridate) not screened by the DTU were 
also evaluated.  Cumulative Assessment Groups for Pesticides update 
 
 
23  EFSA Journal 2013;11(7):3293 
In total, 260 substances were found to have reproductive and developmental effects by ANSES, 68 
substances were found to be neurotoxic by RIVM, and 244 substances were found to cause effects on 
the liver and biliary system, including the gallbladder by ICPS. All the findings (endpoints) that were 
indicated in the contract as indicative for those effects have been reported for each substance, with 
their  respective  NOAELs/LOAELs.  The  selection  of  NOAELs  and  LOAELs  was  performed,  as 
requested by EFSA, without any interpretation of whether an effect is to be considered adverse or not 
adverse. In the report, established or postulated mode of action was reported as well as reference to 
possible sources of information in this respect, which mostly included the open literature. No in-depth 
analysis  of  proposed  or  postulated  mode  of  action  was  performed.  The  authors  of  the  report 
recommended that further work on the establishment of cumulative assessment groups for these organ 
systems should be done by specialists in these areas. 
A comprehensive database with the information collected was provided by the contractors. The data 
collection of neurotoxic effects was the basis for the proposal of cumulative assessment groups for the 
nervous system in this opinion. 
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6.  Grouping methodology  
This  section  describes  the  criteria  developed  for  selecting  specific  effects  of  pesticidal  active 
substances  as  a  basis  to  determine  cumulative  assessment  groups.  The  methodology  has  been 
developed on the basis of toxicity studies involving oral exposure to take into account cumulative 
effects on human health potentially resulting from exposure to a combination of active substances as 
described in the Regulation (EC) 396/2005 on maximum levels of pesticides in or on food and feed of 
plant and animal origin and amending Council Directive 91/414/EEC. The methodology developed 
might  be  applicable  also  for  dietary  and  non-dietary  CRA.  This  general  methodology  deals  with 
grouping of active substances showing common specific effects and was initially applied for grouping 
of active substances affecting the nervous system and the thyroid system. In the future, the approach 
should be implemented upon dealing with specific issues with regard to all other relevant organs and 
organ systems.  
During  the  process  of  the  grouping,  the  Working  Group  took  note  of  any  demonstrated 
modes/mechanisms of action and also on how some effects may be related to each other. Wherever 
possible, the identified effects were qualified with regard to their nature as either acute or chronic for 
the organ system evaluated. 
The  PPR  Panel  notes  that  the  CAGs  in  this  Opinion  based  on  the  outlined  approach  would  be 
provisional.  Groups  are  expected  to  change  if  new  pesticides  are  included,  if  new  data  allows 
exclusion of pesticides from a group, or if new mechanistic data provide more evidence for a specific 
mode of action as a more appropriate basis for a CAG.  
In current practice, mechanistic information, which allows understanding of the ultimate biochemical 
events (or mode of action) causing the different toxic effects, is normally not required in regulatory 
toxicology of pesticides and is therefore generally lacking.  
Consequently, in this Opinion an approach was followed whereby active substances were grouped 
based on the occurrence of toxicologically relevant and unambiguously defined effects on the target 
organ i.e. on specific effects, even if the underlying initial biochemical events causing these effects 
have not (yet) been demonstrated experimentally.  
This methodology elaborates CAGs at several levels; CAG level 1 at organ/organ system level; CAG 
level  2  based  on  specific  phenomenological  effects;  and  potentially  further  refinement  based  on 
information about the specific mode of action.  
This approach follows the recommendations given by the Commission to the PPR Panel with regard to 
grouping, suggesting that in the absence of information a precautionary approach should be followed 
i.e. an “exclusion approach”. This may result in the grouping of substances in the same CAG, although 
they might exert their effects through dissimilar mode of actions. 
The methodology developed comprises four main steps: 
6.1.  Step 1: Identification of specific effects appropriate for grouping for CRA 
This section describes how the effects observed in toxicological studies should be selected as relevant 
effects for CRA. 
The identification of specific effects result from a screening procedure as described below. 
6.1.1.  Step 1.1: Exclusion of local effects 
Local effects mainly refer to health effects that take place at the point or area of contact by a chemical-
physical  action  rather  than  a  biochemical  action.  They  can  be  induced  for  instance  by  caustic 
substances or by corrosive materials, e.g. internally in the gastrointestinal or externally on skin and in 
eyes.  Cumulative Assessment Groups for Pesticides update 
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Local effects are not produced by the potentially absorbed dose. Thus, they are not systemic effects 
and do not form the basis for the setting of reference values for dietary risk assessment. Local effects 
are, therefore, not to be considered as specific effects of combined toxicity to support MRL setting. 
6.1.2.  Step 1.2: Exclusion of non-adverse effects 
The distinction between adverse and non-adverse observed effects is crucial to ensure proper hazard 
identification and is a matter of expert judgement.  
In discriminating between an adverse and a non-adverse effect, consideration is given to its adaptive 
nature, its transient or persistent nature, its magnitude, its association with other alterations, whether it 
is a precursor to a more relevant effect, and its impact on the overall function of the organism (Lewis 
et al., 2002). 
Adaptive responses may not be considered adverse for single exposure. They consist of the initial 
response of the organism to maintain homeostasis, and can be defined as those biological effects that 
do  not  cause biochemical,  physiological,  and  morphological  changes  that  affect the  general  well-
being, growth development or lifespan of the organism (Lewis et al., 2002). In general, effects that are 
non-adverse do not qualify for the basis of setting either a NOAEL or a LOAEL (JMPR, 2005).  
As  recommended  in  the  DTU  report,  some  effects  which  are  considered  in  single  substance 
assessment as being non-adverse if occurring below a certain limit of magnitude were considered in 
the proposed methodology as being potentially adverse and thus relevant within the context of CRA. 
There  are  cases  in  which  effects  for  individual  substances  are  observed  after  a  short  period  of 
exposure,  but  become  undetectable  in  the  course  of  prolonged  exposure.  Such  effects  might  be 
considered  adaptive  for  single  substance  assessment.  However,  it  cannot  be  excluded  that  an 
organism‟s  capacity  for  adaptation  will  be  exhausted  if  there  is  exposure  to  several  substances 
simultaneously. Accordingly, an effect was regarded as being adverse even if it becomes undetectable 
after prolonged exposure. 
6.1.3.  Step 1.3: Exclusion of effects not relevant for human risk assessment 
Effects observed in animal studies have to be assessed also for their relevance to humans before being 
selected as a basis for CRA. Effects not considered as relevant for human risk assessment should not 
be  used for inclusion  of chemicals in  CAGs.  In  the  absence  of  specific  data  demonstrating  non-
relevance, the default assumption is that effects are relevant to humans. 
The expression of toxicity in mammalian systems is dependent on a sequence of key events taking 
place. Thus, for a particular effect, it is necessary to justify the irrelevance to humans. This might be 
possible for effects observed in organs of laboratory animals where there is no equivalent in humans 
and should therefore not be considered for CRA (e.g. the Harderian and Zymbal glands of rats where 
tumours can occur).  
6.1.4.  Step 1.4: Evaluation of the unambiguous nature of the effect 
When performing CRA, it is important that a specific effect considered as relevant is unambiguous 
and well-defined in terms of site and nature. In some instances it is known that the chain of events 
leading to an effect is caused by a single biochemical event (e.g. acetylcholinesterase inhibition). 
When an adverse effect appears in isolation and not in relation to other effects/parameters or patterns 
this should be interpreted very carefully.  
Similarly also after long term exposure any results must be interpreted carefully since they can be 
confounded with effects caused by aging or other physiological processes. Cumulative Assessment Groups for Pesticides update 
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6.1.5.  Step 1.5: Identification of non-specific effects 
Non-specific effects resulting from severe toxicity are not considered relevant for CRA in accordance 
to the DTU report, e.g. acute clinical effects in the presence of mortality. 
However, non-specific effects, being the consequence of a primary effect, in certain cases can be used 
for CRA, if such non-specific effects are not the result of severe toxicity and if a mode of action is 
identified, showing that the non-specific effect, together with the specific effects, might contribute to a 
common outcome. Therefore non-specific effects can also lead to inclusion of substances in groups 
with possibly different modes of action, leading to conservative grouping.  
As an example, a reduction in circulating thyroid hormone levels may be due to different modes of 
action,  some  of  which  directly  affect  the  thyroid  itself  (e.g.  via  inhibition  of  thyroid  hormone 
synthesis).  However,  a  decrease  in  circulating  thyroid  hormone  levels  may  also  occur  as  a 
consequence of enhanced hormone metabolism, owing to enzyme induction mainly in the liver. In this 
case, a challenge to the thyroid hormone system would be regarded as “non-specific” being “indirect” 
or a “secondary”consequence of the specific effect of enzyme induction. However, if several modes of 
action (direct and indirect) feed into a common adverse outcome (e.g. decrease in circulating levels of 
hormones),  it  appears  feasible  not  to  disregard  the  indirect  mode  of  action  for  CRA.  This  is 
exemplified  in  further  detail in  the  Appendix  E  on  grouping  for  substances affecting  the  thyroid 
system. It is noted that only in rare cases mechanistic information could be derived from the DARs. 
Overall, non-specific effects in terms of mode of action need to be assessed on a case by case basis 
following a weight of evidence approach and expert judgement.  
6.2.  Step 2: Characterisation of the specific effects 
After  identification  of  the  specific  effects  of  relevance  for  cumulative  assessment  grouping  for  a 
particular organ/system, it is necessary to characterise these effects, in a consistent way, to decide 
which sub-groups might be distinguished on a phenomenological basis. In particular, it should be 
investigated whether or not several effects may be interrelated. Several different effects may have a 
common general mechanistic basis, or may be the result of toxicity towards a common general target 
structure.  For  example, toxicity  to the  autonomic  nervous  system,  identified in  this  Opinion  as a 
specific effect, may manifest itself in form of a number of different observations, designated in this 
Opinion  as  indicators,  including  miosis,  salivation,  lacrimation  and  urination.  Furthermore,  some 
indicators for a specific effect may be linked to one another by a chain of events. As an example, a 
decrease in circulating thyroid hormone levels would be expected to lead to an increase in TSH levels, 
which would result in stimulation of thyroid follicular cells. Prolonged stimulation of follicular cells in 
the rat may lead to development of follicular cell tumours. If several such observations (or indicators) 
are connected to one another by a chain of events, it is recommended to establish the order of their 
sequential occurrence (as a list of indicators for the CAG).  
In cases in which different indicators are interrelated, these effects may be used to define a common 
phenomenological sub-group. If data on underlying modes of action leading to specific effects are 
available,  they  should  be  considered  to  decide  whether  a  further  refinement  of  grouping  may  be 
feasible. It is noted, however, that information on the causal mode/mechanism of action is missing for 
the majority of the effects observed in toxicological studies.  
The characterisation of the specific effect, the underlying mode of action leading to it, and the possible 
interrelationship between different specific effects is done case by case and is a matter of expert 
judgement. 
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6.3.  Step 3: Data Collection 
After identification and characterization of specific effects and their respective indicators (measured 
endpoints)  for  each  target  organ/organ  system,  the  available  toxicological  data  for  each  active 
substance should be collected. Active substances not considered were micro-organisms, complex and 
poorly defined mixtures of chemicals (e.g. pheromones), those with insufficient toxicological data, and 
substances  considered  as  having  no  harmful  effects  on  human  and  animal  health  (i.e.  with  no 
established reference value). As a result, 224 of the 344 active substances in Annex I (up to 31
st of 
May 2009) were selected by DTU. The same criteria were applied to the active substances included in 
Annex I from 31
st of May 2009 until 1
st of January 2012, resulting in 60 new substances to be screened 
for  CRA.  Three  substances  previously  excluded  by  DTU  were  also  added  to  the  list  of  active 
substances to be screened. The active substances screened for neurotoxicity and thyroid toxicity are 
presented in Appendix H. 
Based on a screening of relevant regulatory toxicity studies, i.e. those studies considered acceptable 
during the peer review of active substances, the retrieved data should include all the relevant indicators 
of a specific effect observed in one or more studies. Specifically, the following information should be 
collected for grouping and further CRA. 
 
  Name of the active substance 
  Target organ/organ system 
  Chemical class 
  Chemical name (IUPAC) 
  CAS number 
  Pesticidal mode of action 
  Study type 
  Species 
  Strain 
  Route of administration 
  Type of administration 
  Indicator (measured endpoint) of a possible common specific effect 
  Specific NO(A)EL acute (mg/kg bw): after single administration 
  Specific LO(A)EL acute (mg/kg bw): after single administration 
  Remarks related to the indicator (used to insert further details about the effect) 
  Remarks related to the study (acceptability, GLP, Guidelines, overall NOAEL, etc.) 
  Specific NO(A)EL rpd (mg/kg bw/day): after repeated administration 
  Specific LO(A)EL rpd (mg/kg bw/day): after repeated administration 
  Remarks related to the indicator (used to insert further details about the effect) 
  Remarks related to the study (acceptability, GLP, Guidelines, overall NOAEL, etc.) 
  Mode/mechanism of action (MoA); known/unknown/presumed 
  Remarks on mode/mechanism of action 
  Reference to the study (author, year) 
  Source of information to the toxicity studies 
  Year of evaluation (publication of EFSA conclusion/Commission‟s review report) 
  Remarks on EFSA conclusion (derivation of the ADI and ARfD, etc) 
 
For dietary CRA, only toxicity studies performed by oral administration (diet, capsule, gavage) should 
be considered. 
In cases in which different specific effects are interrelated, it is recommended to establish the most 
appropriate indicator of a specific toxicological response in the most appropriate/sensitive species. 
After ranking all related specific effects serving as indicators of a specific toxicological response in 
sequential order, it may be that data for all indicators are not available for all the pesticides causing Cumulative Assessment Groups for Pesticides update 
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this specific response. In particular, data to establish the NOAEL for the specific effect may be lacking 
for the most sensitive indicator. In this case, the NOAEL should be established on the basis of the 
alteration of the second-most sensitive indicator. 
6.4.  Step 4: Cumulative Assessment Groups 
Establishment of CAGs for effects on the nervous system was chosen since these effects were a priori 
considered as highly relevant with regard to potential cumulative effects and considering the fact that 
the data collection could discriminate CAGs into acute and chronic effects. Effects on the thyroid 
system were, on the other hand, considered since the thyroid is a frequent target of pesticide toxicity 
and the effects may be an example of potential toxicity to the endocrine system.  
The  PPR  Panel  has  already  carried  out  substantial  work  on  the  establishment  of  many  CAGs  in 
addition to those already presented in the current opinion. Because elaborations on these additional 
CAGs have not been completed they are not mentioned in the opinion. Nevertheless, this work should 
be considered as a starting point for further work on CAGs.  
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7.  Grouping methodology for the nervous system 
7.1.  Hazard identification and characterisation for neurotoxicity (Step 1 and 2) 
In the DTU report (2012), the first level for CAG was defined as „Toxicity to the nervous system‟ as 
the nervous system was identified as a relevant target for some active substances. 
The methodology for hazard identification and characterisation of toxic effects of active substances on 
the  nervous  system  combines  information  provided  by  DTU  (DTU,  2012)  and  RIVM 
(ANSES/ICPS/RIVM,  2013).  These  were  further  confronted  with  information  from  US  EPA  and 
IPCS/WHO reports. The three major functional divisions of the nervous system (motor, sensory and 
autonomic) were identified as potential targets for these substances along with the neurochemistry and 
neuropathology parameters. 
CAG level 1 (organ/organ systems level) 
The most conservative level of grouping on a physiological basis comprised all substances affecting 
the nervous system either central or peripheral. 
 
CAG level 2 (refinement at the effect level) 
Further refinement of grouping on the phenomenological level was based on different general targets 
concerning neurotoxicity and was therefore recommended for neurotoxic hazard characterisation: 
  Effects on motor division (e.g. locomotor activity, muscle strength, coordination and 
equilibrium). 
  Effects on sensory division (e.g. including reflex action or sensory-motor responses and 
neurophysiological assays). 
  Effects on autonomic division (e.g. cholinergic modulation). 
  Neurochemical effects (e.g. brain or erythrocyte acetylcholinesterase inhibition). 
  Neuropathological effects (mainly axonal and myelin degeneration). 
 
The most appropriate indicators for the specific effects are shown in the table for hazard identification 
and characterisation (Table 1). 
Developmental neurotoxicity (DNT) should also be considered for hazard characterization. However, 
specific DNT testing has not been conducted according to OECD guideline 426 since it was developed 
in 2007 (OECD, 2007). Accordingly, the CAGs for DNT effects cannot be considered conclusive 
because the experimental studies available for risk assessment were restricted to developmental and 
reprotoxicity testing. Since results for DNT testing were only available for a few active substances 
(dimethoate,  fenamiphos,  fipronil,  malathion  and  molinate)  DNT  effects  were  not  grouped.  Also, 
because available toxicological data from DARs did not contain sufficient information on effects on 
the cognitive domain (learning and memory), this domain was not considered for grouping.  Cumulative Assessment Groups for Pesticides update 
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Table 1:  Hazard identification/characterisation for neurotoxicity  
  Hazard Identification (Step 1) 
 
Hazard characterisation 
(Step 2) 
Specific effect  Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for humans 
Yes/No 
Remarks 
Unambiguous 
unique 
Yes/No
 
Remarks 
Non-specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall remarks/ 
conclusions 
Most appropriate 
indicator for effect
 
(see Notes 1 and 3) 
Motor division   No  Yes  Yes  Yes 
 
See also 
column 
‘Relevant for 
CRA’. 
 
No 
 
In the 
absence of 
information 
suggesting 
such effects 
being 
related to 
specific 
effects which 
might be 
found when 
doing step 
3). 
Unknown for 
pesticide active 
substances 
 
Overall no 
general MoAs 
for these effects 
(for OPs and N-
methylcarbamat
es modulation of 
cholinergic 
transmission – 
see Note 2). 
Yes 
 
However, if these 
effects result only at 
the high dose and 
together with other 
overt signs of 
toxicity, there is 
less persuasive 
evidence of a direct 
neurotoxic effect. 
Reduced motor activity: 
hypoactivity, recumbency, 
lateral posture, etc. 
Increased motor activity: 
tremor, choreo-athetosis, 
hyperactivity , 
convulsions, etc. 
Muscle strength: 
reduced grip strength, 
increased or decreased 
muscle tone, muscle 
fasciculation, weakness, 
ptosis, inability to stand, 
paresis, paralysis, etc. 
Coordination: 
ataxia, abnormal gait, 
landing foot splay, etc. 
 
Sensory division 
(including 
sensorimotor 
reactivity) 
No 
 
Except 
paraesthes
ia, see 
Note 4. 
Yes  Yes   Yes 
 
See also 
column 
‘Relevant for 
CRA’. 
No 
 
In the 
absence of 
information 
suggesting 
such effects 
being 
related to 
specific 
effects which 
Unknown for 
pesticide active 
substances 
 
Overall no 
general MoAs 
for these effects. 
 
Yes 
 
However, if these 
effects result only at 
the high dose and 
together with other 
overt signs of 
toxicity, there is 
less persuasive 
evidence of a direct 
neurotoxic effect. 
Decreased reactivity: 
Hyporeactivity, righting 
reflex (air drop), touch 
response (handling 
reactivity), approach 
response, pupil response, 
tail pinch response, 
analgesis reflex 
(nociception response), 
patellar reflex, etc. 
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  Hazard Identification (Step 1) 
 
Hazard characterisation 
(Step 2) 
Specific effect  Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for humans 
Yes/No 
Remarks 
Unambiguous 
unique 
Yes/No
 
Remarks 
Non-specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall remarks/ 
conclusions 
Most appropriate 
indicator for effect
 
(see Notes 1 and 3) 
might be 
found when 
doing step 3. 
Increased reactivity: 
Hyperreactivity, 
exaggerated auditory 
response (startle reflex), 
etc. 
 
Propioception: 
Propioception deficit, 
paraesthesia, 
hyperaesthesia, etc. 
 
Autonomic 
division  
No  Yes  Yes  
 
The effects 
also occur in 
humans. 
In principle 
yes  
 
See also  
Notes 1 and 3. 
 
No  
 
In the 
absence of 
information 
suggesting 
such effects 
being 
related to 
specific 
effects which 
might be 
found when 
doing step 3. 
Unknown 
 
No info in DTU 
or preliminary 
RIMV reports. 
Public literature 
to be screened. 
Overall no 
general MoAs 
for these effects 
with the 
exception of 
AChE inhibition 
by OPs and N-
methylcarbamat
es (see Note 2). 
 
Yes 
 
However, if these 
effects result only at 
the high dose and 
together with other 
overt signs of 
toxicity, there is 
less persuasive 
evidence of a direct 
neurotoxic effect. 
Miosis, mydriasis, 
salivation, lacrimation, 
urination, etc. 
Neurochemical 
effects 
No  Yes  
 
Under 
Yes  
 
The effects 
Yes  No 
 
However, 
Known 
 
Modulation of 
Yes 
 
A statistically 
Brain AChE inhibition 
Erythrocyte AChE 
inhibition Cumulative Assessment Groups for Pesticides update 
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  Hazard Identification (Step 1) 
 
Hazard characterisation 
(Step 2) 
Specific effect  Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for humans 
Yes/No 
Remarks 
Unambiguous 
unique 
Yes/No
 
Remarks 
Non-specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall remarks/ 
conclusions 
Most appropriate 
indicator for effect
 
(see Notes 1 and 3) 
certain 
conditions; 
see column 
‘Relevant for 
CRA’. 
also occur in 
humans. 
many 
pesticide 
classes 
induce 
oxidative 
stress that 
may lead to 
a decrease 
in 
erythrocyte 
AChE 
activity (see 
Note 5). 
cholinergic 
transmission. 
significant 
inhibition of brain, 
peripheral nerve or 
erythrocyte AChE ≥ 
20% is considered 
toxicologically 
relevant 
(‘adverse’). The 
inhibition of 20% 
may be considered 
with respect to the 
concurrent control 
group or with 
respect to the ‘pre-
exposure’ values in 
the treated group. 
 
Neuropathological 
effects 
No  Yes  Yes  Yes  No  Unknown  Yes 
 
Sciatic nerve 
axonopathy, 
without concurrent 
changes in motor 
neurons or spinal 
tracts, may be 
consistent with an 
increase of age-
related effects due 
to systemic toxicity 
and diminished 
repair capacity of 
Axonal degeneration, 
myelin degeneration, 
neuronal 
degeneration/necrosis, 
dilated ventricles, etc.  Cumulative Assessment Groups for Pesticides update 
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  Hazard Identification (Step 1) 
 
Hazard characterisation 
(Step 2) 
Specific effect  Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for humans 
Yes/No 
Remarks 
Unambiguous 
unique 
Yes/No
 
Remarks 
Non-specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall remarks/ 
conclusions 
Most appropriate 
indicator for effect
 
(see Notes 1 and 3) 
the nerve. 
Developmental 
neurotoxicity 
(DNT) 
No  Yes  Yes  Yes  No 
 
Current 
information 
is 
inadequate 
to assume 
that 
development
al effects at 
doses 
causing 
minimal 
maternal 
toxicity 
result only 
from 
maternal 
toxicity. 
Unknown  Yes 
 
However, the high 
rate of proliferation 
and regeneration in 
the developing 
nervous system may 
lead to greater 
recovery or 
plasticity which 
could attenuate 
some injuries. 
Neuropathology (brain 
morphometry and weight), 
motor activity, auditory 
startle, behavioural 
ontogeny (righting reflex, 
swimming performance), 
learning and memory 
testing. 
 
Notes:  
 
1)  Given the complexity of the nervous system that detects, integrates/interprets and responds to internal and external stimuli through nerves to effector organs (such as 
muscles and glands), the indicators assessed in neurotoxicology studies are not simple in nature and there are gaps of knowledge as to their physiological basis. This 
also precludes identification of the actual mode of action. 
2)  For organophosphates (OPs) and N-methylcarbamates, some motor, sensory and autonomic responses assessed by functional observational battery (FOB) may be 
based on acetylcholinesterase (AChE) inhibition. However, all these neurotoxic endpoints are considered together for risk assessment purposes. 
3)  A battery of functional tests, in contrast to a single test, is usually needed to evaluate the full complement of nervous system functions in animals. Cumulative Assessment Groups for Pesticides update 
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4)  Paraesthesia may be elicited by dermal exposure of either pyrethrins or pyrethroids, thus it can be considered as a local effect (ATSDR, 2003). 
5)  Since AChE is a membrane bound enzyme, oxidative stress induced by pesticide exposure may indirectly decrease AChE activity (Banerjee et al., 1999). Accordingly, 
AChE depression observed with pesticides other than OPs or N-methylcarbamates should be considered as an indirect effect. 
6)  The different specific effects relevant for inclusion of substances in CAGs have been shaded in different colours Cumulative Assessment Groups for Pesticides update 
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7.2.  Data collection for the nervous system (Step 3) 
After identifying and characterizing the specific effects for the nervous system, a standardised and 
thorough  review  of  relevant  in  vivo  regulatory  toxicity  studies  was  performed  for  all  pesticides 
considered  relevant  for  CRA  (as  described  in  chapter  6.3:  Data  collection).  The  collection  of 
toxicological data was performed by RIVM and EFSA (Appendix B) and includes only pesticides with 
an effect on the nervous system. The data collection contains information on 91 active substances, 
which are listed in Appendix H. A total of 68 active substances were identified by RIVM as having 
specific effects on the nervous system or as showing potential neurotoxic effects and 23 additional 
substances were identified by EFSA (24 if considering also Lufenuron, already included in the data 
collection performed by RIVM).  
Specific considerations for the data collection for neurotoxicity are as follows: 
Single and repeated dose studies were taken into consideration: for each specific effect, an acute or 
chronic  NO(A)EL/  LO(A)EL  was  selected  from  either  an  acute  or  short/long-term  experimental 
animal study. 
In most cases, LD50 studies were not considered by RIVM but are listed by EFSA with additional 
information in the data collection regarding dose-related effects or possible mode of action (e.g. a 
consequence of severe systemic toxicity). 
Doses  provided  in  the  DARs  in  ppm  were  converted  to  mg/kg  bw/d  using  conversion  factors 
recommended by the EFSA Scientific Committee (EFSA, 2012a).  
7.3.  CAGs for the nervous system (Step 4) 
Two tables have been developed for grouping active substances, for acute and chronic effects on the 
nervous system (see Appendix C and D). Data were tabulated according to the specific effects on the 
nervous system, their relevant  indicators, the active substance, its mode of action and the lowest 
experimental toxicity indices (NO(A)EL and LO(A)EL) were selected for each specific indicator of 
neurotoxicity.  Considering  the  concurrence  of  effects  occurring  in  an  unpredicted  manner  in  the 
nervous system, the specific effects were not ranked by a sequential order of indicators of effects. 
Sometimes the indices derived from several toxicological studies reported in the DARs. 
Despite the fact that several  non-specific effects  were also described in the data collection, these 
effects  were  not  considered  for  grouping.  The  same  applied  to  those  effects  that  occur  after 
administration of high doses resulting in severe systemic toxicity. Also, substances that are used on 
non-edible plants were not considered for grouping.  
7.3.1.  Acute cumulative assessment groups for neurotoxicity 
Of the 91 substances evaluated, 47 substances were included in the acute cumulative assessment group 
in  which  45  substances  showed  effects  on  motor  division,  20  on  sensory  division,  and  29    on 
autonomic division. Some substances showed more than one effect and/or indicator and they were 
either observed at the same or similar NO(A)EL/LO(A)EL, possibly indicating a different sensitivity 
for the different effects.  
7.3.2.  Chronic cumulative assessment groups for neurotoxicity 
Of the 91 substances evaluated, 64 substances were included in the chronic cumulative assessment 
groups in which 53 substances showed effects on the motor division, 21 showed effects on the sensory 
division and 24 on the autonomic division. In addition, for chronic cumulative assessment groups, 
neuropathological  changes  were  also  considered  relevant.  This  is  because  some  of  the  active 
substances  after  repeated  exposure  only  showed  neuropathological  changes  whereas  for  other 
substances, neuropathological changes were most sensitive. Neuropathological changes were observed Cumulative Assessment Groups for Pesticides update 
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for 19 active substances. Some substances showed more than one effect and/or indicator and they were 
either  observed  at  the  same  NO(A)EL/LO(A)EL  or  at  a  different  NO(A)EL/LO(A)EL,  possibly 
indicating a different sensitivity for the different effects. 
The  Panel  is  aware  that  the  neurochemical  changes  represent  a  level  of  grouping  for  neurotoxic 
substances based on mechanism of action. However, AChE inhibitors play a prominent role in risk 
assessment and grouping based on neurochemical changes would result in an increased sensitivity for 
some  substances.  For  this  reason,  and  to  keep  consistency  in  the  grouping  approach,  the 
neurochemical parameters should be used for further refinement when this mechanism of action is 
recognised. The number of substances included in CAGs for neurochemical changes were 13 and 15 
for acute and chronic neurotoxicity, respectively. This type of grouping would benefit from further 
refinement when the mechanism of action is recognised and well understood. 
   Cumulative Assessment Groups for Pesticides update 
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8.  Grouping methodology for the thyroid system 
8.1.  Hazard identification and characterisation for thyroid toxicity (Step 1 and 2) 
Hazard identification and characterisation for thyroid were based on the information provided by the 
DTU Report (2012) and the open literature, and are systematically presented in table 2.  
The thyroid functions as a gland that produces systemically acting hormones [calcitonin, thyroxin (T4) 
and triiodothyronine (T3)]. Specific effects were identified that concern the populations of calcitonin-
producing parafollicular cells (C-cells) and thyroid hormone (T3/T4)-producing follicular cells. At 
least for the T3/T4 hormone system, changes in  serum hormone levels may not only result from 
toxicity to the thyroid itself, but may result from modes of actions operating outside the thyroid (e.g. 
enzyme induction in the liver, peripheral metabolism of thyroid hormones). For data collection in step 
3 of the methodology and grouping in step 4, it was therefore decided to consider not only effects 
concerning the thyroid gland itself, but also effects occurring at the thyroid hormone system level.  
CAG level 1 (organ/organ systems level) 
The most conservative level of grouping on a physiological basis comprised all substances affecting 
the thyroid hormone system (gland or hormones).  
CAG level 2 (refinement on the phenomenological effect level) 
Further sub-grouping was based on different general targets including the thyroid tissue (the follicular 
and the parafollicular cell population) and the associated hormone systems. Accordingly, distinction 
between  two  overall  sub-groups  (CAG2A  and  CAG2B)  was  recommended  as  explained  in  the 
following: 
CAG2A: Substances affecting the thyroid parafollicular cells (C-cells) and/or calcitonin system  
The  parafollicular  cells  (C-cells)  produce  the  hormone  calcitonin  which  is  involved  in  calcium 
homeostasis.  While  information  on  serum  levels  of  calcitonin  is  generally  not  available  from 
toxicological studies, two specific effects concerning the C-cells were identified:  
  C-cell hyperplasia  
  C-cell neoplasia 
 
C-cell stimulation leading to hyperplasia is expected to play a promoting role in further progression to 
neoplasia, and hyperplasia and neoplasia are thus interrelated.  It was therefore considered appropriate 
to combine substances displaying either or both of these effects into one level 2 CAG. In the absence 
of specific knowledge on the underlying modes of action leading to C-cell activation/proliferation of 
pesticide active substances, further sub-grouping (refinement based on mechanistic considerations) is 
currently not thought to be feasible. 
CAG 2B: Substances affecting thyroid follicular cells and/or the thyroid hormone (T3/T4) system 
The thyroid follicular cells produce the iodine-containing hormones called iodothyronines (thyroid 
hormones, TH), of which triiodothyronine (T3) and thyroxine (T4) are the most important. In adults, 
THs  not  only  regulate  energy  metabolism,  but  also  participate  in  regulation  and  maintenance  of 
various physiological functions, while they are critical regulators of post-embryonic development. 
THs  are  essential  for  fetal  and  neonatal  neurological  development  and  developing  children  are 
particularly sensitive to perturbations in the thyroid system. Detailed considerations on the relevance 
of thyroid hormone system perturbation to humans have been included in Appendix E. In the context 
of CRA, the decrease in circulating TH levels or a decrease in TH action is regarded as a physiological 
alteration, which may lead to impairment of functional capacity, of general well-being (Lewis et al., Cumulative Assessment Groups for Pesticides update 
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2002) or development (depending on level, duration and timing of exposure to the relevant chemicals), 
and thus is considered as adverse. 
The  following  specific  effects  were  identified  in  animal  studies  for  follicular  cells  or  the  T3/T4 
system: 
  Changes in serum T3 and/or T4 levels (generally in terms of decrease) 
  Changes in serum TSH (generally in terms of increase) 
  Follicular cell hypertrophy/hyperplasia and/or increased relative thyroid weight 
  Follicular cell tumours 
These specific effects are interrelated indicators for perturbations of the T3/T4 system. Typically a 
decrease in TH levels or antagonism of TH action is expected to result in various physiological and 
structural effects, observable in animal studies that represent a common toxicological pathway:  
1.  Perturbation of the thyroid hormone system via one or more mechanisms 
2.  Decrease in circulating thyroid hormone levels/impairment of thyroid hormone action 
3.  Compensatory increase in TSH 
4.  Stimulation of follicular cells 
5.  Follicular cell hyperplasia   
6.  Progression to follicular cell tumours 
 
Although humans are assumed to be quantitatively less susceptible to development of follicular cell 
hyperplasia than e.g. rats, the specific effects listed above and observed in animal studies may be seen 
as important indicators for transient perturbation (transient TSH increase) or prolonged perturbation 
(prolonged  TSH  increase,  follicular  cell  hyperplasia,  follicular  cell  tumour  formation)  of  the 
hypothalamic-pituitary-thyroid  system,  and  were  thus  regarded  to  be  relevant  for  CRA.  Indicator 
effects, such as follicular cell hyperplasia and progression to follicular cell tumour may serve as a 
surrogate for one another for a perturbation of the thyroid hormone system, even in the absence of 
measurements of thyroid hormone (T3/T4, TSH) levels.  
In addition to the specific effects used to define CAG2B and listed above, other effects were identified 
for  some  substances  in  the  DARs.  It  was  concluded  that  specific  inflammation  of  the  thyroid 
gland/lymphocytic thyroiditis, resulting in follicular cell degeneration, may be seen as one general 
mode of action that may impact thyroid function and may lead to changes in T3/T4 or TSH levels. 
Consequently, if inflammation/cell degeneration were clearly treatment-related and not attributable to 
aging alone, they should be considered together with the other listed specific effects in the screening 
of substances and for allocation to CAG2B.  
Treatment-related pigmentation of follicular cells was not regarded as being relevant for grouping on 
its own, since it was not considered to be adverse as an isolated effect. Pigment deposition adversely 
affecting the thyroid would be expected to be accompanied by follicular cell degeneration and/or 
changes in T3/T4 or TSH levels and therefore would be covered by the other specific effects that 
would serve as indicators for inclusion in CAG2B.  
Additional histopathological changes reported in DARs and listed in the DTU report, such as increase 
in  iodine  uptake,  increased/decreased  amount  of  colloid,  small/large  follicles,  different  shapes  of 
follicular cells, increased vascularisation, increased vacuolisation, follicular cysts, follicular atrophy or 
necrosis  of  follicular  cells,  were  regarded  as  being  valid  indicators  for  inclusion  in  a  combined 
CAG2B. As these effects were concomitant with one or more of the specific effects identified in table 
2, they were considered to be covered by these specific effects. 
A number of observations concerning the thyroid were not considered to be relevant for grouping. 
These  included  amyloidosis  in  the  mouse  or  congenital  effects  (thyroglossal  duct  cysts  or 
ultimobranchial cysts resulting from persistence of embryonic structures  (DTU, 2012; Frith et al., Cumulative Assessment Groups for Pesticides update 
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2000). Effects that were regarded as being age-related (e. g. mineralisation within follicular lumina) 
generally  were  not  used  for  grouping.  However,  mineralisation  in  the  follicle  colloid  that  was 
considered to be treatment-related and to reflect premature aging of the thyroid was regarded to be 
relevant for grouping.   
In summary, any of the following specific effects were recommended for data collection in step 3 and 
for allocation to the combined CAG2B in step 4: Changes in serum T3 or T4 levels, changes in serum 
TSH levels, follicular cell hypertrophy/hyperplasia and/or increased thyroid relative weight, follicular 
cell  tumours.  Thyroid  inflammation/cell  degeneration  (and  in  some  cases  mineralisation  in  the 
follicule colloid) may be considered for allocation to the combined CAG2B group, but only if such 
effects have been established as substance-related and specific for the thyroid. Although other effects 
concerning the thyroid should be recorded in data collection in step 3, many of these effects would be 
covered by CAG2B and thus be reflected in one or more of the specific effects defining CAG2B.  
Many  substances  affecting  the  thyroid  follicular  cells  or  the  thyroid  hormone  system  and  thus 
allocated to CAG2B would be expected to generally be associated with a decrease in thyroid hormone 
(T3/T4) levels or ultimate thyroid hormone action. Additional modes of action contributing to the 
complexity  of  modulation  of  thyroid  hormone  action  cannot  be  excluded.  For  example,  some 
substances  may  affect  deiodinase  activity,  and  thus  the  extent  of  activation  of  T4  to  T3  and 
inactivation to rT3, respectively. There may also be substances rather leading to thyroid stimulation or 
enhanced thyroid hormone release. If there is mechanistic information indicating substance-dependent 
direct stimulation of the thyroid or hyperthyroidism (increase in T3/T4, decrease in TSH), it might be 
considered  at  a  later  stage  or  in  subsequent  evaluation  whether  exclusion  of  the  substance  from 
CAG2B would appear feasible. Apart from such potential cases, a further refinement of CAG2B based 
on modes/mechanisms of action is currently not recommended by the Panel for the following reasons:  
  For  many  pesticide  active  substances  affecting  the  thyroid  hormone  system,  the 
mode/mechanism of action has not been defined. 
  In cases in which there is information on the mode/mechanism of action, it might be difficult 
to  agree  on  the  similarity  or  dissimilarity  of  various  modes/mechanisms  of  action.  For 
example, different substances might affect thyroid hormone clearance via enzyme induction 
(particularly in the liver), yet for individual substances this induction may be conveyed by 
different  molecular  pathways  (activation  of  constitutive  androstane receptor (CAR)  versus 
pregnane X receptor (PXR)). 
  Experimental  studies  involving  rats  indicated  that,  for  mixtures  of  substances  causing  a 
decrease in T4 hormone levels via different individual mechanisms, the decrease in T4 levels 
may be predicted with a fair degree of accuracy by applying a dose addition model, especially 
for exposures occurring in the dose range below individual NOELs, while a response addition 
model would be more under-predictive (DTU, 2012; Crofton et al., 2005; Flippin et al., 2009). 
  Some substances may act via several mechanisms, e.g. enzyme induction, displacement of 
endogenous hormone from plasma binding protein (Miller et al., 2009). 
  Downstream organ or tissue effects will be based on the extent of interaction of the effector 
hormone with its cellular receptors. Different mechanisms may feed into the ultimate process 
of decrease/impairment of thyroid hormone action.  
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Table 2:   Hazard identification/characterisation for thyroid toxicity 
Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
Parafollicu-
lar cell (C-
cell) hyper-
trophy and 
hyperplasia 
No  Yes 
 
Precur-
sor effect 
for 
parafolli-
cular cell 
neopla-
sia. 
Yes  Unknown  No  Unknown for pesticide 
active substances 
 
Prolonged elevation of 
serum calcium levels can 
lead to stimulation of C-
cell proliferation (Zabel, 
1976). 
 
Some dithiocarbamates 
have been shown to 
induce rapid and 
sustained increases in 
intracellular calcium in 
PC12 cells (Sook Han et 
al., 2003), yet it is 
unknown whether this 
mechanism is relevant 
for stimulation of C-
cells. 
 
Long-term activation of 
the glucagon-like-pep-
tide-1 (GLP-1) receptor 
in rat C-cells may lead to 
C-cell activation and 
proliferation and 
eventually tumours 
Yes 
 
To be grouped together 
with parafollicular cell 
(C-cell) neoplasia, 
since prolonged C-cell 
proliferation/hyper-
plasia may increase the 
risk for development of 
tumours. 
- C-cell hyper-
plasia 
 
- C-cell tumours 
(neoplasia/ 
adenoma) 
 
-C-cell tumours 
(neoplasia/ 
carcinoma) 
C-cell 
hyperplasia 
seen as 
precursor 
effect for C-
cell tumours. Cumulative Assessment Groups for Pesticides update 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
(Knudsen et al., 2010), 
yet it is unknown whether 
this mechanism may be 
relevant for pesticide 
active substances. 
 
Para-
follicular 
cell (C-cell) 
neoplasia 
No  Yes  Yes 
 
Yes  No   Unknown for pesticide 
active substances 
 
Chronic stimulation of 
C-cells leading to 
sustained proliferation is 
expected to increase the 
risk for tumours. Thus, 
mechanisms outlined 
above leading to C-cell 
hyperplasia may be 
operative. 
 
Yes 
 
To be grouped together 
with parafollicular cell 
(C-cell) hyperplasia, 
since prolonged hyper-
plasia may increase the 
risk for development of 
tumours. 
 
- C-cell hyper-
plasia 
 
- C-cell tumours 
(neoplasia/ 
adenoma) 
 
-C-cell tumours 
(neoplasia/ 
carcinoma) 
C-cell 
hyperplasia 
seen as 
precursor 
effect for C-
cell tumours. 
Changes in 
serum 
thyroid 
hormone 
(T3/T4) 
levels, 
generally in 
terms of de-
crease 
 
(To be indi-
cated 
No  Yes 
 
Change 
in physi-
ology 
that may 
lead to 
impair-
ment of 
func-
tional 
capacity, 
Yes 
 
Although 
fluctua-
tions in 
thyroid 
hormone 
levels may 
be less 
pro-
nounced in 
humans 
Yes  No 
 
Some 
MoAs af-
fect the 
thyroid 
directly 
 
 
 
Other 
MoAs are 
One or more of the fol-
lowing MoAs may apply, 
although information on 
the MoA(s) for 
individual active 
substances is often not 
available: 
Interference with  iodide 
uptake into thyroid fol-
licular cells via Na+/I- 
symporter. 
 
Yes 
 
To be grouped within 
combined group 
CAG2B, together with 
substances eliciting a 
change in circulating 
TSH levels, thyroid 
follicular cell hyper-
trophy/hyperplasia 
/increased thyroid 
weight, or thyroid folli-
-Decrease in 
circulating thy-
roid hormone 
(T3/T4) levels 
 
-compensatory 
increase in cir-
culating TSH 
 
-stimulation of 
follicular cells 
 
 
 
All listed 
effects 
indicate 
perturbation 
of the thyroid 
hormone 
system or 
hypothalamic-
pituitary-
thyroid axis. Cumulative Assessment Groups for Pesticides update 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
during data 
collection 
whether de-
crease or 
increase) 
 
 
 
 
general 
well-be-
ing or 
develop-
ment, 
depend-
ing on 
level, 
duration 
and tim-
ing of 
exposure. 
( DTU,  
2012). 
indirect 
(displace-
ment of 
hormones 
from 
plasma 
protein 
binding; 
enhance-
ment of 
hormone 
metabo-
lism via 
enzyme 
induction 
(mainly in 
the liver). 
Inhibition of TH 
synthesis via inhibition of 
thyroperoxidase. 
 
Displacement of 
hormone from plasma 
protein binding. 
 
Enhancement of thyroid 
hormone 
metabolism/degradation, 
e.g. via enzyme induction 
(mainly in the liver). 
 
Inhibition of conversion 
of T4 to T3. 
 
Degeneration of thyroid 
follicular cells. 
 
(MoAs reviewed in DTU,  
2012, or by Miller et al., 
2009). 
 
cular cell tumours, 
since these effects are 
interrelated. 
-follicular cell 
hyperplasia 
 
-follicular cell 
tumours 
While 
alterations in 
TSH may be 
transient or 
prolonged, 
follicular cell 
hyperplasia 
and tumour 
formation 
indicate 
prolonged 
stimulation via 
TSH / 
prolonged 
perturbation. 
Changes in 
circulating 
TSH, gen-
erally in 
terms of 
increase 
 
(To be indi-
No   
 
Response 
to de-
crease in 
circulat-
ing 
Yes 
 
However, 
fluctua-
tions in 
hormone 
levels may 
Yes  No 
 
Response 
of  hypo-
thalamic-
pituitary 
axis to 
Known MoA: 
 
Compensatory response 
of the hypothalamic-
pituitary axis to a 
decrease in circulating 
T3/T4 levels. 
Yes 
 
To be grouped within 
combined group 
CAG2B, together with 
substances eliciting a 
change in circulating 
 
 
As outlined 
above for 
changes in 
T3/T4 levels. 
   
 
 
As outlined 
above for 
changes in 
T3/T4 levels. Cumulative Assessment Groups for Pesticides update 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
cated 
during data 
collection 
whether de-
crease or 
increase) 
 
 
T3/T4 
levels or 
to 
impaired 
thyroid 
hormone 
action. 
be less 
pro-
nounced in 
humans 
(DTU, 
2012). 
change in 
circulating 
T3/T4 lev-
els. 
 
Direct 
response  
if sub-
stance 
were to 
directly 
interfere 
with thy-
roid hor-
mone ac-
tion at hy-
pothala-
mus or 
pituitary. 
 
Additional possible MoA 
(unknown whether these 
are relevant for pesticide 
active substances): 
Impairment of thyroid 
hormone-dependent 
signalling within target 
cells of hypothala-
mus/pituitary, e.g. via 
antagonism towards 
thyroid hormone  
receptors/impairment of 
thyroid hormone-de-
pendent transcriptional 
activation or inhibition 
of thyroid hormone 
uptake via membrane-
situated transporters. 
T3/T4 levels, thyroid 
follicular cell hyper-
trophy/hyperplasia or 
increased thyroid 
weight, or thyroid fol-
licular cell tumours, 
since these effects are 
interrelated. 
 
Elevation of TSH can 
be considered to be a 
broader indicator of 
disruption of the thy-
roid hormone system in 
terms of underlying 
MoAs, since TSH levels 
would be expected to 
respond not only to 
changes in T3/T4 
levels, but to changes 
in T3/T4 signalling. 
 
Thyroid 
follicular 
cell hyper-
trophy/hype
rplasia  
 
and/or 
increased 
relative 
No   
 
Response 
to pro-
longed 
elevation 
of circu-
lating 
TSH le-
 
 
Limited 
relevance; 
humans 
quantita-
tively less 
susceptible 
to follicu-
Yes  No 
 
Response 
to stimula-
tion by 
TSH 
(not direct 
response of 
follicular 
Known MoA: 
 
Response to stimulation 
by TSH. 
Yes 
 
To be grouped within 
combined group 
CAG2B, together with 
substances eliciting a 
change in circulating 
T3/T4 levels, a change 
in TSH, or thyroid 
 
 
As outlined 
above for 
changes in 
T3/T4 levels. 
 
 
 
As outlined 
above for 
changes in 
T3/T4 levels. 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
thyroid 
weight 
vels.  lar cell 
hyperpla-
sia result-
ing from 
chemically
-induced 
perturba-
tion of 
thyroid 
hormone 
system 
than rats 
(Dellarco 
et al., 
2006). 
 
cells to 
chemical). 
follicular cell tumours, 
since these effects are 
interrelated. 
 
Thyroid 
follicular 
cell tu-
mours 
No  Yes   
 
Limited 
relevance; 
humans 
quantita-
tively less 
susceptible 
to follicu-
lar cell 
tumours 
resulting 
from 
chemically
-induced 
Yes  No 
 
Effect 
based on 
prolonged 
hyperpla-
sia of fol-
licular 
cells, due 
to pro-
longed 
stimulation 
via TSH. 
Known MoA: 
 
Follicular cell 
hyperplasia may 
progress to follicular cell 
adenoma and carcinoma 
(Botts et al., 1991). 
Prolonged hyperplasia 
due to stimulation of 
follicular cells by TSH as 
a promoting factor for 
tumour formation. 
Yes 
 
To be grouped within 
combined group 
CAG2B, together with 
substances eliciting a 
change in circulating 
T3/T4 levels, a change 
in TSH or follicular 
cell hyperplasia, since 
these effects are 
interrelated. 
 
 
 
As outlined 
above for 
changes in 
T3/T4 levels. 
 
 
 
As outlined 
above for 
changes in 
T3/T4 levels. 
 Cumulative Assessment Groups for Pesticides update 
 
 
45  EFSA Journal 2013;11(7):3293 
Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
perturba-
tion of 
thyroid 
hormone 
system 
than rats 
(Dellarco 
et al., 
2006). 
 
Inflam-
mation of 
thyroid 
gland 
(lympho-
cytic thy-
roiditis); 
 
Degen-
erative 
changes in 
thyroid 
follicular 
cells 
No  Yes  Yes  No 
 
Infiltrates 
of 
lymphocyte
s are 
sometimes 
observed 
in older 
rats and 
have been 
considered 
to be an 
incidental 
aging 
change 
(Frith et 
al., 2000), 
but some 
cases of 
lympho-
Yes/No  
 
may be 
specific or 
non-
specific. 
Largely unknown for 
pesticide active 
substances 
 
Immunomodulation has 
been described as a pos-
sible MoA for substance-
related thyroiditis 
(Kitchen et al., 1979), yet 
it is unknown whether 
this MoA may be 
relevant for pesticide 
active substances. 
Degeneration via 
vacuolisation or 
alteration in lysosomal 
function may also be 
possible. For the 
pesticide spinosad, 
thyroid inflammation has 
been associated with 
Yes  
 
For data collection, it 
may be helpful to 
consider thyroid 
inflammation and 
follicular cell 
degeneration as alerts 
for possible specific 
effects concerning 
thyroid function, if 
inflammation or cell 
degeneration are 
clearly substance-
related. As 
inflammation and/or 
cell degeneration may 
be regarded as 
examples of general 
modes of action which 
may lead to changes in 
-Inflammation 
or lymphocytic 
thyroiditis 
 
-Degenerative 
changes in thy-
roid follicular 
cells 
 
(As cells are 
damaged, there 
may be a tran-
sient increase in 
T3/T4 release, 
followed in the 
long run by a 
decline in T3/T4 
hormone pro-
duction and 
increase in TSH 
for compensa-
 
 
Thyroid 
inflammation 
and follicular 
cell 
degeneration 
can be seen as 
some general 
modes of 
action that 
may impact 
thyroid 
function, and 
thus may lead 
to specific 
effects in 
terms of 
changes in 
T3/T4 or TSH 
levels. Cumulative Assessment Groups for Pesticides update 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
cytic thy-
roiditis/ in-
flammation 
or thyroid 
degenerati
on may be 
treatment-
related 
(Kitchen et 
al., 1979; 
Yano et al., 
2002). 
 
vacuolisation, which in 
this case appears to 
correspond to lysosomal 
phospholipidosis (Yano 
et al., 2002). 
T3/T4 or TSH levels, 
inflammation/cell 
degeneration should be 
included among the 
parameters for defining 
the merged group 
CAG2B. 
tion). 
Pigmenta-
tion within 
thyroid 
follicular 
cells or 
follicular 
lumina 
No  No 
 
Not ad-
verse as 
an iso-
lated 
effect,  
but may 
in some 
cases be 
associ-
ated with 
disturbed 
thyroid 
function. 
Yes  No 
 
Pigmenta-
tion may 
be 
observed 
in the 
context of 
normal 
aging, 
and/or be 
treatment-
related 
(Frith et 
al., 2000; 
Tajima et 
al., 1985). 
The 
Yes/No 
 
May be 
specific or 
non-
specific. 
Unknown for pesticide 
active substances 
 
Deposition of pigment 
consisting of the active 
substance or metabolites 
indicates that 
mechanisms leading to 
concentration of the 
substance or its me-
tabolites within follicular 
cells may be operative. 
However, the identity of 
the pigment is usually 
not specified. 
No 
 
Pigmentation alone is 
not regarded as a suffi-
cient basis for group-
ing, but in some cases 
may indicate accumu-
lation of test substance 
or metabolites in the 
thyroid.  
Pigment deposition 
adversely affecting the 
thyroid would be 
reflected by changes in 
thyroid function. In this 
case, such substances 
would be covered by 
the merged group 
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Hazard Identification (Step 1)  Hazard characterisation  
(Step 2) 
Specific 
Effect 
Local  
Yes/No
 
Remarks 
Adverse 
Yes/No
 
Remarks 
Relevant 
for 
humans 
Yes/No 
Remarks 
Unambigu
ous 
unique 
Yes/No
 
Remarks 
Non- 
specific  
Yes/No 
Remarks 
 
MoA  
Known/ 
Presumed/ 
Unknown  
Remarks 
Relevant for CRA  
Yes/No  
Overall 
remarks/conclusions 
Indicators in 
sequence of 
occurence 
Remarks 
Most 
appropriate 
indicator for 
effect
 
Remarks 
identity of 
pigment is 
usually not 
specified. 
CAG2B for substances 
affecting the thyroid 
follicular cells and/or 
the thyroid hormone 
system. 
Mine-
ralisation, 
clumps of 
minerals 
observed 
within 
lumen of 
follicles 
No  No 
 
Minerali
sation 
occurs in 
adult rats 
and is 
consider
ed a 
normal 
aging 
change 
(Frith et 
al., 
2000). 
 
Unknown  Unknown  Unknown  Unknown  No 
 
Unless mineralisation 
of the follicular colloid 
is regarded to be a 
substance-related effect 
reflecting premature 
aging of the thyroid 
   
 
Notes:  
Taking into account the information provided by the DTU Report (DTU, 2012) and the open literature, the following recommendations were made for grouping: 
 
CAG level 1 (organ/systems level) 
CAG level 1 would comprise all substances affecting the thyroid system (the thyroid, T3/T4 and calcitonin systems).  
 
CAG level 2 (refinement on the phenomenological level) 
CAG2A: Substances affecting the thyroid parafollicular cells (C-cells) and/or calcitonin system (effects in yellow) Cumulative Assessment Groups for Pesticides update 
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Two specific effects concerning the C-cells were identified: C-cell hyperplasia and C-cell neoplasia. Since C-cell stimulation leading to hyperplasia is expected to play a 
promoting role in further progression to neoplasia, it was proposed to combine substances displaying either or both of these effects into one level 2 CAG.  
 
Specific effects combined into one CAG2 level for grouping were shaded in yellow. 
 
CAG 2B: Substances affecting the thyroid follicular cells and/or the thyroid hormone system (effects in green) 
It is thought useful to combine substances eliciting any of the following specific effects into one common level 2 CAG, as they are regarded as being interrelated and 
connected to one another by a chain of events:  
 
  Changes in serum T3 and/or T4 levels (generally in terms of decrease) 
  Changes in serum TSH (generally in terms of increase) 
  Follicular cell hypertrophy/hyperplasia and/or increased relative thyroid weight 
  Follicular cell tumours 
 
Specific effects combined into one CAG 2 level for grouping were shaded in green.  
 
In addition to the specific unambiguous effects listed above for defining CAG2B, other effects were identified in the DARs:  
It was concluded that inflammation of the thyroid gland/lymphocytic thyroiditis, resulting in follicular cell degeneration, may be seen as one general mode of action that may 
impact thyroid function and may lead to changes in T3/T4 or TSH levels. Consequently, if inflammation/cell degeneration were clearly treatment-related and not attributable 
to aging alone, they could be considered together with the other listed specific effects in the screening of substances and for allocation to CAG2B.   
 
Treatment-related pigmentation of follicular cells was not regarded as being relevant for grouping on its own, since it was not considered to be adverse as an isolated effect. 
Pigment deposition adversely affecting the thyroid would be expected to be accompanied by follicular cell degeneration and/or changes in T3/T4 or TSH levels and therefore 
would be covered by the other specific effects employed for allocation to CAG2B. Additional histopathological changes reported in DARs and listed in the DTU report, such 
as  increased/decreased  amount  of  colloids,  small/large  follicles,  different  shapes  of  follicular  cells,  increased  vascularisation,  increased  vacuolisation,  follicular  cysts, 
follicular atrophy or necrosis of follicular cells were regarded as being indicators for inclusion in the combined CAG2B. 
 
A  number  of  observations  concerning  the  thyroid  were  not  considered  to  be  relevant  for  grouping.  These  included  amyloidosis  in  the  mouse  and  congenital  effects 
(thyroglossal duct cysts or ultimobranchial cysts resulting from persistence of embryonic structures (DTU, 2012; Frith et al., 2000). Effects that were regarded as age-related 
(e. g. mineralisation within follicular lumina) were generally not used for grouping, although mineralisation in follicle colloid was considered relevant for grouping if it 
reflected substance-related premature aging of the thyroid. 
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8.2.  Data collection for the thyroid system (Step 3)  
After identifying and characterizing the specific effects for thyroid toxicity, relevant toxicological data 
was  screened  for  each  pesticide  (considered  relevant  for  CRA  as  described  in  chapter  6.3:  Data 
collection) through a standardised and thorough review of relevant in vivo regulatory toxicity studies. 
The  collection  of  toxicological  data  was  performed  by  EFSA  (Appendix  F)  and  includes  only 
pesticides causing effects on the thyroid system. The data collection contains information on 113 
active substances, which are listed in Appendix H. 
Specific considerations for the data collection for thyroid toxicity were as follows:  
Only NO(A)ELs/LO(A)ELs from repeated dose studies were considered with regard to the specific 
effects since the thyroid is not being investigated and/or generally less likely to be observed in acute 
toxicity studies. 
While  substances  affecting  the  thyroid  system  were  generally  identified  via  the  specific  effects 
established under chapter 8.1, any additional effects were recorded and subsequently scrutinised with 
respect to relevance for grouping. Data were checked to confirm that effects were specific to the 
thyroid.  For  example,  an  increase  in  relative  thyroid  weight  occurring  in  isolation  without  other 
reported thyroid effects was only regarded as being specific if this was not the result of generalised 
toxicity, e.g. not associated with body weight decrease.  
 
Doses  provided  in  the  DARs  in  ppm  were  converted  to  mg/kg  bw/d  using  conversion  factors 
recommended by the EFSA Scientific Committee 2012 (EFSA, 2012a). 
 
8.3.  CAGs for the thyroid system (Step 4) 
Grouping of substances affecting the thyroid system was performed for substances retrieved during the 
data collection (Appendix F). The result of grouping is shown in Appendix G, in which individual 
substances are listed in relation to CAGs, along with their most sensitive NOAELs/LOAELs for the 
specific effects. Very often, more than one study and more than one specific effect within the data 
collection supported assignment to a sub-group. In such cases, only the most sensitive effect occurring 
in the most sensitive species was listed in the Appendix. In addition, when available, information on 
presumed or known modes/mechanisms of action was provided.    
CAG1 
Of the 113 active substances in the database, 101 substances were found to have an effect on the 
thyroid system. Accordingly, these substances were allocated to CAG1 as the most conservative level 
of grouping.  
Considering the specific effects identified and characterised in chapter 8.1., substances from CAG1 
were sub-grouped to CAG2A and CAG2B.  
CAG2A 
In total, 22 substances displayed one or more of the indicators for substances affecting the thyroid 
parafollicular cells (C-cells), namely C-cell hyperplasia or C-cell neoplasia (C-cell tumours, C-cell 
adenoma, C-cell carcinoma), and were consequently allocated to CAG2A.  
CAG2B 
96 substances were identified as substances affecting the thyroid follicular cells and/or the thyroid 
hormone (T3/T4) system, and allocated to CAG2B. As outlined in chapter 8.1. some effects were 
described in the DARs, such as changes in size of follicles, changes in colloids, different shapes of 
follicular cells, or increased iodide uptake, that generally were concomitant with one or more of the Cumulative Assessment Groups for Pesticides update 
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specific effects identified in table 2, and were thus considered to be covered by the combined group 
CAG2B. 
Comparing the two sub-groups CAG2A and CAG2B, it was noted that 17 of the 22 substances in 
CAG2A were also grouped into CAG2B (and thus displayed effects on the parafollicular C-cells as 
well as on the follicular cells or T3/T4 system), while for the other 5 substances of the CAG2A group, 
effects were only reported on the parafollicular cells. Thus, it appears that at least part of CAG2A 
might be covered by CAG2B. Evidence has been provided in the literature suggesting a functional 
relationship between parafollicular cells and follicular cells or the hypothalamic-pituitary-thyroid axis. 
For example, C-cells express the TSH receptor (Morillo-Bernal et al., 2009). However, the underlying 
mechanisms relevant for the induction of C-cell hyperplasia by pesticide active substances remain to 
be defined. In particular, it needs to be elucidated whether mechanisms affecting the C-cells alone may 
be distinguished from mechanisms linking both C-cell and follicular cell hyperplasia.  
In  conclusion,  two  sub-groups  are  currently  recommended  for  CRA  for  substances  affecting  the 
thyroid system. These CAGs are defined by effects related to the different cell populations within the 
thyroid  system.  This  grouping  may  be  subject  to  revision  as  new  mechanistic  data  on  the 
mode/mechanism of action of individual substances and on the functional interaction between the two 
cell types in the thyroid become available.  
   Cumulative Assessment Groups for Pesticides update 
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9.  Considerations of potency during conduct of CRA  
Pesticides  may  cause  toxic  effects  at  multiple  sites  by  a  single  (e.g.  neurotoxic)  mode  of action. 
Therefore,  substances  can  be  grouped  in  more  than  one  CAG.  The  effects  considered  for  the 
establishment  of  reference  values  (i.e.  Acceptable  Daily  Intake  (ADI)  and  Acute  Reference  Dose 
(ARfD)) are not necessarily representative for the CAGs, i.e. an effect observed at higher dose levels 
may be the specific effect relevant for grouping. Reference values for the specific effects within the 
different CAGs and index compounds (IC) may be established, but such considerations are outside the 
scope of the present Opinion on developing a general methodology. This would represent a future step 
and would require the identification of IC within each CAG (see EFSA, 2008, 2009). 
For each active substance within a CAG, the difference between its critical NOAEL (used in the 
regulatory  context  for  reference  value  setting)  and  its  NOAEL  for  a  specific  effect  should  be 
considered. For instance, the contribution of an active substance to the cumulative toxicity in a CAG 
will be inversely proportional to the difference in values between its NOAEL for the specific effect 
and its critical NOAEL. That is, if the difference between these NOAELs is small the contribution of a 
substance to the cumulative toxicity in a CAG will be higher than the contribution of a substance for 
which the difference between its NOAELs is large.  
As a consequence, if for example the critical NOAEL is 5-fold lower than the NOAEL for a specific 
effect (assuming an uncertainty factor of typically 100 and that the exposure to the pesticide is 100% 
of its ADI), the hazard quotient would be 0.20 for the specific effect (HQ = exposure*100/NOAEL). 
The  pesticide  of  concern  would  contribute  at  most  with  20%  to  the  total  cumulative  exposure. 
Combined exposure to other compounds sharing the specific effect would cease to be acceptable when 
the hazard index exceeds 1.0. Whilst this is relatively modest given the uncertainties in such a risk 
assessment, one might still argue that the margin of difference, i.e. 5-fold, is insufficient. 
Risk  managers  should therefore  decide  as  to  what  would  be  an  appropriate margin  of  difference 
between the critical NOAEL and the NOAEL for a specific effect. It is important to note that without 
clear criteria, all compounds of a CAG will have to be included in the respective CRA, which would 
involve substantial resources, which could be argued to be unjustified. For a transparent approach, 
clear criteria are needed for an efficient use of CAGs, e.g. excluding substances with a very low 
hazard  quotient  for  the  specific  effect  or  those  with  a  NOAEL  for  specific  effects  close  to  the 
maximum dose tested (e.g. tetramethrin and sumithrin that were not included in a common assessment 
group  in  the  US  EPA  assessment  because  low-hazard  pyrethroids  do  not  induce  typical 
neurobehavioral effects at the highest dose tested, as noted in chapter 3.3). 
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10.  Uncertainties and limitations 
The Panel was tasked with developing a methodology for grouping pesticide active substances into 
CAGs  based  on  their  common  or  shared  toxic  effects  for  their  use  in  CRA.  In  the  absence  of 
experimental  information  about  their  actual  combination  effects,  the  combination  effects  of  the 
individual  pesticides  had  to  be  anticipated  on  the  basis  of  their  toxicological  profiles.  This  is  a 
challenging task that stretches the limits of current scientific knowledge. 
The available evidence with experimentally tested mixtures (Kortenkamp et al., 2009) shows that 
combination effects with substances that act via similar mechanisms and modes of action are highly 
likely,  all  the  more  so  when  the  mixture  components  have  a  common  molecular  target,  such  as 
inhibition of the same enzyme by an identical mechanism. Accordingly, chemicals with common 
structural  features  are  likely  to  interact  with  the  same  molecular  targets,  and  can  be  expected  to 
produce  combination  effects  after  simultaneous  exposures.  The  certainty  with  which  combination 
effects  can  be  predicted  in  such  cases  is  quite  high,  but  this  comes  at  the  price  of  potentially 
underestimating risks by ignoring chemicals that might also contribute to a joint response by acting 
further upstream or downstream on an effector chain or through different pathways (US NRC, 2008). 
Conversely,  the  uncertainties  associated  with  predicting  possible  combination  effects  increase  the 
more the assessments are based on effects at a level of biological complexity rather than on molecular 
mechanism of action. This uncertainty has to be balanced against the higher degree of protection that 
is afforded by considering a wider range of chemicals. 
The Panel recognises that the fundamental difficulties in grouping pesticides based on wide inclusion 
criteria can only be resolved in the foreseeable future by obtaining better information on the modes of 
action for each of the toxic effects caused by the substances. Substantial refinements of CAGs may be 
achieved through increased knowledge about the molecular/cellular mechanisms of actions shared by 
groups of pesticides and about the link between mechanisms and effects at the organ and organism 
level. 
Until such information becomes available, the approach proposed by the  Panel represents what is 
achievable based on current scientific data. It is the Panel‟s view that the alternative option of using 
quite narrow grouping criteria derived from molecular mechanisms and modes of action is likely to 
capture only a fraction of the potential cumulative risks. This view is supported by empirical evidence 
on mixtures composed of multiple chemicals that operate through a variety of mechanisms. 
The Panel is aware that information included in the proposed CAGs was only derived from DARs 
provided by the rapporteur member states and not the raw data that underpin the DARs. Considerable 
uncertainties arise from the fact that DARs contain different levels of details on the toxicological 
assessments of the raw data. Also, considerable changes and developments have occurred with regard 
to data requirements and study protocols (e.g. multigeneration study, 28 day study, DNT study) that 
consequently have an impact on the uncertainties associated with the CAGs proposed in this opinion.  
Furthermore, some endpoints considered important today have not been reported in older DARs and 
consequently the lack of information about certain effects  may result in the possibility that some 
substances are not included in certain CAGs. Inconsistent terminology in the DARs is also a source of 
uncertainty, in particular in relation to descriptions of histopathological and developmental findings.  
General  uncertainties  affecting  CRA  have  carefully  been  assessed  in  the  previous  PPR  Opinion 
(EFSA, 2009).  
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11.  Conclusions 
Following a mandate received by EFSA, the PPR Panel has developed a scientific Opinion on the 
identification  of  pesticides  to  be  included  in  CAGs  on  the  basis  of  their  toxicological  profile. 
Consequently, such pesticides have been identified in the present opinion. 
The Opinion does neither present considerations on exposure nor a proposal for an overall framework 
for CRA or considerations on compounds not regulated under the Regulation (EC) 1107/2009
13 as 
such proposals and considerations would not be within the scope of the present mandate.  
The evaluation performed by the PPR Panel is not intended to  challenge peer-reviewed and agreed 
reference values and/or points of departure (NOAEL, LOAEL). 
The Opinion rather describes a CAG methodology, specifically developed for  pesticides, based on 
common toxic effects, defining a general approach and criteria for the grouping of pesticides for CRA. 
Cumulative assessment groups of pesticides  were provided  for the nervous system and the  thyroid 
system. The Panel has taken into acc ount previous PPR Panel opinions on methodologies for the 
assessment of cumulative and synergistic risks from pesticides to human health and on triazole 
fungicides as a working example of grouping  pesticides based on structure and pesticidal  mode of 
action. The present methodology was developed on the basis of oral toxicity studies in order to take 
cumulative effects into account in the decision  on application concerning MRLs.   Although this 
methodology was specifically developed for  dietary exposures to  pesticide  residues,  it could in 
principle be applied to non-dietary exposures (i.e. operator, worker, bystander and resident exposure) 
for CRA.  
The proposed grouping approach in this Opinion followed directions from the European Commission 
and was based on shared patterns of toxicologically relevant and unambiguously defined effects that 
occur  at  the  level  of  tissues,  organs  and  physiological  systems.  The  basis  for  the  grouping 
methodology  assumed  that  pesticides  producing  the  same  toxic  effects  in  tissues ,  organs  and 
physiological systems have the capability of producing joint, cumulative toxicity. This represented a 
significant challenge, considering that evaluations for potential combined effects have to be made with 
very limited experimental data about  cumulative toxicity. The Panel concludes that this grouping 
approach  is  relevant  and  scientifically  justified  in  view  of  evidence  that  chemically  unrelated 
substances may produce common toxicity in target organs, tissues or endpoints ( e.g. developmental 
and reproductive end-points) even without a common mode of action. The PPR Panel envisages that 
further refinements based on common  mechanisms of toxicity could be developed  when information 
on  biochemical  effects  becomes  available  for  more  pesticide  active  substances.  However,  any 
information that justifies deviation from dose-addition might also be necessary to consider.  Based on 
current knowledge, synergistic interactions are not expected to occur at the low exposure levels  that 
are typical of  dietary pesticide residues. Accordingly, the PPR Panel considers that the proposed 
CAGs should be used  in the context of  MRL setting and risk assessment assuming mainly dose 
additive combination effects. 
Although the data collection is confined to EU appr oved pesticides in this opinion, in principle, all 
pesticides that can occur as residues may be considered for CRA based on CAGs as defined according 
to the approach laid down in this opinion. The data collection for establishment of CAGs was based on 
a  standardized  and  thorough  review  of  DARs  although  preferably  all  available  and  relevant 
information (e.g. literature, non EU governmental reports) should also be taken into account. For the 
present Opinion all active substances approved in the EU until 1st January 2012 have been considered.  
                                                       
 
13 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing 
of plant protection products on the market and repealing Council Directives 79/117/EC and 91/414/EEC. Official Journal L 
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In addition, the PPR Panel acknowledges that, based on currently available data sets, non-authorised 
pesticides identified as residues in the EU food commodities cannot be included in CAGs; however, 
their inclusion may be considered as a further development of CRA.  
The methodology in the current Opinion comprises four main steps: 
  Identification of the specific effects as follows:  
 
i) exclusion of local  effects 
ii) exclusion of non-adverse effects 
iii) exclusion of effects not relevant to humans 
iv) evaluation of the unambiguous nature of the effect 
v) identification of non-specific effects 
 
  Characterisation of the specific effects 
  Data collection  
  Grouping of pesticides into cumulative assessment groups 
 
The CAGs for neurotoxic substances were based on results from acute and chronic (repeated-dose) 
experimental studies included in the available DARs. The specific effects were mainly obtained from 
Functional Observation Batteries (FOBs) and thus they were restricted to the  motor, sensory and 
autonomic divisions of the nervous system. For some active substances, neurochemical indicators of 
effects  were  also  available,  particularly  erythrocyte  or  brain  AChE  activity.  Accordingly,  four 
principal groupings were characterized, one for each of the above-mentioned functional divisions of 
the nervous system and another CAG for neurochemical indicators. The latter should be considered as 
a further refinement for grouping because it‟s based on the toxic mechanism of action. Moreover, 
CAGs  were  developed  for  acute  and  chronic  exposure  scenarios,  with  the  latter  also  including 
neuropathological changes as a distinct and additional CAG since acute exposures to pesticides are not 
expected to induce adverse effects at a histopathological level. 
The CAGs for thyroid effects have balanced the presence of different targets within the hypothalamic-
pituitary-thyroid axis, and the limitations of data on mode of actions, as well as the potential for 
different mechanisms of action to result in a common effect, e.g. reduced T3/T4 level. Thus, two 
principal groupings were characterized (substances affecting the thyroid follicular cells and the T3/T4 
system, and those affecting the C-cells/calcitonin system). As a further refinement, substances eliciting 
hyperthyroidism might be identified with the support of expert judgement. Thyroids effects resulting 
from acute exposure were not observed in the DARs, and are regarded to be less likely to occur than 
effects following repeated exposure (OECD Guidance on ARfD setting, 2010). 
Application of this methodology has yielded CAGs with sometimes large numbers of pesticides (see 
below). Although some CAGs contain a large number of pesticides, littlei ndication of cumulative risk 
may be inferred from the size of CAGs per. Even with large CAGs, it is possible that the majority of 
pesticides contribute little to a combination effect, either because exposure is very low, or because 
potency in relation to the effect considered is weak. Instead, cumulative effects are likely to be driven 
mainly by a few active substances.  
Preliminary work already performed on several target organs/tissues (adrenal, eye, liver, reproductive 
system) should be continued in order to achieve a timely advance of CAG application to these other 
organs/systems. The PPR Panel also recognizes that the CAGs based on common toxic effects can be 
changed by adding more information on pesticide mode of actions and toxicity pathways and with a 
better understanding about the relevance of dissimilar modes of action for common toxic effects. 
Moreover, information that justifies any deviation from dose addition must be considered for such a 
refinement. These issues will be explored further by the Panel within its mandate on the relevance on Cumulative Assessment Groups for Pesticides update 
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dissimilar  mode  of  action.  Most  importantly,  CAGs  should  be  updated  by  applying  a  consistent 
methodology. 
EFSA intends to gradually implement CRA in the framework of EU regulations on pesticides by first 
addressing the cumulative risk related to the CAGs established in this opinion. In this context, EFSA 
will  consult  the  European  Commission  and  Member  States  to  guarantee  coherence  between  risk 
assessment and risk management in the conduct of CRA.  
On uncertainties the PPR Panel acknowledges that quantification of the uncertainties is complex and 
that specific guidance for uncertainty analysis regarding hazard and risk characterisation for multiple 
chemicals should be developed. 
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12.  Recommendations 
The PPR Panel makes several recommendations for the implementation of this CAG methodology in 
CRA to support MRL setting: 
  The implementation of the methodology based on specific effects should be supported by 
expert judgement, in order to identify the effects relevant for grouping according to the criteria 
laid down in the opinion.  
  When performing cumulative risk assessment, exposure and potency considerations should be 
taken into account by risk assessors to make best use of resources. 
  The  external  scientific  reports  on  data  collection  for  specific  endpoints  (DTU,  2012; 
ANSES/ICPS/RIVM, 2013) and preliminary work of EFSA, already carried out for relevant 
target organs and tissues should be used as a starting point for future groupings of pesticides 
for effects in organs/organ systems other than the thyroid and the nervous system.  
  The  IPCS  framework  on  CRA  (IPCS,  2009)  should  be  applied  to  assess  and  report 
information on mode of action in future DARs. Further consideration should then be given to 
the  inclusion  of  more  mechanistic  studies  and  new  methodologies  within  the  data 
requirements for pesticides. 
  Guidance  for  the  implementation  of  CAG  methodology  in  the  AIR  (Annex  I  renewal) 
programme should be developed by EFSA and tailored to the different programmes to support 
MRL setting. 
  The CAGs, established following the methodology developed in the current opinion, could 
also be used for non-dietary CRA. 
  All pesticides covered by Regulation (EC) No 396/2005 (including import tolerances) should 
be considered for inclusion in CAGs. In order to do so, other sources of information than EU 
peer-reviewed data should be considered (e.g. JMPR, US EPA). 
  A  procedure  should  be  developed  to  update  the  CAGs  for  the  inclusion  of  new  active 
substances.  
  Specific guidance for uncertainty analysis regarding hazard identification and characterisation 
for multiple chemicals should be developed. 
  The applicability of the “exclusion” approach could be explored when dealing with substances 
other than pesticides under the EFSA remit.  
   Cumulative Assessment Groups for Pesticides update 
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GLOSSARY 
Acute toxicity: Adverse effects of finite duration occurring within a short time (up to 14 d) after 
administration of a single dose (or exposure to a given concentration) of a test substance or after 
multiple doses (exposures), usually within 24 h of a starting point (which may be exposure to the 
toxicant, or loss of reserve capacity, or developmental change, etc.). 
Additive effect: Effect observed after exposure to two or more chemical agents which act jointly but 
do not interact. The total effect is the simple sum of the effects of separate exposure to the agents 
under the same conditions. 
ADI (Acceptable daily intake): Estimate of the amount of substance in food expressed on a body 
weight basis, that can be ingested daily over a lifetime, without appreciable risk to any consumer on 
the basis of all known facts at the time of evaluation, taking into account sensitive groups within the 
population (e.g. children and the unborn). 
Adverse  effect:  Change  in  the  morphology,  physiology,  growth,  reproduction,  development  or 
lifespan  of  an  organism  which  results  in  impairment  of  functional  capacity  to  compensate  for 
additional stress or increased susceptibility to the harmful effects of other environmental influences  
Aggregate risk: Risk associated with all pathways and routes of exposure to a single chemical.  
AIR (Annex I Renewal): Renewal of active substances included in Annex I of Council Directive 
91/414/EEC.  
ARfD (Acute reference dose): Estimate of the amount of substance in food and/or drinking water, 
expressed on a body weight basis, that can be ingested over a short period of time, usually during one 
day, without appreciable risk to the consumer on the basis of the data produced by appropriate studies 
and taking into account sensitive groups within the population (e.g. children and the unborn). 
Chronic effect: Consequence that develops slowly and/or has a long lasting course: may be applied to 
an effect that develops rapidly and is long-lasting. 
Combined toxicity: Response of a biological system to several chemicals, either after simultaneous or 
sequential exposure. It can take three possible forms: dose-addition, response-addition or interaction. 
In the context of this opinion, only dose-addition is considered. 
Common mechanism group: Group of chemicals determined to cause a common toxic effect by a 
common mechanism of toxicity 
Common mechanism of toxicity: Pertains to two or more substances that cause a common toxic 
effect to experimental animals or to human health by the same, or essentially the same, sequence of 
major biochemical events. Hence, the underlying basis of the toxicity is the same, or essentially the 
same, for each chemical. 
Common toxic effect: Two or more substances that are known to cause the same toxic effect in or at 
the same anatomical or physiological site or location (e.g. same organ or tissue). Thus, a toxic effect 
observed in studies involving animals exposed to a pesticide is considered common with a toxic effect 
caused by another chemical if there is concordance with both site and nature of the effect. 
Critical NOAEL: No Observed Adverse Effect Level (NOAEL) for the effect upon which the ADI 
(or ARfD) is based.  
Cumulative assessment group (CAG): Group of active substances that could plausibly act by a 
common mode of action, not all of which will necessarily do so. The first and most conservative level Cumulative Assessment Groups for Pesticides update 
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of grouping is based on the organ or organ system level being the target of the pesticide toxicity (CAG 
1). Further refinement to form a second level of grouping (CAG 2) is based on the identification and 
characterisation of specific effects in the organ or organ system. (Due to shortage of information on 
underlying mechanism/mode of action for many pesticides, further sub-grouping as performed in the 
DTU report (CAG 3 and CAG 4) are not considered relevant to this opinion.) 
Cumulative risk: In the context of this opinion, it corresponds to the risk resulting from exposure to 
more than one pesticidal active substance via the diet.  
Dissimilar mode of action: Occurs when the mode of action and possibly, but not necessarily, the 
nature and sites of toxic effects differ between the chemicals in a mixture, and one chemical does not 
influence the toxicity of another. The effects of exposure to such a mixture are the combination of the 
effects of each component compound (also referred to as response-addition). 
Dose addition: see similar mode of action.  
Exclusion approach: Establishment of CAGs on basis of common toxicological effects even in the 
absence of a clearly established (common) mode of action. A compound is excluded from a CAG only 
when it can be shown that it does not exhibit the common toxicological effect. 
Hazard:  Inherent  property  of  an  agent  (e.g.  pesticide)  or  situation  having  the  potential  to  cause 
adverse effects when an organism, system, or (sub-) population is exposed to that agent or situation. 
Hazard assessment: Process that includes hazard identification and characterisation and focuses on 
the hazard in contrast to risk assessment where exposure assessment is a distinct additional step. 
Hazard characterisation: Qualitative and, wherever possible, quantitative description of the inherent 
property of an agent or situation having the potential to cause adverse effects. This is the second stage 
in the process of hazard assessment. 
Hazard identification: Identification of the type and nature of adverse effects that an agent has an 
inherent capacity to cause in an organism, system, or (sub) population. This is the first stage in the 
process of hazard assessment. 
Hazard index (HI): Sum of Hazard Quotients, i.e. ratios between exposure and the reference value 
for the common toxic effect of each component in the CAG. 
Inclusion approach: Establishment of CAGs on basis of common toxicological effects only if a 
common mode of action is clearly established. 
Index compound (IC): The chemical used as the point of reference for standardizing the common 
toxicity of the chemical members of the CAG. The index compound should have a clearly defined 
dose-response,  be  well  defined  for  the  common  mechanism  of  toxicity,  and  have  a 
toxicological/biological profile for the common toxicity that is representative of the CAG. 
Indicator: In the context of this opinion, an observed or measured effect relevant for grouping which 
is interrelated or linked to one or more specific adverse effects, either by representing a different 
outcome of a common toxicological pathway or a different step within a chain of events. The indicator 
may thus serve as a surrogate for other related effects that have not been determined or measured in a 
particular  study.  For  example,  an  increase  in  circulating  TSH  levels  or  thyroid  follicular  cell 
hypertrophy would be expected to be related to a low circulating thyroid hormone (T3/T4) levels and 
would thus be regarded as indicative of disruption of the thyroid hormone system, even in the absence 
of thyroid hormone measurements.  Cumulative Assessment Groups for Pesticides update 
 
 
65  EFSA Journal 2013;11(7):3293 
Interaction: Umbrella term for synergies (mixture effects greater than expected) and antagonisms 
(mixture  effects  smaller  than  expected).  Interactions  can  be  judged  in  relation  to  additivity 
expectations derived from dose addition or independent action 
Maximum residue level (MRL): Upper legal level of a concentration for a pesticide residue in or on 
food or feed set in accordance with Regulation 396/2005, based on good agricultural practice and the 
lowest consumer exposure necessary to protect vulnerable consumers. 
Mechanism of action: Detailed explanation of the individual biochemical and physiological events 
leading to a toxic effect. 
Mechanism  of  toxicity:  Mechanism  of  toxicity  is  defined  as  the  steps  leading  to  a  toxic  effect 
following interaction of a pesticide with biological targets. All steps leading to an effect do not need to 
be specifically understood. Rather, it is the identification of the crucial events following chemical 
interaction that are required to describe a mechanism of toxicity. In the context of this document, 
mechanism  of  toxicity  refers  to  the  mechanism  by  which  a  pesticide  is  toxic  to  humans  or 
experimental animals, and not the mechanism by which it is toxic to target or intended species (i.e. its 
mechanism  of  pesticidal  action).  With  some  pesticides,  however,  the  mechanism  responsible  for 
causing toxicity to humans or experimental animals is similar to the mechanism of pesticidal action. 
Mode of action (MoA): Biologically plausible sequence of key events leading to an observed effect 
supported  by  robust  experimental  observations  and  mechanistic  data.  It  refers  to  the  major  steps 
leading to an adverse health effect following interaction of the compound with biological targets, it 
does not imply full understanding of mechanism of action at the molecular level.  
NOAEL/LOAEL (No Observed Adverse Effect Level / Lowest Observed Adverse Effect Level): 
In general, effects that are non-adverse do not qualify to be the basis for the setting of neither a 
NOAEL  nor  a  LOAEL  (JMPR,  2006).  However  they  might  be considered  as  specific  effects for 
CAGs. The decision to consider an effect as non-adverse but relevant for a CAG needs to be supported 
by expert judgement. 
NOEL/LOEL:  All  the  findings  (endpoints)  that  were  indicated  in  the  outsourced  contract  as 
indicative for those effects have been reported for each substance, with their respective NOEL/LOELs. 
The selection of NOELs and LOELs was performed, as requested by EFSA, without any interpretation 
on whether an effect is to be considered adverse or not adverse.   
Phenomenological  effect:  In  the  context  of  this  Opinion  corresponds  to  a  range  of  effects, 
morphological and/or functional, that can be observed in a target organ or organ system. These effects 
could also represent a continuum of pathological findings. 
Pesticide formulations, plant protection products (PPP): Mixtures or solutions composed of two or 
more active substances intended for use as a plant protection product or as an adjuvant. 
Rapporteur member state (RMS): Member State which undertakes the task of evaluating the dossier 
of an active substance, safener or synergist. 
Residues: Are consisting of one or more substances present in or on plants or plant products, edible 
animal products, drinking water or elsewhere in the environment and resulting from the use of a plant 
protection product, including their metabolites, breakdown or reaction products. 
Response addition: see dissimilar mode of action 
Risk assessment: Process intended to calculate or estimate the risk to a given target organism, system, 
or (sub-) population, including the identification of attendant uncertainties, following exposure to a Cumulative Assessment Groups for Pesticides update 
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particular pesticide or agent of concern as well as the characteristics of the specific target system. It is 
the first component in a risk analysis process. 
Similar mode of action: Describes the mode of action when all chemicals in the mixture act by the 
same mechanism/mode of action, and differ only in their potencies. The effects of exposure to a 
mixture of these compounds are assumed to be the sum of the potency-corrected effects of each 
component (also referred to as dose-addition). 
Specific  effect:  In  the  context  of  this  opinion,  a  specific  effect  is  a  well  characterized  and 
unambiguous toxicological effect relevant for grouping in the context of cumulative risk assessment. 
For sake of clarity, a specific effect in this Opinion should also be considered in the context of the 
different level of organisation of the nervous system (i.e. effects on motor division, effects on sensory 
division, and effects on autonomic division). 
Substances: Chemical elements and compounds, as they occur naturally or by manufacture, including 
any impurity inevitably resulting from the manufacturing process. Other synonyms are used in this 
opinion: active substances, pesticides. 
Synergism: Pharmacological or toxicological interaction in which the combined biological effect of 
two or more substances is greater than expected on the basis of the simple summation of the toxicity of 
each of the individual substances. 
Toxic effect: Effect known (or can reasonably be expected) to occur in experimental animals and 
presumably  in  humans  that  results  from  exposure  to  a  chemical  substance  and  that  will  or  can 
reasonably be expected to endanger or adversely affect the quality of life. Cumulative Assessment Groups for Pesticides update 
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APPENDICES 
A.  BACKGROUND FOR HAZARD IDENTIFICATION AND CHARACTERISATION FOR EFFECTS ON THE 
NERVOUS SYSTEM 
1.  A methodological approach to neurotoxicity risk assessment
14 
The  nervous  system  is  an  extremely  complex  entity  and  closely  related  to  other  organ  systems, 
especially the immune and endocrine systems. A number of major anatomic and functional divisions 
can  be  identified  as  potential  targets  for  adverse  effects  when  exposed  to  toxic  substances.  The 
anatomic divisions include both the central and the peripheral nervous system. The central nervous 
system  consists  of  the  brain  and  spinal  cord,  while  the  peripheral  nervous  system  includes  both 
afferent  and  efferent  nerve  pathways.  Afferent  nerves  carry  sensory  information  from  peripheral 
receptors toward the brain while efferent nerves carry motor commands from the brain to effector 
organs (muscles or glands). Efferent pathways can in turn be subdivided into somatic nerves, that 
carry motor information to skeletal muscles, and autonomic nerves that carry motor information to 
cardiac muscle, smooth muscles and exocrine glands. Accordingly, motor, sensory and autonomic 
functions are considered as functional divisions of the nervous system. The specialised functions of 
the nervous system make this organ system vulnerable to many toxic compounds that may affect 
multiple targets in different ways. This is the case with insecticides, pesticides designed to control 
insects by interfering with the nervous system of selected target organisms.  
 
Neurotoxicity can be measured at multiple levels of organization. Structural neurotoxic effects include 
neuroanatomical  abnormalities  occurring  at  any  level  of  nervous  system  organisation.  In  turn, 
functional changes encompass neurochemical, neurophysiological or behavioural effects leading to 
alterations in motor, sensory, autonomic and cognitive function.  
 
When identifying a substance as being neurotoxic, it is important to ascertain whether the nervous 
system is the primary target organ of the substance. The type, severity, number and reversibility of the 
effect  should  also  be  considered.  Irreversible  neurotoxic  effects  are  of  high  concern  and  usually 
involve  structural  changes  or  long  lasting  functional  effects.  Transient  overt  effects  do  not,  by 
themselves, exclude the possibility of a permanent lesion has occurred. In contrast to other tissues, 
nerve cells show limited ability to replace or regenerate neural damage. Thus, when cell death has 
occurred, the lack of potential of neurons to achieve full recovery can result in permanent disruption 
and damage of the nervous system. Although the large reserve capacity of this organ system may 
compensate for the damage, the resulting reduction in the reserve capacity should be regarded as an 
adverse effect. Compensation may be suspected when a neurotoxic effect slowly resolves during the 
life span. 
 
The uncertainties associated with data from any neurotoxic indicator can often be greatly reduced if 
interpreted within the context of other neurotoxicological measures and systemic toxicity indicators, 
particularly if such measures are taken concurrently. Studies that contain results from only one type of 
indicator can often be very difficult to interpret; hence multiple measures provide a multidimensional 
approach  that  allows  for  a  better  interpretation  of  effects.  However,  neurotoxic  effects  that  are 
secondary to systemic toxicities should not be considered as adverse because they occur indirectly.  
 
A framework for interpreting data collected in tests must include five categories of endpoints:  a) 
structural  or  neuropathological,  b)  neurophysiological,  c)  neurochemical,  d)  behavioural,  and  e) 
developmental neurotoxicity, all of them being possible indicators of neurotoxic effects. 
 
                                                       
 
14 Based on information reviewed from IPCS/WHO (2001), Moser (2011), Nielsen et al., (2008); US EPA (1998) Cumulative Assessment Groups for Pesticides update 
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1.1. Structural indicators of neurotoxicity 
Structural  indicators  are  defined as  neuropathological lesions  of  the  central  or  peripheral nervous 
system observed by microscopy, including immunohistochemistry and morphometry. Changes in brain 
weight are also considered as a biologically significant neurotoxic effect of the structural endpoint 
regardless of changes in body weight, because brain weight is generally assumed to be spared under 
conditions of mild undernutrition. 
 
Various histological changes can result after exposure to neurotoxicants, for instance changes in nerve 
cell bodies (chromatolysis, vacuolisation and cell death), axons (swelling, degeneration and atrophy) 
and myelin sheath (folding, oedematous splitting and demyelination). The most distal processes of 
longer  axons  are  especially  vulnerable  to  certain  neurotoxins  resulting  in  a  sort  of  dying-back 
axonopathy leading to a peripheral polyneuropathy, as occurs with some organophosphates (OPs). 
Dying neurons can undergo autophagocytosis or apoptosis with a condensation and dissolution of 
chromatin  and  transfer  of  chromatin  into  cytoplasmic  autophagocytic  vacuoles.  Damage  to  the 
capillaries in the brain can lead to a swelling characteristic of encephalopathy. Gliotic activation is a 
neuroglial response that can be associated with sublethal insults to neurons. In relatively mild injury, 
the  astrocytic  properties  supporting  homeostasis  can  restore  the  damage.  Injury  sufficient  to  kill 
neurons is usually accompanied by a reactive change in astrocyte structure and function. Reactive 
astrocytes  (astrogliosis)  display  hypertrophy,  extend  thick,  long  processes,  elevated  glutamine 
synthetase and oxido-reductive enzyme activity, and significantly increase their cytoplasmic content of 
glial fibrillary acidic protein (GFAP). 
 
Although axonopathies and myelinopathies may correlate with decreased nerve conduction velocity 
(changes in motor or sensitive nerve latencies or peak amplitude; section 1.2.4), both endpoints are 
usually less sensitive than behaviour effects (section 1.4). 
 
1.2.  Neurophysiological indicators of neurotoxicity 
Neurophysiological studies measure the electrical activity of the nervous system. 
 
1.2.1.  Electroencephalography (EEG) 
There is a relationship between specific patterns of EEG waveforms and behavioural states ranging 
from  alertness  to  sleep.  Chemically-induced  seizure  activity  detected  in  EEG  is  evidence  of  a 
neurotoxic effect. Sometimes, changes in the EEG pattern can precede alterations in other objective 
signs of neurotoxicity. However, EEG is of little help for the detection of subtle toxicant-induced 
dysfunction.  
 
1.2.2.  Nerve conduction studies 
Nerve conduction studies are generally performed on peripheral nerves and are useful for investigating 
possible  peripheral  neuropathy.  The  most  critical  measurements  are  nerve  conduction  velocity, 
amplitude of electric potentials and refractory period. A decrease in amplitude of electric potential 
reflects a loss of active nerve fibres and may occur prior to a decrease in conduction velocity in the 
course of peripheral neuropathy. Hence, changes in amplitude of electric potential are better sensitive 
measurements of axonal degeneration. However, when the damage to nerve fibres is not extensive 
enough, the damage may not be reflected in these endpoints. Thus, the interpretation of data may be 
enhanced if evaluations such as nerve pathology or other structural measures are also included. A 
decrease in nerve conduction velocity may be indicative of demyelination. In cases where the primary 
toxic effect is axonal degeneration, nerve conduction velocity may not be reduced unless the fastest-
conducting axons are affected. For this reason, a measurement of normal nerve conduction velocity 
does not necessarily rule out the presence of axonal degeneration. 
 
1.2.3.  Electromyogram (EMG) 
EMG records and analyses the electric activity in skeletal muscles. Changes in the EMG include 
amplitude and firing frequency of spontaneous firing; evoked muscle responses to nerve stimulation Cumulative Assessment Groups for Pesticides update 
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can be used to study alterations in a motor unit, which includes the alpha motor neuron, nerve root, 
peripheral  nerve,  neuromuscular  junction  and  muscle.  The  single-fibre  EMG  (a  more  sensitive 
measure than the EMG with repetitive nerve stimulation) has been used to detect the blockage of 
neuromuscular transmissions induced by organophosphates (OPs). 
 
1.2.4.  Sensory, motor, and other evoked potentials  
Evoked potentials reflect the function of the system under study, including sensory (visual, auditory or 
somatosensory), motor (involving motor nerves and innervated muscles) or other neural pathways in 
the  central  or  peripheral  nervous  system.  The  latency  (time  from  stimulus  onset)  and  amplitude 
(voltage) of the positive and negative voltage peaks are commonly identified and measured. Increases 
in  latencies  can  reflect  deficits  in  nerve  conduction,  including  demyelination  or  delayed  synaptic 
transmission, and are indicators of a neurotoxic effect.  
 
1.3.  Neurochemical indicators of neurotoxicity 
The  integrity  of  nerve  cells  can  be  determined  by  using  general  biochemical  indices,  including 
endpoints  of  cellular  toxicity,  changes  in  energy-linked  functions  or  changes  in  synthesis  of  cell 
constituents  or  proteins.  Persistent  or  irreversible  chemically-induced  neurochemical  changes  are 
indicative  of  neurotoxicity.  If  these  changes  are  expected  to  have  neurophysiological, 
neuropathological or neurobehavioural correlates, then the neurochemical changes could be regarded 
as neurotoxic effects. 
 
The assessment of cholinesterase-inhibiting chemicals should be done on a case-by-case basis using a 
weight-of-evidence approach in which all of the available data (e.g. brain, blood and other tissue 
cholinesterase activity, as well as the presence or absence of clinical signs) are considered in the 
evaluation. Plasma cholinesterase inhibition is considered not relevant. 
 
The WHO-FAO Joint Meeting of Experts on Pesticide Residues (JMPR) has given recommendations 
on interpretation of cholinesterase inhibition. In line with the JMPR (1998), the Netherlands National 
Institute for Public Health and the Environment (RIVM) regards a statistically significant inhibition of 
AChE  ≥  20%  in  the  central  or  peripheral  nervous  system  and  in  erythrocytes  as  toxicologically 
relevant or „adverse‟ (Luttik and Raaij, 2001). The inhibition of 20% may be considered with respect 
to the concurrent control group or with respect to the „pre-exposure‟ values in the treated groups. The 
normal inter-individual variation for brain and erythrocyte AChE activity is roughly ≤ 20%. The US-
EPA considers the value of 20% inhibition as a toxicological effect, but a 1997 policy document 
(Sette, 1997) states that only „statistically significant decreases in brain AChE are generally considered 
toxicologically significant‟. The document „Guidelines for Neurotoxicity Risk Assessment‟ of the US-
EPA (1998) does not include any statement on the toxicologically relevant level of AChE inhibition. 
Nevertheless, statistically signiﬁcant inhibition of less than 20% or statistically insigniﬁcant inhibition 
above 20% indicates that a more detailed analysis of the data should be undertaken (Nielsen et al., 
2008). 
 
A subset of OPs also produces organophosphate-induced delayed neuropathy (OPIDN) after acute or 
repeated exposure. OPIDN is characterized by degeneration of long axons in both peripheral nerves 
and the spinal cord. Inhibition and aging of neuropathy target esterase (NTE) are associated with the 
initiation of OPIDN. However, OPIDN develops when more than 70% of NTE inhibition/aging has 
occurred (Lotti, 1991). This suggests that a certain degree of NTE inhibition, although not correlated 
with clinical neuropathy, can potentially cause OPIDN. 
 
Chemically  induced  injury  to  the  central  nervous  system  can  be  accompanied  by  hypertrophy  of 
astrocytes, leading to an increase in GFAP, the major intermediate filament protein in astrocytes. 
GFAP  can  either  be  measured  biochemically  in  serum  or  by  light  microscopy  with 
immunohistochemical stains (see Structural endpoints of neurotoxicity section). The interpretation of a Cumulative Assessment Groups for Pesticides update 
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chemical-induced change in GFAP is greatly facilitated by corroborative data from the neuropathology 
evaluation. 
1.4.   Behavioural indicators of neurotoxicity 
Behaviour  reflects  the  integration  of  the  various  functional  components  of  the  nervous  system, 
including sensory, motor and associative functions. Neurotoxic substances can adversely affect one or 
more of these functions or disrupt learning and memory processes, resulting in detrimental behavioural 
effects.  Therefore,  behaviour  is  generally  considered  a  sensitive  indicator  of  neuronal  function, 
irrespective of the strong subjective bias that is implied in recording of behavioural effects, and may 
serve as a robust means of monitoring the neurotoxic potential of chemicals.  
 
Changes in behaviour can arise from a direct effect of a toxicant on the nervous system or indirectly 
from its effects on other physiological systems. These changes may be observed in the absence of 
neuropathological  evidence  of  structural  damage.  Tilson  (1993)  proposed  two  distinct  tiers  of 
functional testing of neurotoxicants. In the first tier, functional observational batteries (FOB) and 
motor activity tests may  be used as a screening procedure to identify the neurotoxic effects of a 
chemical. The second tier involves many other measures of behaviour, including specialized tests of 
motor and sensory function and of learning and memory that allows for a more complete description 
of the effects and for dose-response relationships. Neurochemical and electrophysiological tests can 
also be included in the second tier based on the results of the core studies (Moser, 2011). 
 
1.4.1.  Functional Observational Battery (FOB).  
 
A FOB is designed to detect and quantify major overt behavioural, physiological and neurological 
signs. It is based on the Irwin screen test, a gross neurological assessment of basic sensory-motor 
performance. For regulatory testing, the FOB provides information on effects at low doses and is 
sensitive to chemicals acting by different modes of action. 
 
Sometimes,  FOB  data  can  be  grouped  into  more  than  one  neurological  functions  which  do  not 
necessarily map to specific regions of the nervous system. A typical FOB includes the following 
domains: 
  Motor function. Motor function may be measured in terms of motor activity, coordination, 
equilibrium  and  strength.  Motor  effects  have  been  classified  into  four  types:  weakness 
(decreased strength), incoordination, tremor and abnormal motor movements (myoclonia or 
spasms). Gait has been assessed as an index of coordination. Dose-dependent increases or 
decreases on the motor activity are common neurobehavioral endpoints reflecting pesticide 
neurotoxicity. Changes in motor activity often occur at exposure levels that affect other types 
of  behaviour  and  at  levels  of  exposure  that  do  not  produce  gross  signs  of  intoxication. 
However, interpretation of motor activity data in isolation can be problematic. 
  Sensory testing used in first-tier screening involves either testing simple reflexes (e.g. pinna 
reflex) or evaluation of the motor response to a variety of sensory stimuli such as auditory, 
nociceptive or somatosensory (e.g. startle response, tail pinch response, splay reflex).  
  Autonomic function: e.g. pupil response to light, pupil size (miosis, mydriasis), salivation, 
lacrimation, urination.  
 
Many FOB tests are essentially clinical neurological examinations that rate the presence or absence of 
specific neurological signs. If neurological signs result only at the high dose and together with other 
overt  signs  of  toxicity  (e.g.  systemic  toxicity,  large  decreases  in  body  weight,  decreases  in  body 
temperature or debilitation) there is less persuasive evidence of a direct neurotoxic effect
15. In contrast, 
                                                       
 
15 The external scientific report (CFT/EFSA/PRAS/2012/07) concludes that great care is needed when considering clinical 
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when affected measures in a battery of tests are dose-dependent, the data are considered to be evidence 
of a neurotoxic effect, especially in the absence of systemic toxicity.  
 
1.4.2.  Specialized tests for neurotoxicity (that include specific neurobehavioral functions):  
  Motor  Function.  Specialized  tests  used  to  assess  muscle  weakness  include  quantitative 
measures  of  limb  grip  strength,  swimming  endurance,  suspension  from  a  hanging  rod, 
discriminative motor function and landing foot splay. Automated rotorod and quantitative gait 
assessments measure coordination, while rating scales and spectral analysis techniques are 
used to quantify tremor and other abnormal movements.  
  Sensory Function. Gross perturbations of sensory function may not be sufficiently sensitive to 
detect  subtle  sensory  changes.  Several  approaches  have  been  devised  to  measure  sensory 
deficits, including discriminated conditioning and startle reflex modification. 
  Cognitive Function. Measurement of changes in learning and memory should be separated 
from other changes in behaviour that do not involve cognitive or associative processes (e.g. 
motor function, sensory capabilities, motivational factors). Examples of procedures to assess 
cognitive  function  include  tests  for  spatial  learning  and  memory,  spatial  or  positional 
navigation  of  mazes,  simple  or  complex  conditioned  responses  and  operant  training  of 
positively or negatively reinforced behaviours. Many of the current cognitive procedures are 
either water-based mazes or shock-motivated (i.e. simple conditioned avoidance of shock, 
such as passive  avoidance).  Many  cognitive  tests are  conducted as  part of  developmental 
neurotoxicity assessment. 
 
1.5.  Developmental neurotoxicity (DNT) 
The DNT study is a specialized type of developmental toxicity study designed to screen for adverse 
effects of pre- and postnatal exposure on the development and function of the nervous system and to 
provide  dose–response  characterizations  of  those  outcomes.  The  US  EPA  (1998)  developed  test 
guidelines for assessing DNT of pesticides, among other environmental chemicals, as tier 2 studies for 
active  substances  showing  any  evidence  of  neurotoxicity,  endocrine  modulation  or  certain 
developmental or reproduction toxicity.  Similarly, Regulation (EU) No 283/2013 of 1 March 2013 
provides  that,  when  indicated  by  observations  in  other  studies  or  the  mode  of  action  of  the  test 
substance,  supplementary  studies  or  information  may  be  required  to  provide  information  on  the 
postnatal manifestation of effects such as developmental neurotoxicity. A reference to the OECD Test 
Guideline 426 is given in the Commission Communication 2013/C 95/01. 
Both the prenatal and postnatal periods to the time of sexual maturation are critical developmental 
windows wherein functional competence may be disrupted as a result of pesticide exposure. This 
means that foetuses, infants and children may be differentially sensitive and not comparable between 
rodents  and  humans
16  because of the potential of these chemicals to impair the appearance or 
maturation of sensorimotor reflexes. While the developing nervous system is often more sensitive to 
insult (depending on the stage of development), the high rate of proliferation and regeneration in the 
developing nervous system may lead to greater recovery or plasticity (an ability of one portion of the 
nervous system to assume the function of an injured area), which could attenuate some injuries. 
 
The behaviours measured in DNT studies include the development of motor, sensory, autonomic and 
cognitive (learning and memory) functions. Tests are performed at different time-points (weaning and 
adulthood)  to  cover  all  neurodevelopmental  stages.  Neuropathological  and  morphometric 
examinations are also performed to detect growth defects and morphologic abnormalities. Since many 
of  the  behaviours  evaluated  are  the  same  as  those  used  in  adult  rats,  additional  features  in 
developmental studies include assessing the ontogeny of these behaviours or whether there are 
persistent behavioural changes lasting into adulthood. „In vitro‟ DNT tests provide complementary 
                                                       
 
16 The early postnatal stages of the development of nervous system in rodents correspond to the late prenatal phase in 
humans. Cumulative Assessment Groups for Pesticides update 
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information  since  they  are  based  on  key  events  of  brain  development  such  as  proliferation, 
differentiation, growth, synaptogenesis, myelination or apoptosis. 
 
Functional deficits are observed at dose levels below those at which other indicators of developmental 
toxicity are evident or at minimally toxic doses in adults. Information available so far is inadequate to 
assume  that  developmental  effects  at  doses  causing  minimal  maternal  toxicity  result  only  from 
maternal toxicity; rather, it may be that the mother and developing organism are equally sensitive to 
that dose level.  
 
2.  Neurological disorders in humans potentially associated with long-term pesticides exposure 
Acute  (short-term)  effects  of  overdoses  of  most  pesticides  are  well  characterised  and  they  vary 
depending  on  the  active  substance, the  dose  and  the  susceptibility  of  the  individual  exposed.  By 
contrast, the scientific community is less certain about the long-term health effects that may result 
from repeated exposures over time. Despite this, there is growing epidemiological data supporting an 
association between neurological effects and pesticide exposure. Recent studies point to some possible 
long-term health effects from repeated low-level exposure to pesticides, although this data are still 
inconclusive.  
 
A  recent  meta-analysis  suggests  a  relationship  between  pesticide  exposure  and  neurodegenerative 
diseases such as Parkinson‟s disease, Alzheimer‟s disease and amyotrophic lateral sclerosis. Thus, 
exposure to herbicides and insecticides could increase the risk of Parkinson‟s disease (van der Mark et 
al.,  2012).  However,  a  prospective  study  has  found  a  weak  but  dose-related  association  between 
pesticide exposure and risk for Parkinson's disease, although it was based on a small number of cases 
(Kenborg et al., 2012). It is known from animal experiments that rotenone can cause symptoms that 
are typical for Parkinson‟s disease. These symptoms have pathological correlates that include, for 
example, cytoplasmic inclusions in the neurons of the  substantia nigra, a region of the midbrain 
involved in the pathogenesis of Parkinson‟s disease. Rotenone can lead to a progressive degeneration 
and loss of nigrostriatal dopaminergic neurons (BfR, 2006). The mechanisms underlying rotenone-
induced Parkinson‟s symptoms in mice (Pan-Montojo et al., 2012) can therefore be interpreted as 
further indications of a possible association between rotenone exposure and Parkinson‟s-like disease. 
Other  meta-analysis  has  found  that  exposure  to  pesticides  as  a  group  is  associated  with  the 
development  of  amyotrophic  lateral  sclerosis,  although  the  analysis  of  Agricultural  Health  Study 
(AHS) data points in particular to organochlorine pesticides use (Kamel et al., 2012; Malek et al., 
2012).  
 
Occupational pesticide exposure has been reported to increase the risk of dementia and Alzheimer 
disease in late life (Hayden et al., 2010). Environmental pesticide exposure has also been linked to the 
development of Alzheimer‟s disease (Parrón et al., 2011). 
 
There is growing evidence that the nervous system in young animals is particularly vulnerable to some 
insecticides, hence early life environmental exposure to pesticides could play a critical role in the 
onset of age-related diseases. There is some experimental basis for this because postnatal exposure to 
cypermethrin  in  rats  enhances  the  susceptibility  of  animals  to  dopaminergic  neurodegeneration  if 
rechallenged during adulthood (Singh et al., 2012). 
 
Human epidemiological studies have found associations between environmental exposure to pesticides 
and prenatal and postnatal adverse effects. The results reported by a small number of longitudinal birth 
cohort studies suggest that prenatal exposure to OP pesticides in the early stages may adversely affect 
the  developing  nervous  system  of  the  child,  in  particular  the  cognitive  function  (e.g.  pervasive 
developmental  disorders,  delays  in  cognitive  development  and  attention  deficit).  However,  the 
experimental evidence for adverse neurodevelopmental effects in children after postnatal exposure to 
these  compounds  is  less  persuasive.  Behavioural  problems,  poorer  short-term  memory  and  motor 
skills, and longer reaction time have been observed in cross-sectional studies (London et al, 2012). Cumulative Assessment Groups for Pesticides update 
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3.  Establishment of CAG for toxic effects on the nervous system 
3.1.  CAG level 1 
In the DTU report (2012), CAG level 1 was defined as „Toxicity to the nervous system‟ as the nervous 
system was identified as the relevant organ and target tissue.   
3.2.  CAG level 2 
The DTU proposed three distinct CAG 2 levels: 
  Functional  changes  related  to  the  motor  division  (53  pesticides),  involving  effects  on  the 
movement  of  muscles  (motor  activity,  ataxia,  choreoathetosis,  abnormal  gait,  paralysis, 
neuromuscular dysfunction), effects on locomotion (decreased locomotion) and  neuropathy 
(peripheral neuropathy, particularly OP-induced delayed polyneuropathy). 
  Effects on reflex action (16 pesticides), which involves either sensory (afferent stimuli) or 
motor (efferent response) division of the nervous system in an involuntary manner. 
  Effect  on  cognition  (7  pesticides),  an  intellectual  process  that  involves  all  aspects  of 
perception, thinking, reasoning and remembering. 
 
The DTU did not consider the presence of vacuoles in brain, changes in relative brain weight and 
induction of neoplasm (particularly astrocytomas) as relevant for CAG level 2 as these three effects 
were  viewed  as  non-adverse,  not  to  be  treatment-related  and  not  to  be  statistically  significantly 
different  from  control  groups,  respectively.  Besides,  brain  neoplasms  (astrocytomas)  are  rarely 
described in experimental studies and no statistically significant differences have been found between 
treated and control groups, hence they should not be taken into account for CRA. 
 
The active substances identified as neurotoxic by the RIVM contractor (ANSES/ICPS/RIVM, 2013) 
have  been  included  in  a  reporting  table  along  with  relevant  information  on  critical  endpoints, 
NOEL/LOEL  in  the  most  sensitive  species  and  the  neurotoxic  mode  of  action.  However,  for  32 
pesticides identified as neurotoxic the specific mode of action is still unknown. RIVM proposed the 
following effects (indicators) for grouping: 
  AChE inhibition. 
  Tremor. 
  Salivation. 
  Ataxia (abnormal gait, among other synonyms). 
  Motor activity (impaired mobility, open field activity, ambulatory activity, hypo/hyperactivity, 
decreased rearing activity). 
  Reflex/sensory response (hypersensitivity, absence of pupil response, lack of touch response, 
lack of startle response, negative air drop, decreased analgesic reflex). 
  Cognition  (learning,  memory,  maze  test  performance,  performance  in  active/passive 
avoidance test). 
 
A number of effects (such as prostration, convulsion, opisthotonus, laboured breathing, tachypnea, 
hunched position/posture, dyspnoea, exopthalmos, lethargy, piloerection, curved body position, coma, 
hypothermia, vomiting and alopecia) were considered as non-specific by RIVM, often secondary to 
general  systemic  toxicity  after  high  doses  rather  than  a  neurotoxic  property  of  the  pesticide. 
Accordingly, they are not deemed appropriate for establishing CAGs unless they appeared at low 
doses. Piloerection can also be considered an autonomic sign. 
 
The evaluation summarised in the table for hazard identification and characterisation (see chapter 7) 
combines information from the DTU report (DTU, 2012) and RIVM (ANSES/ICPS/RIVM, 2013). 
The information was also combined with information hazard identification and characterisation from Cumulative Assessment Groups for Pesticides update 
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US-EPA and IPCS/WHO reports. The following toxicological effects are therefore recommended for 
the nervous system CAG 2: 
CAG 2.1. Functional effects on motor division 
CAG 2.2. Functional effects on sensory division (including sensory-motor reactivity or reflex   
action) 
CAG 2.3. Functional effects on autonomic division 
CAG 2.4. Neurophysiological alterations 
CAG 2.5. Neurochemical endpoints (AChE inhibition) 
CAG 2.6. Neuropathological endpoints 
 
This approach does not meet the systematic order described in section 1 of this Annex because the 
available  toxicological  data  failed to contain  information  for some  of the  categories  of  endpoints 
described,  as  occurred  for  cognitive  (learning  and  memory)  and  developmental  neurotoxicity 
indicators  of  adverse  effects.  In  addition,  data  related  to  neurochemical  endpoints  are  limited  to 
acetylcholinesterase  inhibition  in  blood  or  brain  and  only  few  neurophysiological  and 
histopathological  data  are  available.  Since  most  of  experimental  data  were  collected  from  FOB 
studies, behavioural data (motor, sensory and autonomic functions) predominate.  
 
Further refinement of the above mentioned adverse effects was made for the hazard characterisation 
(step 2). 
 
3.3.  CAG level 3. Data collection 
The  majority  of  the  data  collection  for  neurotoxicity  had  been  performed  by  DTU  and  later  re-
evaluated by RIVM prior to the finalization of step 1 and 2. A minor part of the data collection was 
performed by EFSA at a later stage. This would explain any differences in the approach taken for the 
data collection between DTU, RIVM and EFSA. 
 
From the 224 active substances included in Annex I of the Council Directive 91/414/EEC prior to 31
st 
May 2009, only 67 were identified by DTU as having effects on the nervous system. Then, from 31
st 
May 2009 until 1
st of January 2012, 60 new active substances were added to Annex I.  
 
In total, 130 active substances have been scrutinised by RIVM for their neurotoxic potential, including 
the 3 substances not previously assessed by DTU (flurtamone, oxadiargyl and pyridate), although only 
pyridate  showed  potentially  neurotoxic effects.  Evaluation  of  the  60 pesticides  added  to  Annex  I 
during the period 31
st of May 2009 until 1
st of January 2012 revealed that 9 had clear neurotoxic 
properties. However, two of these (zinc phosphide and aluminium sulphate) were not included in the 
final reporting table as their targeted use (rodenticide and bactericide on cut flowers, respectively) 
does not involve edible plants and it is unlikely to find significant residues in plant or animal products. 
In fact, no MRLs have been set for these substances in either plant or animal products. 
 
After performing a re-evaluation of all data, RIVM found no convincing evidence for 8 pesticides 
identified as neurotoxic by the DTU report (dimoxystrobin, dinocap, florasulam, fosetyl-aluminium, 
phenmedipham, prosulfocarb, sulcotrione and triflusulfuron-methyl). Although some of them are able 
to inhibit cholinesterase or to develop some neurotoxic effects, they are of slight magnitude, non-
specific  or  secondary  to  high-dose  systemic  toxicity.  Accordingly,  they  were  not  considered  for 
grouping  purposes.  The  RIVM  database  included  the  active  compounds  desmedipham  and 
chlorpropham,  however  given  that  they  are  structurally  very  similar  to  each  other  and  to 
phenmedipham  (all  of  them  are  phenylcarbamate  herbicides),  their  toxicological  profile  was 
scrutinised  and  no  evidence  of  neurotoxic  potential  was  found.  Nevertheless,  desmedipham  and 
chlorpropham  remain  in  the  grouping  table  because  their  DARs  have  identified  several  specific 
endpoints of neurotoxicity. 
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A  number  of  active  substances  excluded  by  the  DTU  report  showed  neurotoxic  effects  just  as  a 
consequence of a generalised secondary effect or at dose levels close to those that produced mortality. 
This  is  the  case  of  aluminium  phosphide,  benzoic  acid,  benthiavalicarb,  bifenazate,  copper 
compounds, cyromazine, difenoconazol, etofenprox, etoxazole, fenpyroximate, magnesium phosphide, 
metamitron,  metribuzin,  pymetrozine,  pyriproxyfen,  tebufenpyrad,  thiophanate-methyl  and 
tolylfluanid. Accordingly, none of the compounds showing neurotoxic effects as a result of general 
toxicity were included in the grouping table. By contrast, other active substances also excluded by 
DTU, such as tebuconazole and tetraconazole, were identified as producing some toxic effects on the 
nervous system. Thus, both of them were considered for grouping. 
In summary, a total of 68 active substances placed on Annex I of the Council Directive 91/414/EEC 
prior to 1
st of January 2012 were identified as having neurotoxic properties by RIVM.  
 
3.4.  CAG level 4. Grouping 
Different approaches can be used for grouping active substances, like structural similarities of the 
parent compounds (or their toxic metabolites), degree of knowledge of their mechanism of toxic action 
or  a  common  toxic  effect.  The  approaches  might  be  different  from  each  other  if  used  for  risk 
assessment or for MRL setting. Despite the fact that the most appropriate criteria for further refining 
cumulative assessment groups are based on the mode of action, this information is unknown for many 
of the active substances identified as neurotoxic. Although a number of neurotoxic pesticides share 
common specific effects, the underlying toxic mechanism at biochemical level is often unknown. 
 
For  this  reason,  grouping  of  active  substances  was  based  on  observed  specific  indicators  for 
neurotoxic effects, which is an imperfect criterion since they can differ as a function of the dose or the 
duration of the treatment. Accordingly, this preliminary approach must be considered as non-definitive 
grouping that needs further refinement, when knowledge gaps related to the mode of action are filled. 
In addition, this would represent the most precautionaryapproach that takes advantage of the available 
toxicological database on neurotoxic effects of many active substances. One important limitation of 
this approach is the lack of a clear definition of a common endpoint in terms of identical cell types 
affected, identical pathology or identical biological response in the same target organ.  
 
The  testing  methodology  for  DNT  has  not  been  a  requirement  in  the  European  Union  and  this 
circumstance contributes to the lack of characterization of these specific effects. Specific DNT testing 
has  not  been  conducted  according  to  OECD  guideline  426  since  it  was  developed  in  2007. 
Accordingly,  the  exercise  of  DNT  grouping  cannot  be  considered  fully  correct  because  the 
experimental studies available for risk assessment were restricted to developmental and reproductive 
toxicity testing. For this reason, DNT effects have not been grouped together with the rest of the 
indicators of neurotoxic effects.  
 
Two  tables  have  been  developed  for  grouping  active  substances, one  for  acute  and  the  other for 
chronic indicators of neurotoxic effects. The latter also includes data from subchronic studies. Data 
were tabulated according to the level of organisation of the nervous system (category of neurotoxic 
endpoints), the specific indicator of toxic effect, the active substance, its mode/mechanism of action 
and the lowest experimental toxicity indices (NOAEL and LOAEL) for each specific indicator of 
neurotoxicity. Sometimes the indices derived from several toxicological studies reported in the DARs 
 
According to the criteria employed for grouping, each active substance may show more than one 
NOAEL/LOAEL, depending on the number of toxic effects identified in the databases used. A number 
of pesticides may share the same toxic endpoints via similar or dissimilar mechanism of action and 
therefore  have  been  grouped  together;  however  for  many  of  them  the  mechanisms  of  action  are 
unknown. Certain neurotoxic signs (such as tremors, lack of motor coordination, ataxia, decreased 
motor activity and abnormal posture) may result from the activation of the nicotinic receptor. Thus, 
these signs can appear after exposure to pesticides showing different mechanisms of toxic action but a 
similar mode of action (modulation of cholinergic synaptic transmission). 
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The following considerations have been taken into account for grouping active substances: 
 
  Given  the  complexity  of  the  Nervous  system,  most  DARs  rely  on  a  functional  observational 
battery (FOB) as indicators of specific effects. 
  Indicators  for  specific  neurotoxic  effects  selected  for  the  grouping  table  are  based  on  the 
information collected and included in the RIVM database and in an additional database developed 
by EFSA containing compounds excluded by the DTU report. Since no one cognitive indicator of 
effects  has  been  identified  in  the  databases,  this  neurologic  domain  has  not  been  considered 
separately. 
  Only studies where the active substance was administered by oral route have been considered for 
grouping. 
  Data from reproductive toxicity studies were not considered since toxicological endpoints were 
not always clearly reported as pertaining to dams or pups. 
  Developmental toxicity studies were also disregarded as they did not properly assess toxic effects 
on the developmental nervous system. 
  Sometimes, the same specific effect is reported with different names, depending on the DARs and 
the experimental studies. This has been also acknowledged by the DTU and RIVM. 
  Some effects were described in a very general way (e.g. head shaking, head movements) and they 
have been reinterpreted (e.g. choreoathetosis). 
  Non-specific or secondary effects are often described in the database but they have not been 
considered  for  grouping.  This  is  the  case  of  emesis,  hypothermia,  headache,  exopthalmus, 
aggression, opisthotonus, nystagmus and vocalisation. The same applies to those effects that occur 
after administration of high doses of the active substances resulting in general toxicity, such as 
laboured breathing, emaciation or prostration. 
  Some  effects  (e.g.  convulsion)  may  occur  after  high  doses,  as  a  result  of  general  toxicity. 
However, they can be also a specific effect of an active substance (e.g. tonic-clonic convulsions of 
pyrethroids).  
  Some NOAEL for acute effects do not derive from acute neurotoxicity studies but they are based 
on 14-, 28- or 90-day studies, with observations being performed on the first day of dosing.  
  Salivation has been considered as an autonomic effect. Nonetheless, it is also a particular effect 
produced by type II (α-cyano) pyrethroids, the so-called CS (choreoatetosis-salivation) syndrome. 
  Abnormal posture of animals, especially lateral recumbency, has been considered as a neurotoxic 
effect since it may be observed in cerebellar lesions. 
  Decreased limb strength may be associated with dragging of the feet along the floor, hindlimb 
paresis/paralysis, foot splay, hopping gait and eventually ataxia.  All these clinical outcomes are in 
fact a continuum of effects that can or cannot be considered as a single effect for the purpose of 
grouping. 
  Several experiments have been carried out with a given pesticide and different animal species and 
dose  regimes.  The  lowest  NOAEL  and  LOAEL  were  selected  for  each  specific  indicator  of 
neurotoxicity  based  on  combined  data  from  two  or  more  studies.  Thus,  some  NOAELs  and 
LOAELs derive from different studies or reports. 
  Studies  considered  unacceptable  by  EFSA  have  not  been  taken  into  consideration  (e.g.  not 
guidelines, not GLP).  
  Modes of action are based primarily on the information included in RIVM database and for some 
active substances the open scientific literature has been reviewed. 
  The neurochemical endpoints represent a level of grouping for neurotoxic substances based on 
mechanism of action. However, to keep consistency in the group methodology, the cumulative 
assessment grouping was limited to phenomenological observations following the motor, sensory 
and autonomic division of the nervous system. Indeed, the AChE inhibitors play a prominent role 
in  the  risk  assessment  and  grouping  neurochemical  endpoints  would  result  in  an  increased 
sensitivity for some substances and this grouping should be used for further refinement where this 
mechanism of action is recognised. Cumulative Assessment Groups for Pesticides update 
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  Molinate,  desmedipham  and  toclofos-methyl  were  not  considered  for  grouping  within  the 
„neurochemical endpoints‟ because they are atypical cholinesterase inhibitors showing a weak 
AChE inhibition potential. For tolclofos-methyl, the only neurotoxicity data collected by RIVM 
was AChE inhibition. Although this compound is an organothiophosphate ester used as herbicide, 
there is a lack of consistency between older and new studies regarding AChE inhibition. Besides, 
clinical signs of cholinergic overstimulation were not observed in experimental studies. On the 
other  hand,  it  has  been  acknowledged  the  unlikelihood  of  being  exposed  to  tolclofos-methyl 
residues through the diet (EPA, 2013) 
  Neuropathological endpoints were considered relevant only for chronic cumulative assessment 
grouping. This is because, for chronic treatments, some active substances were only showing 
neuropathological  findings  as  well  as  for  some  other  active  substances,  neuropathological 
endpoints were the most sensitive.   Cumulative Assessment Groups for Pesticides update 
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B.  DATA COLLECTION FOR EFFECTS ON THE NERVOUS SYSTEM 
B.1. Data collection for neurotoxicity - RIVM 
See separate file. 
B.2. Data collection for neurotoxity – EFSA 
See separate file. 
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C.  ACUTE CAGS FOR THE NERVOUS SYSTEM 
 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
Functional 
effects on Motor 
division 
Ataxia  Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Formetanate  1  10  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Fenamiphos  1.25  2.31  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Abamectin  1.5  6  Presumed  Binding to GABA receptors and GABA gated 
ion channels. 
  Ataxia  Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Ataxia  Alpha-
Cypermethrin 
2.3  6.8  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Tefluthrin  5  10  Presumed  Type I pyrethroid. Opening of sodium channels 
in the nervous system 
  Ataxia  Fosthiazate  5.4  26.8  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Cypermethrin  7.5  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Phosmet  9  36  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Milbemectin
1  10  30  Presumed   Binding to GABA receptors and GABA gated 
ion channels 
  Ataxia  zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Ataxia  2,4-D  < 15  15  Unknown   Cell and mitochondrial membrane damage, 
uncoupling of oxidative phosphorylation and 
interference of cellular metabolism? 
  Ataxia  Ziram  < 15  15  Presumed  Neurotoxic effect might be due to its metabolite 
CS2 
  Ataxia  Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Ataxia  Clothianidin  60  177  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Ataxia  Flufenacet  < 75  75  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress 
  Ataxia  Tebuconazole
1  < 100  100  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Ataxia  Dicamba  < 300  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Ataxia (poor 
coordination) 
Tetraconazole
1  < 300  300  Unknown  Neurotoxic potential of 1,2,4-triazole, a 
metabolite common to a number of triazole-
derivative pesticides 
  Choreoatetosis  Cyfluthrin  1  2.5  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Choreoatetosis  Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Convulsions  zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Convulsions  Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Convulsions  Clothianidin  60  177  Known  Nicotinic acetylcholine receptor (nAChR) Cumulative Assessment Groups for Pesticides update 
 
 
81  EFSA Journal 2013;11(7):3293 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
agonist 
  Convulsions  Pirimiphos-methyl  150  1500  Known  Inhibition of acetylcholinesterase (AChE) 
  Higher grip 
strength 
Thiamethoxam
1  100  500  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Hunched 
posture 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Hunched 
posture 
Pirimicarb  10  40  Known  Inhibition of acetylcholinesterase (AChE) 
  Hunched 
posture 
zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Hunched 
posture 
Ziram  < 15  15  Presumed  Neurotoxic effect might be due to its metabolite 
CS2 
  Hunched 
posture 
Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Hunched 
posture 
Glufosinate  100  500  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Hunched 
posture 
Tetraconazole
1  < 300  300  Unknown  Neurotoxic potential of 1,2,4-triazole, a 
metabolite common to a number of triazole-
derivative pesticides 
  Increased motor 
activity 
Triadimenol (a 
metabolite of 
Triadimefon) 
2  35  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Landing-foot 
splay 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Landing-foot 
splay 
Fipronil  0.5  5  Presumed  Blocking the passage of chloride ions through 
the GABA receptor 
  Landing-foot 
splay 
Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Landing-foot 
splay 
Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Landing-foot 
splay 
Tefluthrin  5  10  Presumed  Type I pyrethroid. Opening of sodium channels 
in the nervous system 
  Landing-foot 
splay 
zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Landing-foot 
splay 
Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Muscle 
fasciculation 
Methiocarb  <2.5  2.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Motility 
disturbances 
Tebuconazole
1  < 100  100  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Recumbency  Tebuconazole
1  < 100  100  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Recumbency  Tetraconazole
1  < 300  300  Unknown  Neurotoxic potential of 1,2,4-triazole, a 
metabolite common to a number of triazole-
derivative pesticides 
  Reduced grip 
strength 
Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Reduced grip 
strength 
Thiram  5  150  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Reduced grip 
strength 
zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Reduced grip 
strength 
Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced grip 
strength 
Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Reduced grip 
strength 
Dicamba  < 300  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Reduced motor 
activity 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced motor 
activity 
Beta-Cyfluthrin  0.5  2  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Reduced motor 
activity 
Lambda-
Cyhalothrin 
0.52  1.3  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Reduced motor 
activity 
Formetanate  1  10  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced motor 
activity 
Thiacloprid  3.1  11  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Reduced motor 
activity 
Ethoprophos  5  10  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced motor 
activity 
Acetamiprid  10  30  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Reduced motor 
activity 
Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced motor 
activity 
Pyridate  20  60  Unknown   
  Reduced motor 
activity 
Tri-allate  36  72  Unknown   
  Reduced motor 
activity 
Chlorpropham  50  125  Unknown  Impairment of mitochondrial function related to 
oxidative phosphorylation leading to ATP 
depletion? 
  Reduced motor 
activity 
Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Reduced motor 
activity 
Mepiquat  58  174  Presumed   Activation of nicotinic and muscarinic 
acetylcholine receptors 
  Reduced motor 
activity 
Clothianidin  60  177  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Reduced motor 
activity 
Flufenacet  < 75  75  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress 
  Reduced motor 
activity 
Dicamba  < 300  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Tremor  Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Fluquinconazole  0.45  1.79  Unknown   
  Tremor  Methomyl  0.75  2  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Formetanate  1  10  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Tremor  Methiocarb  < 2.5  2.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Tefluthrin  5  10  Presumed  Type I pyrethroid. Opening of sodium channels 
in the nervous system 
  Tremor  Phosmet  9  36  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Acetamiprid  10  30  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Tremor  Milbemectin
1  10  30  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Tremor  zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Pyrethrins  20  63  Known  Opening of sodium channels in the nervous 
system Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Tremor  Imidacloprid  23.5  45.4  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Tremor  Metaldehyde  < 75  75  Unknown  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? 
Functional 
effects on 
Sensory division 
Abnormal 
righting reflex. 
Increased tail 
flick latency 
time 
Dicamba  < 300  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Absence of 
pupil response 
Dimethoate  2  20  Known  Inhibition of acetylcholinesterase (AChE) 
  Approach 
response, tail 
pinch response, 
air righting 
reflex. 
Fipronil  5  25  Presumed  Blocking the passage of chloride ions through 
the GABA receptor 
  Decrease in 
acoustic startle 
response 
amplitude 
Deltamethrin  < 1  1  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Decreased 
arousal 
Clothianidin  < 100  100  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Decreased touch 
responses, tail 
pinch response 
and impaired 
righting. 
Beta-Cyfluthrin  2  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Diminished 
reaction to tail 
pinch test, 
abnormal 
response to 
visual placing 
Formetanate  1  10  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
test, auditory 
startle response 
  Exaggerated 
startle response 
Pyrethrins  63  200  Known  Opening of sodium channels in the nervous 
system 
  Handling 
reactivity, 
approach 
response, startle 
response, air 
righting 
Thiram  5  150  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Hypersensitivity 
to noise 
Cypermethrin  7.5  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Increased 
reaction to 
touch, increased 
reaction to tail 
pinch 
Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Increased 
reactivity 
Imidacloprid  42  151  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Lack of 
pupillary reflex 
Mepiquat  174  697  Presumed   Activation of nicotinic and muscarinic 
acetylcholine receptors 
  No reaction to 
tail-pinch 
stimulus 
Methomyl  1  1.9  Known  Inhibition of acetylcholinesterase (AChE) 
  Poor reflexes  Tebuconazole
1  < 100  100  Unknown   
  Reduced splay 
reflex 
Abamectin  0.5  1.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels. 
  Reduced 
righting reflex, 
reduced toe/tail 
Metaldehyde  150  250  Unknown  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
pinch response 
  Righting reflex  zeta-Cypermethrin  10  50  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Righting reflex, 
tail pinch 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Uncoordinated 
landing in the 
righting reflex 
Thiamethoxam
1  100  500  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
Functional 
effects on 
autonomic 
division 
Lacrimation  Methomyl  0.75  2  Known  Inhibition of acetylcholinesterase (AChE) 
  Lacrimation  Methiocarb  < 2.5  2.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Lacrimation  Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Lacrimation  Tri-allate  < 500  500  Unknown   
  Miosis  Formetanate  1  10  Known  Inhibition of acetylcholinesterase (AChE) 
  Miosis  Fenamiphos  1.52  2.31  Known  Inhibition of acetylcholinesterase (AChE) 
  Miosis  Fipronil  5  50  Presumed  Blocking the passage of chloride ions through 
the GABA receptor 
  Miosis  Pirimicarb  10  40  Known  Inhibition of acetylcholinesterase (AChE) 
  Miosis  Ethephon  <500  500  Known  Inhibition of acetylcholinesterase (AChE) 
  Mydriasis  Deltamethrin  1  2.5  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Mydriasis  Thiacloprid  53  109  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Mydriasis  Metaldehyde  < 75  75  Unknown  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? 
  Piloerection  Fenamiphos  1.52  2.31  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Salivation  Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Methomyl  0.75  2  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Esfenvalerate  1.8  1.9  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Salivation  Beta-Cyfluthrin  2  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Cyfluthrin  2.5  7.5  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Methiocarb  < 2.5  2.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation 
(accompanied 
by vomiting) 
Milbemectin
1  3  10  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Salivation  Alpha-
Cypermethrin 
4  10  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Phosmet  9  36  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Ethoprophos  12  25  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Dimethoate  20  200  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Pyridate  30  80  Unknown   
  Salivation  Pyrethrins  63  200  Known  Opening of sodium channels in the nervous 
system 
  Salivation 
(accompanied 
by vomiting and 
retching) 
Chlorpropham  125  625  Unknown  Impairment of mitochondrial function related to 
oxidative phosphorylation leading to ATP 
depletion? 
  Salivation  Tebuconazole
1  250  500  Unknown   
  Salivation  Tri-allate  < 500  500  Unknown   Cumulative Assessment Groups for Pesticides update 
 
 
89  EFSA Journal 2013;11(7):3293 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
  Urination  Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  Urination  Thiram  5  150  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Urination  Acetamiprid  10  30  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Urination  Cypermethrin  20  60  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Urination  Indoxacarb  50  100  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Urination  Thiacloprid  53  109  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Urination  Pyrethrins  63  200  Known  Opening of sodium channels in the nervous 
system 
  Urination  Flufenacet  < 75  75  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress 
Neurochemical 
end-points 
AChE inhibition 
(brain) 
Formetanate  0.1  1  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Methomyl  0.25  0.5  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Fosthiazate  0.5  5.4  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Pirimicarb  < 2  2  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Fenamiphos  2.7  9.3  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Phosmet  4.5  22.5  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition  Pirimiphos-methyl  15  150  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
LO(A)EL 
mg/kg bw 
Mode/mechanism of action 
(brain) 
  AChE inhibition 
(erythrocytes) 
Formetanate  0.1  1  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Oxamyl  0.1  0.75  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Methomyl  0.25  0.5  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Methiocarb  < 0.5  0.5  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Dimethoate  1  2  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Ethoprophos  < 5  5  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Malathion  10  > 10  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Pirimiphos-methyl  15  150  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Ethephon  22  66  Known  Inhibition of acetylcholinesterase (AChE) 
NO(A)EL/LO(A)EL are expressed in mg/kg/day or mg/kg 
1Substance excluded by DTU Cumulative Assessment Groups for Pesticides update 
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D.   CHRONIC CAGS FOR THE NERVOUS SYSTEM 
 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
Functional 
effects on motor 
division 
Ataxia  Abamectin  0.25  0.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Ataxia  Fluquinconazole  0.44  4.77  Unknown   
  Ataxia  Lambda-
Cyhalothrin 
0.5  3.5  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Fosthiazate  0.54  5.4  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Oxasulfuron  1.3  11  Unknown   
  Ataxia  Oxamyl  1.69  15.3  Known  Inhibition of acetylcholinesterase (AChE) 
  Ataxia  Molinate  1.8  13  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
  Ataxia  Beta-Cyfluthrin  2  8.9  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Alpha-
Cypermethrin 
2.3  6.8  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Cyfluthrin  2.4  11  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia  Indoxacarb  2.6  14  Presumed  Presumed blocking of sodium channels (in 
insects) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Ataxia  Cypermethrin  3.7  15  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Ataxia (Hind-
limb 
wheelbarrowing
) 
Propineb  4.3  41.4  Unknown  Actin depolymerisation, disruption of 
cytoskeletal organisation and further 
acetylcholine release. 
  Ataxia  Glufosinate  4.5  8.4  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Ataxia  Fenpropidin  5  20  Unknown  Disturbance of cholesterol supply/synthesis by 
Schwann cells 
  Ataxia  Desmedipham  < 9.6  9.6  Unknown   
  Ataxia  Chlormequat  10  32  Unknown  Weak agonistic activity on muscarinic and 
nicotinic receptors 
  Ataxia  Carbetamide  30  150  Unknown   
  Ataxia  Pyrethrins  30  86  Known  Delaying of the closing of sodium channels in 
the nervous system 
  Ataxia  Tri-allate  36  72  Unknown   
  Choreoatetosis              
(Ruffling of 
body, pawing) 
tau-Fluvalinate  0.5  1  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Choreoatetosis 
(Repetitive 
pawing) 
Beta-Cyfluthrin  2  8.9  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Convulsions  Fipronil  0.019  0.057  Presumed  Blocking the passage of chloride ions through 
the GABA receptor 
  Convulsions  Lambda-
Cyhalothrin 
0.5  3.5  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Convulsions  Lufenuron  1.9  20  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Convulsions  Glufosinate  4.5  8.4  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Convulsions  Mepiquat  32  95  Presumed   Activation of nicotinic and muscarinic 
acetylcholine receptors 
  Deficits in stride 
width 
Flufenacet  1.14  27  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress 
  Dragging of 
hind feet and tail 
Thiram  5.3  20  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Hunched 
posture 
Fluquinconazole  0.44  4.77  Unknown   
  Hunched 
posture 
Oxamyl  1.69  15.3  Known  Inhibition of acetylcholinesterase (AChE) 
  Hunched 
posture 
Lambda-
Cyhalothrin (study 
performed with 
Cyhalothrin) 
1.8  9.2  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Hunched 
posture 
Indoxacarb  2.6  14  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Hunched 
posture 
Acetamiprid  7.1  17.5  Known   Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Hunched 
posture 
Pirimiphos-methyl  9  36  Known  Inhibition of acetylcholinesterase (AChE) 
  Hunched 
posture 
Tetraconazole
1  17  65  Unknown  Neurotoxic potential of 1,2,4-triazole, a 
metabolite common to a number of triazole-
derivative pesticides 
  Hyperactivity  Lambda-
Cyhalothrin (study 
performed with 
Cyhalothrin) 
1.8  9.2  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Hyperactivity  Spinosad  67.5  185  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Hyperactivity 
followed by 
hypoactivty 
Glufosinate  4.5  8.4  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Increased motor 
activity 
Beta-Cyfluthrin  2  8.9  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Increased motor 
activity 
Triadimenol (a 
metabolite of 
Triadimefon) 
3.4  45  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Landing-foot 
splay 
Fenpropimorph  0.8  8.5  Unknown   
  Landing-foot 
splay 
Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Landing-foot 
splay 
zeta-Cypermethrin  5  26  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Landing-foot 
splay 
Tri-allate  32  177  Unknown   
  Lateral position  Mepiquat  32  95  Presumed   Activation of nicotinic and muscarinic 
acetylcholine receptors 
  Limited use of 
hindlilmbs 
Isoxaflutole  20  300  Unknown   
  Muscle 
weakness 
Chlorpyrifos-
methyl 
10  50  Known  Inhibition of acetylcholinesterase (AChE) 
  Muscle 
weakness 
Methiocarb  2.2  8.6  Known  Inhibition of acetylcholinesterase (AChE) 
  Paralysis  Thiram  5.3  20  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Paralysis  Metaldehyde  < 10  10  Presumed  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Paralysis  Mancozeb  49  328  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Paresis limbs  Fenpropidin  5  20  Unknown  Disturbance of cholesterol supply/synthesis by 
Schwann cells 
  Paresis limbs  Pyrethrins  30  86  Known  Delaying of the closing of sodium channels in 
the nervous system 
  Paresis limbs  Maneb  75  200  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Ptosis  Oxamyl  1.69  15.3  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced grip 
strength 
Metiram  25.4  81.4  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Reduced grip 
strength 
Beta-Cyfluthrin  2  8.9  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Reduced grip 
strength 
Ethoprophos  2.65  27.11  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced grip 
strength 
Esfenvalerate  3.2  7.3  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Reduced grip 
strength 
Tri-allate  32  177  Unknown   
  Reduced motor 
activity 
Ethoprophos  2.65  27.11  Known  Inhibition of acetylcholinesterase (AChE) 
  Reduced motor 
activity 
Fenpropidin  5  20  Unknown  Disturbance of cholesterol supply/synthesis by 
Schwann cells 
  Reduced motor 
activity 
zeta-Cypermethrin  5  26  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Reduced motor 
activity 
Desmedipham  < 9.6  9.6  Unknown   
  Reduced motor  Clothianidin  35.8  52.3  Known  Nicotinic acetylcholine receptor (nAChR) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
activity  agonist 
  Reduced motor 
activity 
Dicamba  50  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Reduced motor 
activity 
Tebuconazole
1  100  300  Unkown   
  Reduced motor 
activity 
Milbemectin
1  101  213    Binding to GABA receptors and GABA gated 
ion channels 
  Transient 
hyperactivity 
followed by 
hypoactivty 
tau-Fluvalinate  0.5  1  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Abamectin  0.25  0.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Tremor  Fluquinconazole  0.44  4.77  Unknown   
  Tremor  Lambda-
Cyhalothrin 
0.5  3.5  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Tefluthrin  0.5  1.5  Presumed  Type I pyrethroid. Delaying of the closing of 
sodium channels in the nervous system 
  Tremor  Fenamiphos  0.56  1.7  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Deltamethrin  1  10  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Formetanate  1  3  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Methiocarb  2.2  8.6  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Alpha-
Cypermethrin 
2.3  6.8  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Ethoprophos  2.65  27.11  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Pirimicarb  3.5  10  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Tremor  Cypermethrin  3.7  15  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Tremor  Glufosinate  4.5  8.4  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Tremor  Methomyl  6  16  Known  Inhibition of acetylcholinesterase (AChE) 
  Tremor  Desmedipham  < 9.6  9.6  Unknown   
  Tremor  Imidacloprid  23.5  45.4  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Tremor  Pyrethrins  30  86  Known  Delaying of the closing of sodium channels in 
the nervous system 
  Tremor  Tri-allate  36  72  Unknown   
  Tremor  Dicamba  50  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
Functional 
effects on sensory 
division 
Decrease in 
alertness and/or 
startle response 
Glufosinate  < 521  521  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Decreased pupil 
reactivity 
Abamectin  0.25  0.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Decreased 
responsiveness 
to sensory 
stimuli, increase 
in click response 
tau-Fluvalinate  2  6  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Diminished 
reflex response 
Chlormequat  50  62.5  Unknown  Weak agonistic activity on muscarinic and 
nicotinic receptors 
  Hindlimb flexor 
reflex 
Oxasulfuron  83  199  Unknown   
  Hyperreactivity, 
absent pupillary 
Oxamyl  1.69  15.3  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
 
 
98  EFSA Journal 2013;11(7):3293 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
response 
  Hyperreactivity  Indoxacarb  2.6  14  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Hyperreactivity  Cymoxanil  30  90  Unknown   
  Hyperreflexic 
patellar reflexes 
Molinate  10  50  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
  Hypersensitivity 
to noise 
Deltamethrin  4  14  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Hypersensitivity 
to noise 
Cypermethrin  5  15  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Hypersensitivity 
to noise 
Esfenvalerate  15  25  Presumed  Appear to exhibit characteristics of both type I 
and type II pyrethroids. Interaction with voltage-
gated sodium channels in the nervous system 
  Hypo-reactivity, 
reduced reaction 
to movement 
and sound, 
hyperreactivity 
Flufenacet  27  59  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress 
  Increased 
alertness, 
impaired 
righting reflex 
Tri-allate  32  177  Unknown   
  Increased 
reactivity, 
exaggerated 
auditory 
response 
Beta-Cyfluthrin  2  8.9  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Increased 
response to 
sound 
Tefluthrin  1.5  5.9  Presumed  Type I pyrethroid. Delaying of the closing of 
sodium channels in the nervous system 
  Minimal 
reactivity to 
handling 
2,4-D  < 5  5  Unknown  Cell and mitochondrial membrane damage,  
uncoupling of oxidative phosphorylation and 
interference of cellular metabolism? 
  Negative air 
drop, pupillary 
responses, 
decreased 
analgesic reflex 
Ethoprophos  2.65  27.11    Inhibition of acetylcholinesterase (AChE) 
  No reaction to 
noise 
Metaldehyde  30  90  Presumed  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? 
             
  Retarded 
pupillary reflex 
Fenpropimorph  7.1  71  Unknown   
  Sensory changes 
(proprioceptive 
deficit) 
Propineb  4.3  41.4  Unknown  Actin depolymerisation, disruption of 
cytoskeletal organisation and further 
acetylcholine release. 
  Sensory changes 
(presthesia, 
proprioception 
deficit) 
Molinate  10  50  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
Functional 
effects on 
autonomic 
division 
Lacrimation  Oxamyl  0.1  1.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Lacrimation  tau-Fluvalinate  0.5  1  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Lacrimation  Ethoprophos  2.65  27.11  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
 
 
100  EFSA Journal 2013;11(7):3293 
CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Lacrimation  Tri-allate  32  177  Unknown   
  Mydriasis  Abamectin  0.25  0.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Mydriasis  Deltamethrin  1  2.5  Presumed  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Piloerection  Fluquinconazole  1.73  8.81  Unknown   
  Piloerection  Lambda-
Cyhalothrin (study 
performed with 
Cyhalothrin) 
1.8  9.2  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Piloerection  Tefluthrin  11.6  26.6  Presumed  Type I pyrethroid. Delaying of the closing of 
sodium channels in the nervous system 
  Piloerection  Triadimenol (a 
metabolite of 
Triadimefon) 
40  209  Unknown  Increased dopamine turnover in nigrostriatal and 
mesolimbic brain dopamine pathways? 
  Salivation  Methiocarb  0.05  0.5  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Abamectin  0.25  0.5  Presumed  Binding to GABA receptors and GABA gated 
ion channels 
  Salivation  tau-Fluvalinate  0.5  1  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Molinate  1  10  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
  Salivation  Lambda-
Cyhalothrin (study 
performed with 
Cyhalothrin) 
2.5  10  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Ethoprophos  2.65  27.11  Known  Inhibition of acetylcholinesterase (AChE) 
  Salivation  Lufenuron  3.64  29.8  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Salivation  Chlormequat  5  10  Unknown  Partial agonist of the nicotinic acetylcholine 
receptor (nAChR) 
  Salivation  Cypermethrin  6  20  Known   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Salivation  Clothianidin  19.3  40.9  Known  Nicotinic acetylcholine receptor (nAChR) 
agonist 
  Salivation  Metaldehyde  30  90  Presumed  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? 
  Salivation  Dicamba  50  300  Unknown  Disruption of cell metabolism, uncoupling of 
oxidative phosphorylation? 
  Salivation  Carbetamide  150  300  Unknown   
  Salivation  Mepiquat  < 166  166  Presumed   Activation of nicotinic and muscarinic 
acetylcholine receptors 
  Trismus 
salivation 
Glufosinate  4.5  8.4  Presumed  Inhibition of glutamine synthetase and 
interference of nitrogen metabolism 
  Urination  Indoxacarb  2.6  14  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Urination  Pirimicarb  10  25  Known  Inhibition of acetylcholinesterase (AChE) 
  Urination  2,4-D  75  150  Unknown  Cell and mitochondrial membrane damage,  
uncoupling of oxidative phosphorylation and 
interference of cellular metabolism? 
Neurochemical 
end-points
 
AChE inhibition 
(brain) 
Pirimiphos-methyl  0.25  > 0.25  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Phosmet  < 1  1  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Methomyl  9  95  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(brain) 
Pirimicarb  10  25  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  AChE inhibition 
(erythrocytes) 
Ethoprophos  0.025  1  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Chlorpyrifos  0.03  0.1  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Dimethoate  0.04  0.2  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Fenamiphos  0.042  0.15  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Methiocarb  < 0.05  0.05  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Chlorpyrifos-
methyl 
0.1  3.9  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Formetanate  0.37  1.75  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Pirimiphos-methyl  0.4  2  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Fosthiazate  0.48  0.97  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Oxamyl  1.69  15.3  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Malathion  3  35  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Pirimicarb  10  25  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Ethephon  13  66  Known  Inhibition of acetylcholinesterase (AChE) 
  AChE inhibition 
(erythrocytes) 
Methomyl  41  55  Known  Inhibition of acetylcholinesterase (AChE) 
Neuropathologic
al end-points 
Axonal 
degeneration 
Flufenacet  1.14  27  Presumed  Metabolic lesions due to limitations in 
glutathione interdependent pathways and 
antioxidant stress Cumulative Assessment Groups for Pesticides update 
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specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Axonal 
degeneration 
Oxasulfuron  1.5  99  Unknown   
  Axonal 
degeneration 
Molinate  1.8  13  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
  Axonal 
degeneration 
Indoxacarb  4  20  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Axonal 
degeneration 
Cymoxanil  5  38  Unknown   
  Axonal 
degeneration 
Tri-allate  6.4  32  Unknown   
  Axonal 
degeneration 
Ziram  9  27  Presumed  Neurotoxic effect might be due to the metabolite 
CS2 
  Axonal 
degeneration 
Metaldehyde  10  50  Presumed  Decreased brain concentration of 
neurotransmitters (GABA, NE, 5-HT)? 
  Axonal 
degeneration 
tau-Fluvalinate  < 10  10  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Axonal 
degeneration 
Isoxaflutole  20  500  Unknown   
  Axonal 
degeneration 
(degeneration of 
trigeminus and 
increased 
galactosidase 
activity) 
Cypermethrin  25  50  Unknown   Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Cerebral cortex 
vacuolisation 
Sulfuryl fluoride  1.4  5.6  Unknown   
  Encephalomalac
ia 
(vacuolisation) 
Tetraconazole
1  < 0.5  0.5  Unknown  Neurotoxic potential of 1,2,4-triazole, a 
metabolite common to a number of triazole-
derivative pesticides Cumulative Assessment Groups for Pesticides update 
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CAG 2  Indicator of 
specific effect 
Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
  Myelin 
degeneration 
(secondary to 
axonal 
degeneration) 
Oxasulfuron  1.5  99  Unknown   
  Myelin 
degeneration 
Molinate  1.8  13  Unknown  Inhibition of aldehyde dehydrogenase and 
further accumulation of endogenous neurotoxic 
metabolites of neurotransmitters (e.g. dopamine) 
  Myelin 
degeneration 
Quinoclamine  3.82  40.2  Unknown   
  Myelin 
degeneration 
Cymoxanil  5  38  Unknown   
  Myelin 
degeneration 
Fenpropidin   5  20  Unknown  Disturbance of cholesterol supply/synthesis by 
Schwann cells 
  Myelin 
degeneration 
Tri-allate  6.4  32  Unknown   
  Myelin 
degeneration  
(myelin damage 
and Schwann 
cell 
proliferation) 
Mancozeb  8.2  49  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
  Myelin 
degeneration 
tau-Fluvalinate  < 10  10  Known  Type II (α-cyano) pyrethroid. Delaying of the 
closing of sodium channels in the nervous 
system 
  Myelin 
degeneration (a 
treatment-
related 
exacerbation of 
spontaneous 
age-related 
Pirimicarb  15.6  47.4  Known  Inhibition of acetylcholinesterase (AChE) Cumulative Assessment Groups for Pesticides update 
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Active substance  NO(A)EL 
mg/kg bw 
per day 
LO(A)EL 
mg/kg bw 
per day 
Mode/mechanism of action 
changes?) 
  Myelin 
degeneration 
Isoxaflutole  20  500  Unknown   
  Myelin 
degeneration 
Pyridate  60  200  Unknown   
  Neuronal 
degeneration/ 
necrosis 
Indoxacarb  4  20  Presumed  Presumed blocking of sodium channels (in 
insects) 
  Sciatic nerve 
lesions (not 
specified) 
Thiram  1.4  14  Unknown  Neurotoxic effect might be due to the metabolite 
CS2 (common metabolite of dithiocarbamates) 
 
1 Substance excluded by DTU 
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E.   BACKGROUND FOR HAZARD IDENTIFICATION AND CHARACTERISATION FOR EFFECTS ON THE 
THYROID SYSTEM 
Considerations  on  elaboration  of  CAGs  for  substances  affecting  the  thyroid  or  thyroid  hormone 
system. 
1. CAG level 1 
In the DTU report (2012), CAG level 1 was defined as “Toxicity to the thyroid gland”. A number of 
major  specific  effects  identified  by  DTU  concern  the  populations  of  calcitonin-producing 
parafollicular cells (C-cells) and thyroid hormone (T3/T4)-producing follicular cells. Both of these cell 
populations secrete specific hormones which act systemically. At least for the thyroid hormone system 
involving T3/T4, changes in serum hormone levels may not only result from toxicity to the thyroid 
itself, but may be due to mode of action operating outside the thyroid (e.g. enzyme induction in the 
liver). Consequently, it appears sensible to expand the CAG level 1 to actually comprise not only 
toxicity  to  the  thyroid  gland  itself,  but  also  to  the  hypothalamic-pituitary-thyroid  axis  (affecting 
function of thyroid hormones and calcitonin). 
2. CAG level 2 
The  evaluation  summarised  in  section  8.1.  for  the  thyroid  distinguishes  between  specific  effects 
concerning the parafollicular cells and specific effects concerning the thyroid follicular cells or the 
thyroid hormone system. This is in line with the general distinction made within the DTU report. 
2.1. CAG 2A: Substances affecting the thyroid parafollicular cells (C-cells) or the calcitonin 
system 
It is noted that information on serum levels of calcitonin, a hormone that plays a role in calcium 
homeostasis, is generally not available from toxicological studies. However, concerning the calcitonin-
producing  C-cells,  two  specific  effects  were  identified:  C-cell  hyperplasia/hypertrophy  and  C-cell 
neoplasia. Since C-cell stimulation leading to cell proliferation and hyperplasia is expected to play a 
promoting role in further progression to neoplasia, it is proposed to combine substances displaying 
either or both of these effects into one phenomenological level 2 CAG. In the absence of specific 
knowledge  on  the  underlying  modes  of  action  for  pesticide  active  substances  leading  to  C-cell 
activation/proliferation, further subgrouping is not recommended.   
2.2. CAG 2B: Substances affecting the thyroid follicular cells or the thyroid hormone system 
2.2.1. General considerations 
Chemicals disrupting the thyroid hormone (TH) system may be broadly defined as “xenobiotics that 
interfere with TH signalling” (Miller et al., 2009), including xenobiotics that alter the structure or 
function  of  the  thyroid  gland,  affect  enzymes  associated  with  thyroid  hormone  (TH:  T3  or  T4) 
homeostasis,  change  circulating  or  tissue  concentrations  of  thyroid  hormones  or  alter  binding  of 
thyroid  hormones  to  cellular  receptors  (Miller  et  al.,  2009;  Crofton  et  al.,  2005).  Accordingly, 
perturbations of the thyroid hormone system may result in manifestations concerning the thyroid itself 
(e.g. histological changes, thyroid enlargement, thyroid tumours), or effects regarding non-thyroid TH-
dependent tissues.  
The following figure 1 (from Miller et al., 2009) illustrates pathways controlling thyroid hormone 
homeostasis  and  possible  targets  for  thyroid  hormone  system  disruption.  A  variety  of 
modes/mechanisms of action that may play a role in disruption of the thyroid hormone system have 
also been addressed in the DTU Report.  Cumulative Assessment Groups for Pesticides update 
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Figure  1:  Thyroid  hormone  system  with  potential  targets  for  disruption  by  xenobiotics  (blue).  NIS, 
sodium/iodide  symporter;  TBG,  thyroid  hormone-binding  globulin;  TH,  thyroid  hormone  (T3/T4);  T3, 
triiodothyronine; T4, thyroxine; TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; TTR, 
transthyretin;  UDPGTs, UDP-glucuronosyl transferases (Miller et al., 2009). 
 
As  a  consequence  of  changes  in  circulating  and  tissue  thyroid  hormone  levels,  compensatory 
mechanisms including activation of the hypothalamic-pituitary-thyroid axis following a decline in 
peripheral thyroid hormone levels with subsequent increased production and secretion of TSH (thyroid 
stimulating hormone) may be expected to result in adjustment of bioavailable thyroid hormone levels, 
rendering changes in circulating or tissue T3/T4 hormone levels transient.  
 
2.2.2. Relevance of thyroid hormone system disruption to humans 
Concerning effects on the thyroid itself, prolonged enhanced secretion by the pituitary of TSH as a 
response to decreased circulating thyroid hormone levels in rat studies leads to thyroid follicular cell 
hypertrophy and hyperplasia, which eventually may act as a promoting factor in the development of 
benign and malignant follicular cell tumours. Although compensatory mechanisms based on feedback 
loops within the hypothalamic-pituitary-thyroid axis are also operative in humans from a qualitative 
point  of  view,  it  appears that  humans  are  quantitatively  less  susceptible  to  follicular  cell  tumour 
formation resulting from thyroid hormone system imbalance than rats, based on marked quantitative 
differences in kinetics of circulating thyroid hormones and in the extent of response to changes in 
thyroid hormone levels (Dellarco et al., 2006). Nevertheless, alterations in animal studies such as 
thyroid hypertrophy and hyperplasia may also be seen as general indicators of disturbance of thyroid 
hormone homeostasis or of preceding changes in systemic thyroid hormone levels. Alterations in 
circulating bioavailable thyroid hormone levels may have serious impact on other organs or organ 
systems besides the thyroid itself also in humans, particularly if perturbations occur during critical 
windows of development.  
The DTU report lists a number of reasons why humans may be less sensitive to perturbations of the 
thyroid hormone system than rats. It appears plausible that the healthy human adult individual displays 
a certain propensity for coping with challenges to the thyroid hormone system, owing to buffering 
mechanisms (e.g. plasma protein binding of thyroid hormones, storage of thyroglobulin in follicular 
colloid),  and  to  the  presence  of  various  compensatory  mechanisms  directed  at  reestablishment of Cumulative Assessment Groups for Pesticides update 
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thyroid hormone homeostasis. Nevertheless, epidemiological studies suggest that higher TSH levels 
(as  an  indicator  of  challenges  to  thyroid  hormone  homeostasis  and  subsequent  activation  of  the 
hypothalamic-pituitary-thyroid axis), even in the context of subclinical hypothyroidism, are associated 
with  increased  risks  for  adverse  organ  effects  in  adults,  e.g.  regarding  cardiovascular  endpoints 
(reviewed in Miller et al., 2009).  
There are indications that the developing child is particularly sensitive to perturbations of the thyroid 
hormone  system,  in  that  an  inadequate  supply  of  thyroid  hormones  during  critical  windows  of 
development may severely impact development or even lead to irreversible effects. Before onset of 
fetal thyroid function during the second trimester of pregnancy, placental transfer of maternal thyroid 
hormones appears to represent the sole source of thyroid hormone to the developing child (Gilbert et 
al., 2012). Even in more advanced stages of pregnancy, maternal thyroid hormones are thought to 
contribute to adequate fetal supply. In addition, very limited storage capacity for thyroid hormone 
appears  to  exist  for  humans  during  the  fetal,  newborn  and  early  infant  stages  in  comparison  to 
extensive storage within the thyroid follicular colloids in adults (reviewed in Woodruff et al., 2008), 
and  T4  appears  to  also  display  a  shorter  half-life  as  compared  to  adults,  pointing  to  a  higher 
susceptibility also on a kinetic basis towards effects resulting from thyroid hormone imbalance.  
Studies regarding the outcome of human pregnancies in respect to maternal thyroid function provide 
evidence  that  even  moderate  or  transient  thyroid  hormone  deficiency  during  critical  periods  of 
development may affect among others neurodevelopmental endpoints such as intelligence of the child 
(Haddow et al., 1999; Morreale de Escobar et al., 2000; Kooistra et al., 2006). For example, infants of 
seemingly healthy mothers with maternal free T4 serum levels below the 10
th percentile during the 
first trimester showed significantly lower scores on a neonatal behavioral assessment orientation index 
(Kooistra  et  al.,  2006).  In  conclusion,  even  transient  changes  in  T3  and  T4  levels  in  humans, 
depending on the duration, timing and extent of relative T3 and T4 insufficiency, may affect the 
developing nervous system of the unborn child. 
Thyroid hormone homeostasis may not only be affected by exposure to man-made xenobiotics as 
individual substances or as mixtures, but is also influenced by other dietary or lifestyle factors, e.g. 
extent of iodine ingestion, exposure to inhibitors of thyroid hormone production such as thiocyanate 
via ingestion of cruciferous vegetables or smoking (Steinmaus et al., 2007). In addition, the basal 
functional  state  of  the  thyroid  may  already  be  challenged  due  to  individual  biological  processes 
(pregnancy) or compromised in disease conditions (e.g. autoimmune thyroiditis). Thus, variability in 
the  population  concerning  susceptibility  towards  additional  chemical  insults  affecting  the  thyroid 
hormone system can be assumed. 
 
2.2.3  Phenomenological  effects  regarded  as  being  relevant  for  assignment  to  cumulative 
assessment groups 
 
For the evaluation of the common toxicological profile for assignment of an active substance to a 
CAG, different indicators may be taken into account, which could comprise downstream endpoints 
with obviously adverse target organ effects or upstream precursor effects, e.g. a decrease in T4 levels, 
that may eventually lead to manifestation of an adverse organ effect. 
Based on the assumption that the developing child is particularly sensitive to changes in circulating 
hormone levels that may still be tolerated by the mother, but also the epidemiological evidence for 
adults linking even subclinical hypothyroidism to increased risk for cardiovascular disease, it has 
recently been concluded that: 
“…TDC [thyroid disrupting chemical] exposures that would result in reduced T4 in a population 
should be considered an adverse effect” (Woodruff et al., 2008) and that Cumulative Assessment Groups for Pesticides update 
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“Any degree of thyroid disruption that lowers TH levels on a population basis should be considered a 
biomarker  of  increased  risk  of  adverse  outcomes,  which  may  have  important  societal  outcomes” 
(Miller et al., 2009). 
In the context of CRA, it is therefore proposed to also consider the physiological change preceding 
adverse manifestations in target organs (changes in circulating thyroid hormone levels) and indicators 
of perturbation of thyroid hormone homeostasis (e.g. elevation of TSH or thyroid enlargement), to be 
of relevance for definition of cumulative assessment groups. This approach has been followed in the 
DTU report.  
 
2.2.4   Specific effects and indicators leading to assignment to a common CAG2B: 
The following specific effects were identified by DTU for the thyroid and confirmed in the course of 
the review of the report as being related to the T3/T4-associated thyroid hormone system: 
 
  Changes in serum T3 and/or T4 (in rare cases there was information on total vs. free 
hormone) 
  Changes in serum TSH 
  Follicular cell hyperplasia/hypertrophy and/or increased thyroid weight 
  Follicular cell tumours 
These effects may be used for screening of toxicological databases and allocation of substances to 
CAG2B. These effects are interrelated and connected by a chain of events with one another, even if 
detailed mechanistic information is not available. This was supported by the comparison of different 
single effect groups that were documented in the DTU report, in that the tentative single effect groups 
displayed considerable overlap with one another. For example, in our data collection, all substances 
fulfilling the single phenomenological criterion “TSH increase” also affected serum T3 and/or T4 
levels, with the exception of three, which, however, did lead to follicular cell hyperplasia/hypertrophy. 
Almost all substances displaying an increase in TSH and most of the substances affecting T3/T4 levels 
according  to the  DTU report  also led  to  follicular  cell  hypertrophy/hyperplasia  or  thyroid  weight 
increase. Finally, the preliminary group based on thyroid follicular tumours was actually a subgroup of 
the “Follicular cell hyperplasia/hypertrophy” effect group. As stated in the DTU report: 
“As already described under CAG level 2, the different effects on the thyroid follicular cells or on the 
thyroid hormone levels are often not independent effects, but rather consequences of each other. The 
combined mode of action model illustrates that many different mechanisms of action may lead to 
serum T3 and T4 changes. Subsequently, TSH is increased to compensate for the decreased T3 and/or 
T4. Persistent elevation of TSH may lead to histopathological changes such as thyroid follicular cell 
hypertrophy and even thyroid follicular cell tumours (at least in rodents).” 
In conclusion, the single effects listed above may serve as indicators or surrogates for each other. 
Consequently, substances displaying at least one of the above listed effects would be allocated to the 
combined phenomenological CAG2B. In addition to the specific effects mentioned above, the DTU 
report identified inflammation of the thyroid and/or degeneration of the thyroid gland as a general 
mode of action leading to damage of follicular cells. Thyroid inflammation, and possibly also other 
processes  leading  to  degenerative  changes  in  follicular  cells,  may  be  expected  to  affect  thyroid 
function, resulting in changes in T3/T4 or TSH levels. It was therefore concluded by the Panel that 
substances  adversely  affecting  thyroid  function  via  inflammation  and/or  degeneration  should  be 
included in CAG2B. Thus, in the process of data collection, effects of thyroid inflammation and 
follicular cell degeneration, if clearly shown to be substance-related, should be considered as alerts for 
other effects concerning thyroid function. Additional histopathological changes reported in DARs and 
listed  in  the  DTU  report,  such  as  increased/decreased  amount  of  colloids,  small/large  follicles, Cumulative Assessment Groups for Pesticides update 
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different shapes of follicular cells, increased vascularisation, increased vacuolisation, follicular cysts, 
follicular cell pigmentation, follicular atrophy or necrosis of follicular cells were regarded as being 
covered by the combined CAG2B. 
It  is  noted  that,  although  e.g.  the  new  extended  one  generation  study  (OECD,  2012)  contains 
provisions for measurement of thyroid hormones or TSH, standard OECD guidelines for repeated dose 
toxicity testing do not include hormone determinations as a mandatory requirement. This may pose a 
limitation in terms of availability of information on hormone levels and thus theoretically impede use 
of thyroid functional parameters for allocation to CAG2B. However, histopathological evaluations of 
the thyroid are performed in the standard repeated-dose toxicity studies, and thus an information gap 
concerning hormone levels can be expected to be largely compensated for by other specific effects 
associated with CAG2B.   
In  preparation  for  CRA,  the  NOAELs  from  the  specific  effects  determining  the  allocation  of  an 
individual substance to CAG2B would be compared to define the most sensitive relevant NOAEL to 
be used for CRA.  
2.2.5 Mechanistic considerations concerning substances in CAG2B - General mode of action: 
Toxicity to thyroid follicular cells or to the T3/T4 system 
A  number  of  pesticide  active  substances  may  influence  the  thyroid  system  through  one  or  more 
mechanisms.  Based  on  the  interrelationship  between  different  targets  within  the  thyroid  hormone 
system, there may be concern that combinations of individual substances potentially affecting the 
thyroid hormone system may feed into common processes which in the end may result in impairment 
of effector hormone- (basically T3-) dependent receptor signalling.  
A list of mode of actions affecting the thyroid or thyroid hormone system has been summarized within 
the DTU report. Figure 2 shows a scheme, based on the review by Miller et al., 2009, which outlines 
several general toxicological targets within the thyroid hormone system. It refers to both thyroidal and 
extrathyroidal targets and illustrates that different modes/mechanisms of action may contribute to a 
common clinical outcome, e.g. impairment of brain development. A similar scheme is also presented 
in the DTU report. In addition to the scheme in the DTU report, interference with binding of thyroid 
hormones to circulating blood proteins is also considered as a potentially relevant mode of action. 
Displacement of T4/T3 from plasma protein would be expected to contribute to a shorter half-life of 
circulating hormone. 
 
Figure 2: Examples of targets of thyroid hormone (T3/T4) system disruption and potential outcomes.  Cumulative Assessment Groups for Pesticides update 
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T3,  triiodothyronine;  T4,  thyroxine;  TH,  thyroid  hormone;  TTR,  transthyretin  (major  T4-binding 
protein in rats); UDPGT, UDP-glucuronosyl transferases. Modified from Miller et al., 2009. 
 
In the EFSA Opinion and Triazole exercise (2008, 2009) it was advised that, starting from a group of 
chemicals producing the same toxic effect, further refinement of grouping can be achieved based on 
the mode/mechanism of action of each individual substance under consideration of the key events 
involved.  
Although most substances affecting the thyroid follicular cells or the thyroid hormone system appear 
to generally be associated with a decrease in thyroid hormone (T3/T4) levels or ultimate thyroid 
hormone action, there may be substances that stimulate thyroid or enhance thyroid hormone release. 
Theoretically, specific mechanistic information might be used to consider exclusion of a substance 
from the combined CAG2B group.  
Apart from the above mentioned exception, a further sub-grouping of CAG2B based on different 
modes/mechanisms  of  action  is  currently  not  recommended.  The  reasons  for  this  conclusion  are 
detailed below. 
  For many substances affecting the thyroid or the thyroid hormone system on an effect basis, 
the  mechanism  of  action  has  not  been  defined.  From  a  conservative  point  of  view,  such 
substances might be considered for inclusion in CRA if indicators for perturbation of thyroid 
hormone homeostasis have been observed. This is in accordance with the recommendations 
received from the EU Commission. 
 
  In particular, the degree of similarity or dissimilarity of various modes/mechanisms of action 
may  be  difficult  to  define  or  to  agree  upon  in  studies  concerning  mixtures  of  chemicals 
affecting the thyroid hormone system. For example, different chemicals may affect thyroid 
hormone clearance via a mode of action related to enzyme induction, yet individual substances 
may convey this induction via different cellular pathways (activation of the Aryl hydrocarbon 
(Ah) receptor vs. activation of nuclear receptors such as CAR or PXR) and may thus modulate 
expression of distinct patterns of enzymes involved in thyroid hormone metabolism.  
 
  Some substances may act via several mechanisms, e.g. enzyme induction, displacement from 
plasma protein binding, interference with thyroid hormone receptor-dependent transactivation 
(Miller et al., 2009). 
  In the paper by Crofton et al., 2005, individual substances affecting thyroid hormone clearance 
via different molecular mechanisms and their mixtures were tested in rats over a short-term 
exposure period of 4 days. Mixtures were tested at several doses, the highest dose levels being 
below or corresponding to individual NOELs. It was reported that the cumulative effect of the 
mixture was predicted by dose-dependent additivity at low doses and synergism at high doses. 
More precisely, the mixture dose-response curve in the lower dose range (up to about a factor 
of 10 lower than the highest concentration tested) was in accordance with the dose-dependent 
additivity prediction, although this was the non-linear part of the dose response, in which it is 
difficult to discern any changes in the response. With higher concentrations of the mixture 
however, the observed response was in accordance with synergism, and was underpredicted 
by the dose-additivity model. Noteworthy is the fact that the dose-dependent additivity model 
up to the individual NOELs would have been less underpredictive than an effect addition 
prediction. According to the latter, no response towards the mixture would be expected if all 
components are below their individual effect levels. In a more recent paper (Flippin et al., 
2009)  rats  were  treated  with  dilutions  of  a  mixture  of  21  substances,  containing  both 
stimulators of T4 clearance in the liver and substances affecting TH synthesis. Predictive 
modelling was performed, comparing three additivity model predictions (dose addition, effect 
addition and integrated addition). It was found that both dose and integrated addition models 
provided similar results, with better predictions than the effect-addition model. Consequently, 
in the DTU report, it is concluded that: “These two studies suggest that it may be possible to 
predict a decreased level of T4 in a mixture of chemicals with a fair degree of accuracy using Cumulative Assessment Groups for Pesticides update 
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dose  addition  models  without  knowing  the  detailed  mechanism  behind  the  decreased  T4 
level”.   
  Ultimately, downstream organ or tissue effects will be based on the interaction or perturbation 
of interaction of the effector hormone (predominantly T3) on the receptor level. Different 
mechanisms  outlined  in  the  DTU  report  may  principally  affect  processes  expected  to  be 
integrated concerning the extent of thyroid hormone action.   
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F.   DATA COLLECTION FOR EFFECTS ON THE THYROID SYSTEM 
F.1. Data collection for thyroid toxicity- EFSA Part 1  
See separate file. 
F.2. Data collection for thyroid toxicity – EFSA Part 2 
See separate file. 
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G.  CAGS FOR THE THYROID SYSTEM 
CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
CAG2A   C-cell adenoma  Quizalofop-P-
tefuryl 
1.7  48.7  Unknown   
Effects on the 
parafollicular (C-) 
cells or the calcitonin 
system 
C-cell adenoma  Mepanipyrim  <2.45  2.45  Unknown   
  C-cell adenoma  Fenbuconazole  3  31  Unknown   
  C-cell adenoma  2,4-DB  <3  3  Unknown   
  C-cell adenoma  Bromuconazole  6.48  43.3  Unknown   
  C-cell adenoma  Thiram  7.31  14.66  Unknown   
  C-cell adenoma  Oryzalin  12  36  Unknown   
  C-cell adenoma  Hexythiazox  29.3  207  Unknown   
             
  C-cell adenoma / carcinoma  Oxyfluorfen  1.94  57  Unknown   
  C-cell adenoma / carcinoma  Lenacil  16  160  Unknown   
  C-cell adenoma / carcinoma  Penoxsulam  50  250  Unknown   
  C-cell hyperplasia  Amitrole 
(aminotriazole) 
0.3  13  Unknown   
  C-cell hyperplasia  Fenamidone  2.8  7.1  Unknown   
  C-cell hyperplasia  Desmedipham  3.18  15.71  Unknown   
  C-cell hyperplasia  Dichlorprop-P  <3.5  3.5  Unknown   
  C-cell hyperplasia  Ziram  7.7  23.7  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  C-cell hyperplasia  Buprofezin  8.71  89.5  Unknown   
  C-cell hyperplasia  Imidacloprid  51.3  102.6  Unknown   
  C-cell hyperplasia  2,4-D  75  150  Unknown   
  C-cell hyperplasia  Folpet  1800  4000  Unknown   
  C-cell hyperplasia / 
adenoma / carcinoma 
Dodine  20  42  Unknown   
  C-cell neoplasia  Ioxynil  0.6  1.8  Unknown   
CAG2B Substances 
affecting follicular 
cells and/or thyroid 
hormone (T3/T4) 
system 
Decreased circulating T3 
and/or T4 levels 
Fipronil  <0.02  0.02  Known  Enhanced T4 clearance from blood, 
enhanced biliary clearance 
  Decreased circulating T3 
level / follicular cell 
adenoma / carcinoma 
Ioxynil  <0.2  0.2  Presumed  Hepatic enzyme induction 
  Decreased circulating T3 
and T4 levels 
Bromoxynil  <0.9  0.9  Unknown   
  Decreased circulating T4 
and T3 levels / increased 
circulating rT3 level / 
follicular hypertrophy / 
follicular hyperplasia 
Proquinazid  1.2  12  Presumed  Induction of UDP-glucuronosyl 
transferase, leading to decreased half-
life of T4 and increase in TSH. An 
increase in rT3 and decrease in T3 
may be in line with decreased activity 
of hepatic 5´-deiodinase 
  Decreased circulating T3 
and/or T4 levels 
Flufenacet  1.7  6.9  Presumed  Increased T4 metabolism 
  Decreased circulating free 
T3/T4 level / follicular cell 
hypertrophy / increased 
relative thyroid weight 
Haloxyfop-P 
(Haloxyfop-R) 
2  5  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  Decreased circulating T3 
and T4 levels 
Dithianon  < 2.5  2.5  Unknown   
  Decreased circulating T4 
levels 
Desmedipham  <3.86  3.86  Unknown   
  Decreased circulating T3 
and T4 levels / follicular 
cell hyperplasia 
Metiram  5  15  Known  Inhibition of thyroid peroxidase 
(metabolite ETU) 
  Decreased circulating T3 
level 
Fluoxastrobin  3  24  Presumed  Hepatic enzyme induction 
  Decreased circulating T3 
level 
Pyrethrins  <6.6  6.6  Presumed  Hepatic enzyme induction 
  Decreased circulating T4 
level 
Lufenuron  7  30  Unknown   
  Decreased circulating T3 
level 
Lenacil  <22.5  22.5  Unknown  Pigmentation at higher doses in rats 
indicates accumulation in follicular 
cells 
  Decreased circulating T4 
level 
Pyridate  177  500  Unknown   
  Disappearance of thyroid 
colloid 
Formetanate  <5  5  Unknown   
  Mineralisation in follicle 
colloid (reflecting 
premature aging of the 
thyroid) 
Imidacloprid  5.7  16.9  Unknown   
  Enlarged thyroid  Ethofenprox  1.1  3.7  Known  Liver enzyme induction 
  Enlarged thyroid / follicular 
cell hypertrophy 
Clodinafop  10.2  26.3  Unknown   
  Enlarged thyroid / follicular 
cell hyperplasia / follicular 
cell adenoma 
Pethoxamid  17  70  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  Follicular cell adenoma  Cyhalofop-butyl  0.1  0.2  Unknown   
  Follicular cell adenoma / 
carcinoma 
Oxadiargyl  2.1  21.5  Unknown   
  Follicular cell adenoma  Diclofop  2.25  22.5  Unknown   
  Follicular cell adenoma 
/carcinoma 
Etridiazole  5  30  Unknown   
  Follicular cell adenoma  Thiabendazole  10  30  Presumed  Hepatic enzyme induction 
  Follicular cell adenoma / 
follicular cell carcinoma 
Diethofencarb  42.7  220.3  Known  Increased T4-UDP-glucuronosyl 
transferase activity 
  Follicular cell adenoma / 
adenocarcinoma 
Penoxsulam  50  250  Unknown   
  Follicular cell carcinoma  Mepanipyrim  <2.45  2.45  Unknown   
  Follicular cell hyperplasia / 
adenocarcinoma 
Fluquinconazole  0.44  4.77  Unknown   
  Follicular cell hyperplasia / 
follicular cell adenoma 
Isoxaflutole  2  20  Presumed  Result of hepatic effects 
  Follicular cell hyperplasia  Maneb  3.7  14  Known  Inhibition of thyroid peroxidase (by 
metabolite ETU); inhibition of iodide 
uptake 
  Follicular cell hyperplasia  Terbuthylazine  6.97  41.5  Unknown   
  Follicular cell hyperplasia / 
adenoma 
Propyzamide  8.5  42.6  Presumed  Heptic enzyme induction (increased 
biliary clearance in 15-week rat study) 
  Follicular cell hyperplasia  Benthiavalicarb  9.9  249  Presumed  Pigmentation in mouse follicular cells 
indicates accumulation of substance in 
follicular cells. 
  Follicular cell hyperplasia / 
adenoma / carcinoma 
Oryzalin  36  111  Unknown  Unknown for rats; reduced T4 protein 
binding considered for dogs 
  Follicular cell hyperplasia /  Silthiofam  50.5  149.8  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
adenoma / carcinoma 
  Follicular cell hyperplasia  Folpet  68.4  224  Unknown   
  Follicular cell hyperplasia  Hymexazol  98  292  Unknown   
  Follicular cell hypertrophy  Propineb  0.18 (overall 
NOEL) 
0.9  Presumed  Inhibition of thyroid peroxidase 
  Follicular cell hypertrophy  Ziram  0.56  5.5  Unknown   
  Follicular cell hypertrophy 
/hyperplasia 
Buprofezin  0.9  8.7  Presumed  Increased metabolism of T4/(T3) in 
liver 
  Follicular cell hypertrophy  Tetraconazole  1  8.3  Presumed  Hepatic enzyme induction; no 
inhibition of deiodinase activity 
converting T4 to T3 
  Follicular cell hypertrophy  Thiacloprid  1.2  2.5  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy  Quizalofop-P-
tefuryl 
1.3  39.5  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy / 
hyperplasia 
Picolinafen  1.7  12.5  Unknown   
  Follicular cell hypertrophy  Cyprodinil  3.14  19  Unknown   
  Follicular cell hypertrophy  Aclonifen  3.6  35.4  Unknown   
  Follicular cell hypertrophy / 
hyperplasia 
Fenamidone  3.6  7.1  Presumed  Results of effects occurring in liver 
  Follicular cell hypertrophy / 
decreased circulating T4 
level  
Mancozeb  4  17  Known  Inhibition of thyroid peroxidase (by 
metabolite ETU); inhibition of iodide 
uptake 
  Follicular cell hypertrophy  Fenbuconazole  5.7  28  Presumed  Liver enzyme induction leading to 
increased hormone clearance 
  Follicular cell hypertrophy  Dinocap  10  100  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  Follicular cell hypertrophy  Fenoxycarb  10.1  49.6  Unknown   
  Follicular cell hypertrophy / 
hyperplasia / pigmentation 
Pyrimethanil  17  221  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy / 
decreased circulating T4 
level 
Oxadiazon  17.8  62.1  Unknown   
  Follicular cell hypertrophy  Carbetamide  20.1  150.3  Presumed  Pigmentation of follicular cells in rats 
indicates substance accumulation in 
the thyroid 
  Follicular cell hypertrophy  Amidosulfuron  23.7  121.2  Unknown   
  Follicular cell hypertrophy  Cyproconazole  24.7  52.8  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy / 
hyperplasia 
Fluopicolide  32  109  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy / 
pigmentation 
Pendimethalin  43  88  Known  Hepatic enzyme induction; (presumed: 
pigmentation indicates accumulation 
of substance in thyroid follicular cells) 
  Follicular cell hypertrophy / 
hyperplasia 
Maleic hydrazide  63  625  Unknown   
  Follicular cell hypertrophy  Imazosulfuron  75  150  Unknown   
  Folllicular cell hypertrophy 
/ hyperplasia 
Benalaxyl  100  800  Unknown   
  Follicular cell hypertrophy  Thiamethoxam  198.6  710.6  Presumed  Hepatic enzyme induction 
  Follicular cell hypertrophy  Zoxamide  281  1054  Unknown   
  Increased circulating T4 
level 
Clofentezine  1.73  17.3  Presumed  Increased hepatic metabolism; 
circulating TSH level elevated in rat 
studies 
  Increased circulating 
TSH/T4 level 
Spirodiclofen  14.72  110.14  Unknown  (Both T4 and TSH increase were 
observed in rat at higher doses.) 
  Decreased circulating T4  Prothioconazole  5  50  Presumed  Hepatic enzyme induction Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
level 
  Increased relative thyroid 
weight 
Amitrole 
(aminotriazole) 
0.3  1  Known  Inhibition of thyroid hormone 
synthesis (Inhibition of thyroid 
peroxidase, inhibition of iodide uptake 
into follicular cells) 
  Increased thyroid weight  MCPA 
(metabolite of 
MCPB) 
0.95  9.3   Unknown  (MCPA-thioethyl) 
  Increased relative thyroid 
weight 
2,4-D  1  5  Unknown   
  Increased relative thyroid 
weight 
Dazomet  1  3.1  Unknown   
  Increased relative thyroid 
weight / follicular cell 
adenoma 
Oxyfluorfen  1.94  57  Unknown   
  Increased relative thyroid 
weight 
Spinosad  2.7  8.2  Presumed  Inflammation of thyroid, vacuolization 
of follicular cells which is consistent 
with phospholipidosis (Yano et al., 
2002). Vacuolisation occurring also in 
other organs (i. a. liver, kidney, 
adrenals) 
  Increased relative thyroid 
weight 
Quinoclamine  2.9  38.3  Unknown   
  Increased relative thyroid 
weight 
Bupirimate  3  15  Presumed  Increased metabolism of T4 /(T3) and 
excretion into the bile; inhibition of 
thyroid hormone synthesis 
  Increased thyroid weight  Propaquizafop  3  15  Unknown   
  Increased relative thyroid 
weight 
Fuberidazole  3.6  18  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  Increased relative thyroid 
weight / decreased 
circulating T3 and T4 levels 
Chlorprofam  5  50  Unknown   
  Increased relative thyroid 
weight / follicular cell 
hyperplasia /  adenoma/  
carcinoma 
Benfluralin  5.4  136  Unknown   
  Increased relative thyroid 
weight 
Bromuconazole  6.48  87.2  Unknown   
  Increased relative thyroid 
weight / decreased 
circulating T4 level 
Thiophanate-
methyl 
8  40  Unknown   
  Increased relative thyroid 
weight 
Carboxin  12  37  Unknown   
  Increased relative thyroid 
weight 
Tepraloxydim  14  66  Prsumed  Hepatic enzyme induction 
  Increased relative thyroid 
weight 
Myclobutanil  15  51.5  Unknown   
  Increased thyroid weight  Tribenuron (aka 
metometurun) 
15  73  Unknown   
  Increased relative thyroid 
weight / follicular cell 
adenoma 
Beflubatamid  17.7  150  Unknown   
  Increased thyroid weight  Flumioxazin  19.3  90  Unknown   
  Increased relative thyroid 
weight 
Cyflufenamid  20  120  Presumed  Enhanced hepatic metabolism 
  Increased relative thyroid 
weight 
Boscalid  22  57  Unknown   
  Increased relative thyroid 
weight 
Prochloraz  25  100  Unknown   
  Increased relative thyroid 
weight 
Tolylfluanid  33  93  Unknown   Cumulative Assessment Groups for Pesticides update 
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CAG2  Indicator of specific effect 
(only most sensitive 
indicator(s)) observed) 
Active substance  NO(A)EL  
mg/kg bw 
per day 
LO(A)EL  
mg/kg bw 
per day 
Mode/mechanism of action 
  Increased relative thyroid 
weight 
Flutolanil  37  299  Unknown   
  Increased relative thyroid 
weight 
Cycloxydim  50  250  Unknown   
  Increased relative thyroid 
weight 
Clethodim  62  250  Unknown   
  Increased relative thyroid 
weight 
Tritosulfuron  92  287  Presumed  Enzyme induction 
  Increased relative thyroid 
weight / increased 
circulating TSH level 
Metribuzin  <5  5  Unknown   
  Inflammatory and 
degenerative changes in the 
thyroid 
Pymetrozine  3  14  Unknown   
 
 Cumulative Assessment Groups for Pesticides 
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H.  LIST OF EXAMINED SUBSTANCES IN THE DATA COLLECTION (STEP 3) AND THOSE SELECTED 
FOR CAGS (STEP 4) 
Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
1-
Methylcyclopropene 
-  -  -  - 
1-
Naphthylacetamide 
(1-NAD) 
-  -  1-NAD  - 
1-Naphthylacetic 
acid (1-NAA) 
-  -  1-NAA  - 
2,4-D  2,4-D  2,4-D  2,4-D  2,4-D 
2,4-DB (metabolized 
to 2,4-D) 
-  -  2,4-DB  2,4-DB 
2-Phenylphenol 
(including sodium 
salt orthophenyl 
phenol) 
-  -  -  - 
6-Benzyladenine  -  -  -  - 
Abamectin (aka 
avermectin) 
Abamectin  Abamectin  -  - 
Acetamiprid  Acetamiprid  Acetamiprid  -  - 
Acibenzolar-S-
methyl 
(benzothiadiazole) 
-  -  -  - 
Aclonifen  -  -  Aclonifen  Aclonifen 
Alpha-Cypermethrin 
(aka alphamethrin) 
alpha-
Cypermethrin 
alpha-
Cypermethrin 
-  - 
Aluminium 
phosphide 
Aluminium 
phosphide 
-  -  - 
Aluminium 
ammonium sulphate 
-  -  -  - 
Amidosulfuron  -  -  Amidosulfuron  Amidosulfuron 
Amitrole 
(aminotriazole) 
-  -  Amitrole  Amitrole 
Azimsulfuron  -  -  -  - 
Azoxystrobin  -  -  -  - 
Beflubutamid  -  -  Beflubutamid  Beflubutamid 
Benalaxyl  -  -  Benalaxyl  Benalaxyl 
Benfluralin  Benfluralin  -  Benfluralin  Benfluralin 
Bensulfuron  -  -  -  - 
Bentazone  -  -  -  - 
Benthiavalicarb  Benthiavalicarb  -  Benthiavalicarb  Benthiavalicarb 
Benzoic acid  Benzoic acid  -  -  - 
Beta-Cyfluthrin  Beta-Cyfluthrin  Beta-Cyfluthrin  -  - 
Bifenazate  Bifenazate  -  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Bifenox  -  -  -  - 
Bispyribac  -  -  -  - 
Boscalid  -  -  Boscalid  Boscalid 
Bromadiolone  -  -  -  - 
Bromoxynil  -  -  Bromoxynil  Bromoxynil 
Bromuconazole  -  -  Bromuconazole  Bromuconazole 
Bupirimate  -  -  Bupirimate  Bupirimate 
Buprofezin  -  -  Buprofezin  Buprofezin 
Calcium phosphide  -  -  -  - 
Captan  -  -  -  - 
Carbendazim  -  -  -  - 
Carbetamide  Carbetamide  Carbetamide  Carbetamide  Carbetamide 
Carboxin  -  -  Carboxin  Carboxin 
Carfentrazone-ethyl  -  -  -  - 
Carvone  -  -  -  - 
Chloridazon (aka 
pyrazone) 
-  -  -  - 
Chlormequat 
(chloride) 
Chlormequat  Chlormequat  -  - 
Chlorothalonil  -  -  -  - 
Chlorotoluron  -  -  -  - 
Chlorpropham  Chlorpropham  Chlorpropham  Chlorpropham  Chlorpropham 
Chlorpyrifos  Chlorpyrifos  Chlorpyrifos  -  - 
Chlorpyrifos-methyl  Chlorpyrifos-
methyl 
Chlorpyrifos-
methyl 
-  - 
Chlorsulfuron  -  -  -  - 
Cinidon ethyl  -  -  -  - 
Clethodim  -  -  Clethodim  Clethodim 
Clodinafop  -  -  Clodinafop  Clodinafop 
Clofentezine  -  -  Clofentezine  Clofentezine 
Clomazone  -  -  -  - 
Clopyralid  -  -  -  - 
Clothianidin  Clothianidin  Clothianidin  -  - 
Copper compounds  Copper 
compounds 
-  -  - 
Cyazofamid  -  -  -  - 
Cyclanilide  -  -  -  - 
Cycloxydim  -  -  Cycloxydim  Cycloxydim 
Cyflufenamid  -  -  Cyflufenamid  Cyflufenamid 
Cyfluthrin  Cyfluthrin  Cyfluthrin  -  - 
Cyhalofop-butyl  -  -  Cyhalofop-butyl  Cyhalofop-butyl 
Cymoxanil  Cymoxanil  Cymoxanil  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Cypermethrin  Cypermethrin  Cypermethrin  -  - 
Cyproconazole  -  -  Cyproconazole  Cyproconazole 
Cyprodinil  -  -  Cyprodinil  Cyprodinil 
Cyromazine  Cyromazine  -  -  - 
Daminozide  -  -  -  - 
Dazomet   -  -  Dazomet  Dazomet 
Deltamethrin  Deltamethrin  Deltamethrin  -  - 
Desmedipham  Desmedipham  Desmedipham  Desmedipham  Desmedipham 
Dicamba  Dicamba  Dicamba  -  - 
Dichlorprop-P  -  -  Dichlorprop-P  Dichlorprop-P 
Diclofop  -  -  Diclofop  Diclofop 
Diethofencarb  -  -  Diethofencarb  Diethofencarb 
Difenoconazole  Difenoconazole  -  -  - 
Diflubenzuron  Diflubenzuron  -  -  - 
Diflufenican  -  -  -  - 
Dimethachlor  -  -  -  - 
Dimethenamid-P  -  -  -  - 
Dimethoate   Dimethoate  Dimethoate  -  - 
Dimethomorph  -  -  -  - 
Dimoxystrobin  -  -  -  - 
Dinocap  -  -  Dinocap  Dinocap 
Diquat (dibromide)  -  -  -  - 
Dithianon  -  -  Dithianon  Dithianon 
Diuron  -  -  -  - 
Dodemorph  -  -  -  - 
Dodine  -  -  Dodine  Dodine 
Epoxiconazole  -  -  -  - 
Esfenvalerate  Esfenvalerate  Esfenvalerate  -  - 
Ethephon  Ethephon  Ethephon  -  - 
Ethofumesate  -  -  -  - 
Ethoprophos  Ethoprophos  Ethoprophos  -  - 
Ethoxysulfuron  -  -  -  - 
Etofenprox  Etofenprox  -  Etofenprox  Etofenprox 
Etoxazole  Etoxazole  -  -  - 
Etridiazole  -  -  Etridiazole  Etridiazole 
Famoxadone  -  -  -  - 
Fenamidone  -  -  Fenamidone  Fenamidone 
Fenamiphos (aka 
phenamiphos) 
Fenamiphos  Fenamiphos  -  - 
Fenazaquin  -  -  Fenazaquin  - 
Fenbuconazole  -  -  Fenbuconazole  Fenbuconazole Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Fenbutatin oxide  -  -  -  - 
Fenhexamid  -  -  -  - 
Fenoxaprop-P  -  -  -  - 
Fenoxycarb  -  -  Fenoxycarb  Fenoxycarb 
Fenpropidin  Fenpropidin  Fenpropidin  -  - 
Fenpropimorph  Fenpropimorph  Fenpropimorph  -  - 
Fenpyroximate  Fenpyroximate  -  -  - 
Fipronil  Fipronil  Fipronil  Fipronil  Fipronil 
Flazasulfuron  -  -  Flazasulfuron  - 
Flonicamid (IKI-
220) 
-  -  Flonicamid  - 
Florasulam  -  -  -  - 
Fluazifop-P  -  -  -  - 
Fluazinam  -  -  -  - 
Fludioxonil  -  -  -  - 
Flufenacet (formerly 
fluthiamide) 
Flufenacet  Flufenacet  Flufenacet  Flufenacet 
Flumioxazin  -  -  Flumioxazin  Flumioxazin 
Fluometuron  -  -  -  - 
Fluopicolide  -  -  Fluopicolide  Fluopicolide 
Fluoxastrobin  -  -  Fluoxastrobin  Fluoxastrobin 
Flupyrsulfuron-
methyl (DPX KE 
459) 
-  -  -  - 
Fluquinconazole  Fluquinconazole  Fluquinconazole  Fluquinconazole  Fluquinconazole 
Flurochloridone  -  -  -  - 
Fluroxypyr  -  -  -  - 
Flurtamone  -  -  -  - 
Flusilazole  -  -  -  - 
Flutolanil  -  -  Flutolanil  Flutolanil 
Flutriafol  -  -  Flutriafol  - 
Folpet  -  -  Folpet  Folpet 
Foramsulfuron  -  -  -  - 
Forchlorfenuron  -  -  -  - 
Formetanate  Formetanate  Formetanate  Formetanate  Formetanate 
Fosetyl  -  -  -  - 
Fosthiazate  Fosthiazate  Fosthiazate  -  - 
Fuberidazole  -  -  Fuberidazole  Fuberidazole 
Gibberellin  -  -  -  - 
Glufosinate  Glufosinate  Glufosinate  -  - 
Glyphosate 
(including trimesium  
aka sulfosate) 
-  -  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Haloxyfop-P/R  -  -  Haloxyfop-P/R  Haloxyfop-P/R 
Hexythiazox  -  -  Hexythiazox  Hexythiazox 
Hymexazol  -  -  Hymexazol  Hymexazol 
Imazalil (aka 
enilconazole) 
-  -  -  - 
Imazamox  -  -  -  - 
Imazaquin  -  -  -  - 
Imazosulfuron  -  -  Imazosulfuron  Imazosulfuron 
Imidacloprid  Imidacloprid  Imidacloprid  Imidacloprid  Imidacloprid 
Indoxacarb  Indoxacarb  Indoxacarb  -  - 
Iodosulfuron  -  -  -  - 
Ioxynil  -  -  Ioxynil  Ioxynil 
Iprodione  -  -  -  - 
Iprovalicarb  Iprovalicarb  -  -  - 
Isoproturon  -  -  -  - 
Isoxaben  -  -  Isoxaben  - 
Isoxaflutole  Isoxaflutole  Isoxaflutole  Isoxaflutole  Isoxaflutole 
Kresoxim-methyl  -  -  -  - 
Lambda-Cyhalothrin  Lambda-
Cyhalothrin 
Lambda-
Cyhalothrin 
-  - 
Lenacil  -  -  Lenacil  Lenacil 
Linuron  -  -  -  - 
Lufenuron  Lufenuron  Lufenuron  Lufenuron  Lufenuron 
Magnesium 
phosphide 
Magnesium 
phosphide 
-  -  - 
Malathion  Malathion  Malathion  Malathion  - 
Maleic hydrazide  -  -  Maleic 
hydrazide 
Maleic 
hydrazide 
Mancozeb   Mancozeb  Mancozeb  Mancozeb  Mancozeb 
Maneb   Maneb  Maneb  Maneb  Maneb 
MCPA  -  -  MCPA  MCPA 
MCPB  -  -  -  - 
Mecoprop  -  -  -  - 
Mecoprop-P  -  -  -  - 
Mepanipyrim  -  -  Mepanipyrim  Mepanipyrim 
Mepiquat  Mepiquat  Mepiquat  -  - 
Mesosulfuron  -  -  -  - 
Mesotrione  -  -  -  - 
Metalaxyl-M  -  -  -  - 
Metaldehyde  Metaldehyde  Metaldehyde  -  - 
Metamitron  Metamitron  -  -  - 
Metazachlor  -  -  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Metconazole  -  -  Metconazole  - 
Methiocarb (aka 
mercaptodimethur) 
Methiocarb  Methiocarb  -  - 
Methomyl  Methomyl  Methomyl  -  - 
Methoxyfenozide  -  -  -  - 
Metiram  Metiram  Metiram  Metiram  Metiram 
Metosulam  -  -  -  - 
Metrafenone  -  -  -  - 
Metribuzin  Metribuzin  -  Metribuzin  Metribuzin 
Metsulfuron-methyl  -  -  -  - 
Milbemectin  Milbemectin  Milbemectin  -  - 
Molinate  Molinate  Molinate  -  - 
Myclobutanil  -  -  Myclobutanil  Myclobutanil 
Napropamide  -  -  -  - 
Nicosulfuron  -  -  -  - 
Oryzalin  -  -  Oryzalin  Oryzalin 
Oxadiargyl  -  -  Oxadiargyl  Oxadiargyl 
Oxadiazon  -  -  Oxadiazon  Oxadiazon 
Oxamyl  Oxamyl  Oxamyl  -  - 
Oxasulfuron  Oxasulfuron  Oxasulfuron  -  - 
Oxyfluorfen  -  -  Oxyfluorfen  Oxyfluorfen 
Paclobutrazol  -  -  -  - 
Penconazole  -  -  -  - 
Pencycuron  -  -  -  - 
Pendimethalin  -  -  Pendimethalin  Pendimethalin 
Penoxsulam  -  -  Penoxsulam  Penoxsulam 
Pethoxamid  -  -  Pethoxamid  Pethoxamid 
Phenmedipham  -  -  -  - 
Phosmet  Phosmet  Phosmet  -  - 
Picloram  -  -  Picloram   
Picolinafen  -  -  Picolinafen  Picolinafen 
Picoxystrobin  -  -  -  - 
Pirimicarb  Pirimicarb  Pirimicarb  -  - 
Pirimiphos-methyl  Pirimiphos-
methyl 
Pirimiphos-
methyl 
-  - 
Prochloraz  -  -  Prochloraz  Prochloraz 
Profoxydim (aka 
Clefoxydim) 
-  -  -  - 
Prohexadione 
(including 
Prohexadione-
calcium) 
-  -  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
Propamocarb  Propamocarb    -  - 
Propaquizafop  -  -  Propaquizafop  Propaquizafop 
Propiconazole  -  -  -  - 
Propineb    Propineb  Propineb  Propineb  Propineb 
Propoxycarbazone  -  -  -  - 
Propyzamide  -  -  Propyzamide  Propyzamide 
Proquinazid  -  -  Proquinazid  Proquinazid 
Prosulfocarb  -  -  -  - 
Prosulfuron  -  -  -  - 
Prothioconazole  -  -  Prothioconazole  Prothioconazole 
Pymetrozine  Pymetrozine  -  Pymetrozine  Pymetrozine 
Pyraclostrobin  -  -  -  - 
Pyraflufen-ethyl  -  -  -  - 
Pyrethrins  Pyrethrins  Pyrethrins  Pyrethrins  Pyrethrins 
Pyridaben  -  -  -  - 
Pyridate  Pyridate  Pyridate  Pyridate  Pyridate 
Pyrimethanil  -  -  Pyrimethanil  Pyrimethanil 
Pyriproxyfen  Pyriproxyfen  -  -  - 
Quinmerac  -  -  Quinmerac   
Quinoclamine  Quinoclamine  Quinoclamine  Quinoclamine  Quinoclamine 
Quinoxyfen  -  -  -  - 
Quizalofop-P 
(including  ethyl and 
tefuryl) 
-  -  Quizalofop-P  Quizalofop-P 
Rimsulfuron (aka 
renriduron) 
-  -  -  - 
Silthiofam  -  -  Silthiofam  Silthiofam 
Sintofen (aka 
Cintofen) 
-  -  -  - 
S-Metolachlor  -  -  -  - 
Sodium 5-
nitroguaiacolate 
-  -  -  - 
Sodium hypochlorite  -  -  -  - 
Sodium o-
nitrophenolate 
-  -  -  - 
Sodium p-
nitrophenolate 
-  -  -  - 
Spinosad  Spinosad  Spinosad  Spinosad  Spinosad 
Spirodiclofen  -  -  Spirodiclofen  Spirodiclofen 
Spiroxamine  -  -  -  - 
Sulcotrione  Sulcotrione    -  - 
Sulfosulfuron  -  -  Sulfosulfuron  - 
Sulfuryl fluoride  Sulfuryl fluoride  Sulfuryl fluoride  -  - Cumulative Assessment Groups for Pesticides 
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Substances  Nervous system 
Step 3 
Nervous system 
Step 4 
Thyroid system 
Step 3 
Thyroid system 
Step 4 
tau-Fluvalinate  tau-Fluvalinate  tau-Fluvalinate  -  - 
Tebuconazole  Tebuconazole  Tebuconazole  -  - 
Tebufenozide  -  -  -  - 
Tebufenpyrad  Tebufenpyrad  -  -  - 
Teflubenzuron  -  -  -  - 
Tefluthrin  Tefluthrin  Tefluthrin  -  - 
Tepraloxydim  -  -  Tepraloxydim  Tepraloxydim 
Terbuthylazine  -  -  Terbuthylazine  Terbuthylazine 
Tetraconazole  Tetraconazole  Tetraconazole  Tetraconazole  Tetraconazole 
Thiabendazole  -  -  Thiabendazole  Thiabendazole 
Thiacloprid  Thiacloprid  Thiacloprid  Thiacloprid  Thiacloprid 
Thiamethoxam  Thiamethoxam  Thiamethoxam  Thiamethoxam  Thiamethoxam 
Thifensulfuron-
methyl 
-  -  -  - 
Thiophanate-methyl  Thiophanate-
methyl 
-  Thiophanate-
methyl 
Thiophanate-
methyl 
Thiram  Thiram  Thiram  Thiram  Thiram 
Tolclofos-methyl  Tolclofos-
methyl 
-  -  - 
Tolylfluanid    Tolylfluanid  -  Tolylfluanid  Tolylfluanid 
Tralkoxydim  -  -  -  - 
Triadimenol  Triadimenol  Triadimenol  -  - 
Tri-allate  Tri-allate  Tri-allate  -  - 
Triasulfuron  -  -  -  - 
Triazoxide  -  -  -  - 
Tribenuron (aka 
metometuron) 
-  -  Tribenuron  Tribenuron 
Triclopyr  -  -  -  - 
Trifloxystrobin  -  -  -  - 
Triflumizole  -  -  -  - 
Triflumuron  -  -  -  - 
Triflusulfuron  -  -  -  - 
Trinexapac (aka 
cimetacarb ethyl) 
-  -  -  - 
Triticonazole  -  -  -  - 
Tritosulfuron  -  -  Tritosulfuron  Tritosulfuron 
zeta-Cypermethrin  zeta-
Cypermethrin 
zeta-
Cypermethrin 
-  - 
Zinc phosphide  -  -  -  - 
Ziram (including 
impurity TMTU) 
Ziram  Ziram  Ziram  Ziram 
Zoxamide  -  -  Zoxamide  Zoxamide 
Total = 287  Total = 91  Total = 67  Total = 113  Total = 101 Cumulative Assessment Groups for Pesticides 
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Notes 
1.  Substances  considered  not  exerting  relevant  effects  and  thereby  not  included  in  the  data 
collection are marked with the symbol – 
2.  Substances that are not highlighted in any colour are those approved until 31
st of May 2009 
and evaluated by both DTU, RIVM and EFSA 
3.  Substances highlighted in green are those approved between  31
st of May 2009 and 1
st of 
January 2012, and evaluated by RIVM and EFSA 
4.  Substances highlighted in red are those approved prior to 31
st of May 2009 but not evaluated 
by DTU and therefore added to the list and evaluated by RIVM and EFSA 
 
 